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Data from a Croatian isolate population are analysed in a genome-wide association 
study (GWAS) for a variety of disease-related quantitative traits. A novel genome-
wide approach to analysing pedigree-based association data called GRAMMAR is 
utilised. One of the significant findings, for uric acid, is followed up in greater detail, 
and is replicated in another isolate population, from Orkney. The associated SNPs are 
located in the SLC2A9 gene, coding for a known glucose transporter, which leads to 
identification of SLC2A9 as a urate transporter too (Vitart et al., 2008). These SNPs 
are later implicated in affecting gout, a disease known to be linked with high serum 
uric acid levels, in an independent study (Dehghan et al., 2008). Subsequently, 
investigation into different ways in which to use SNP data to identify quantitative 
trait loci (QTL) for genome-wide association (GWA) studies is performed. Several 
multi-marker approaches are compared to single SNP analysis using simulated 
phenotypes and real genotype data, and results show that for rare variants haplotype 
analysis is the most effective method of detection. Finally, the multi-marker methods 
are compared with single SNP analysis on the real uric acid data. Interpretation of 
real data results was complicated due to low sample size, since only founder and 
unrelated individuals may be used for population-based haplotype analysis, 
nonetheless, results of the prior analyses of simulated data indicate that multi-marker 
methods, in particular haplotypes, may greatly facilitate detection of QTL with low 
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“The search for … linkage will certainly be lengthy, and at first, disappointing.” – R. 
A. Fisher (1935). 
 
The concept of using molecular markers to correlate visible phenotypes with regions 
of the genome has a rich and diverse history. Indeed, before molecular markers were 
even known, phenotypes themselves were noted to be linked. The theory 
underpinning the key concept of linkage has remained broadly constant, yet the 
methods employed in achieving end results have changed beyond all recognition, 
particularly in the more recent past. It has been known since the work of Gregor 
Mendel (or at least, since its rediscovery by Hugo de Vries in 1900) that differences 
in hereditary material could be responsible for variation in the physical appearances 
of natural organisms. Before anything was known of genes, or even the structure of 
genomes other than the existence of chromosomes, Bateson reported “coupling” 
between traits in the sweet pea (Bateson, 1905), representing the first example of 
linkage reported in any organism (Edwards, 2005). 
 
 10 
This was followed by a conceptual breakthrough in 1911 when Morgan hypothesised 
that if the “factors” responsible for coupling of traits were on chromosomes, then not 
only would a linear arrangement of these factors on the same chromosome explain 
coupling, but also that the strength of linkage would be determined by their mutual 
proximity (Morgan, 1911). At this stage, all that was lacking was a rigorous statistical 
framework with which to begin linkage estimation, and this was provided by Ronald 
Fisher in 1922, with his introduction of the theory of maximum likelihood (Fisher, 
1922). Since that time, there has been ever more focus on associating traits of interest 
first with one another, and later with molecular markers, in an attempt to map the 
genome. This is evident in the works of, for example, Bell and Haldane (1937) and 
Lawler and Renwick (1959), who used blood-group systems as molecular markers to 
infer linkage to certain diseases. These blood-group systems, such as the Lutheran, 
Rhesus and ABO systems, were the first true molecular markers used to assess 
linkage – however this is still one step removed from using the actual DNA 
polymorphisms themselves, as is commonplace today. 
 
It wasn’t until after the discovery of the structure of DNA as the unit of heredity in 
1953, and the vast amounts of subsequent research into DNA, that linkage analysis 
was at last applied to human genetic variation and phenotypes. The first type of 
sequence-based molecular marker to be identified was restriction fragment length 
polymorphism (RFLP). RFLPs flag polymorphisms in restriction enzyme recognition 
sites because they result in differential lengths of DNA product, which are then 
separable when run on a gel. They were particularly useful due to their property of 
being co-dominant, where heterozygotes are distinguishable from both homozygotes. 
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RFLPs were first used as a tool for genetic analysis in 1974, and were used to create 
the first human genetic maps in 1980 (Botstein et al., 1980). They were also used in 
early attempts at what can be seen as more genome-wide approaches to genetic 
mapping (Lander and Botstein, 1988). 
 
A number of other DNA-based markers, such as minisatellites, amplified fragment 
length polymorphisms (AFLPs) and random amplification of polymorphic DNA 
(RAPDs) became available with the advent of the Polymerase Chain Reaction (PCR) 
in 1983. AFLPs and RAPDs were favoured fleetingly due to ease of use in the 
laboratory, and although AFLPs are still used in plant studies (Woodhead et al., 
2005), their use in human mapping in particular was compromised by virtue of them 
being dominant rather than co-dominant markers (Vignal et al., 2002). Therefore, the 
next major class of marker that was widely utilised in genetic mapping was 
microsatellites: these are hypervariable, co-dominant markers consisting of differing 
numbers of short (usually less than 100 bases) tandemly repeated sequences, easily 
assayed using PCR (Sunnucks, 2000). Microsatellites are also numerous and fairly 
evenly distributed across the entire genome, therefore it wasn’t long before human 
genetic maps were constructed using this new type of marker (Schlotterer, 2004). 
 
Microsatellites became very popular for assessing linkages of disease with specific 
regions of the genome. Genome-wide scans consisting of 300-400 microsatellites at 
an average spacing of around 10cM became the norm, and several statistically 
significant linkages were found – particularly for Mendelian (monogenic) disorders. 
However, successes for more complex diseases or traits were far more modest, and 
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the time and cost required for microsatellite arrays made larger studies unfeasible. At 
this point attention turned to a new type of molecular marker, a marker which has 
heralded an unprecedented level of understanding of the human genome and of the 




As the name may imply, single nucleotide polymorphisms (or SNPs) refer to a single 
base in the genome which exhibits variation from one individual in a population to 
another. In general, SNPs are classed as common or rare depending on the frequency 
of the minor allele in the population. In general, the minor allele frequency (MAF) 
must be greater than 5% for a SNP to be classed as common, although this varies in 
the literature, and is often relaxed to just 1%. While in theory any one of the four 
possible bases A, T, C and G could be present at any one locus, in practice there is 
usually only one of two bases at a SNP locus, hence SNPs are regarded as biallelic 
markers. This is due both to the very low mutation rate, and the fact that mutations 
are heavily biased towards transitions (A <-> G or C <-> T) as opposed to 
transversions (any other single base substitution) (Vignal et al., 2002). While it may 
seem counterintuitive to replace the highly polymorphic, and therefore vastly more 
informative (on a per marker basis), microsatellites with biallelic SNPs to assess 
linkage, there are a number of advantages which SNPs have that more than make up 
for the loss in information content. 
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From a practical point of view, SNPs are extremely well suited to automation, and 
therefore fast high-throughput techniques are possible. This in turn makes genotyping 
much less expensive and more cost-effective. In a comparison of microsatellites and 
SNPs, the time taken to perform genome-wide genotyping for analysis decreased 
from many months to just a few weeks (John et al., 2004). Since this comparison was 
made, SNP genotyping has improved by many orders of magnitude both in terms of 
speed and cost-efficiency. 
 
Other than the increase in genotyping speed, there is another major benefit of using 
SNPs. Even when compared to microsatellites, SNPs are vastly more abundant in the 
genome. Most recent estimates suggest there are somewhere around seven million 
SNPs in the human genome with a minor allele frequency of at least 5%, and a further 
four million or so with minor allele frequencies between 1% and 5% (Frazer et al., 
2009). It is this massive increase in the number of SNPs compared to microsatellites 
that entirely negates the loss of information content when comparing on a per marker 
basis, because information content incorporates both level of polymorphism at a locus 
(heterozygosity) and marker density. For this reason, SNPs provide higher overall 
information content across the genome than do microsatellites. 
 
In a comparison of information content provided by SNPs and microsatellites, it was 
shown that for realistic densities of each type of marker, SNPs are considerably more 
informative than microsatellites (Kruglyak, 1997). The information content afforded 
by microsatellites spaced 10cM apart (the usual distance for most linkage studies) is 
0.68 with 10 alleles each of equal frequency (the best possible scenario), but for SNPs 
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spaced 1cM apart this value is 0.88. Importantly, even at more extreme allele 
frequencies (where heterozygosity will fall, thus reducing information), the results are 
not changed drastically for SNPs. In general, to provide the same information content, 
a SNP marker map would need to be around 2.5 times as dense as a microsatellite 
map, which means as little as 750 – 1,000 SNP markers. 
 
With an estimated 11 million SNPs in the human genome with MAF >1%, human 
genetics is almost spoilt for choice regarding which of these polymorphisms to use in 
searching for disease genes. The majority of studies in recent years have been based 
upon 300,000 – 500,000 genome-wide SNPs selected either randomly, or as will be 
seen shortly, by more intelligent SNP selection criteria, but this number is set to 
increase further to a million or even more. It is armed with this plethora of newly 
discovered DNA variation to explore that the human genetics community has real 




One of the main driving forces behind the development of new markers, and the 
methods to test them for linkage, is to try to understand the genetics behind common 
complex diseases in the human population. Most methods were designed explicitly 
for the detection of disease genes, and consequently in this chapter “disease” is often 
used where in fact any given trait could be the phenotype under study. The vast 
majority of diseases studied to date, particularly those studied at the conception of 
linkage analysis design, essentially comprise a binary presence / absence (or affected 
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/ unaffected) trait; that is, a qualitative trait composed of discrete categories. One of 
the earliest and most renowned examples of linkage to a common disease was to 
cystic fibrosis in 1989 (Kerem et al., 1989), and there has been numerous reports of 
success in locating genes involved in other diseases since then. While this is 
encouraging, one thing most of these success stories have in common is that they 
generally involve diseases which turn out to have only one gene explaining all or 
nearly all of the cases (i.e., Mendelian disorders), or where there were rare variants 
segregating within single families which conferred a high risk to the given disease 
(Botstein and Risch, 2003). There are much fewer successes regarding diseases which 
appear to have a more complex aetiology, the so-called common complex diseases 
such as diabetes, cancers, schizophrenia, hypertension and obesity-related diseases. 
 
Much of the difficulty in being able to detect linkages to genes influencing common 
complex diseases can be attributed to the fact that in reality many of these diseases 
are not under the control of a single gene. One way in which this could happen would 
be for a disease to be under the control of many genes that are all fully penetrant, 
therefore any one of a number of genes would be causal. Another possibility is that 
many genes are involved in a given disease, but that none are directly responsible and 
individually contribute only a fraction of the overall disease risk. This idea may be 
more readily obvious in diseases where diagnosis is based on a threshold for example, 
where many genes may each increment the value by a small amount. Although the 
clinical endpoint of disease is the binary outcome of disease status (i.e., affected or 
unaffected), all common complex diseases are under the control of numerous genes, 
each predisposing to disease but not necessarily requisite. Additionally, many 
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diseases can be further divided into the products of numerous risk factors, many of 
which are quantitative in nature. A quantitative trait is one that is measured on a 
continuous, i.e., numerical, scale, rather than having categories into which all samples 
can be assigned, and genes influencing quantitative traits are known as quantitative 
trait loci (QTL). 
 
When a disease is referred to as “complex” it usually means the disease is thought to 
be composed of multiple components, a proportion of which will be genetic. In 
general, complex diseases can be broken down into a genetic component resulting 
from the action of many genes each of small individual effect, and a non-genetic, or 
environmental, component. It is also possible for there to be interactions both within 
and between these components. This means that, excluding any rare high risk alleles, 
any one risk allele is neither necessary nor sufficient to cause a disease; it is the 
cumulative effect of many alleles and interacting factors that is most important 
(Bourgain and Genin, 2005). In addition to this, the set of all possible genes that 
could affect any given complex disease may include genes involved in numerous 
different underlying pathways or risk factors. This fact somewhat undermines the 
attempt to classify and analyse complex diseases in the simple binary manner that has 
been so successful for Mendelian traits: how can the individual causes of a complex 
disease be teased apart when there are so many different ways the disease can 
develop, and furthermore, when a large proportion of these diseases and their 
potential causes are being analysed as a binary outcome when they are in fact 
quantitative in nature? 
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One way to help tackle this issue is to decompose diseases into a set of likely risk 
factors and analyse these individually, in an attempt to increase the genetic signal to 
noise ratio. The idea behind this is that while a disease may be extremely 
heterogeneous in its causes, a genetic risk factor conferring susceptibility to disease is 
more likely to be caused by the same genes across the population. That is, across a 
population, a disease may develop as a consequence of some combinations of risk 
factor genes, however each risk factor itself should be determined by the same set of 
genes. Since many of these factors – referred to as intermediate phenotypes – are 
quantitative, analysing them as such can increase the power to detect genes affecting 
them. Even so, genes influencing quantitative, as opposed to Mendelian, traits are 
more difficult to detect since there are more of them, and by definition each one must 
explain a smaller proportion of variation in the trait than if the trait was Mendelian. In 
general, the more genes there are involved in the control of a trait, the less variation 
each one individually explains. 
 
There is a current theory building on this idea that common complex diseases are 
controlled by many QTL. This theory suggests that the majority of QTL involved in 
controlling common complex disease are common (>5% minor allele frequency) in 
the population, are numerous and have modest effect sizes. The hypothesis states that 
because genes conferring only a modest increased risk to a given disease are unlikely 
to experience strong purifying selection, they act in a largely evolutionarily neutral 
manner which allows them to reach a moderate frequency in the population. More 
formally, this theory is known as the common disease / common variant (CD/CV) 
hypothesis (Reich and Lander, 2001), and while not universally accepted, there is 
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evidence to suggest common disease risk alleles conferring small and modest effect 
sizes do segregate in populations (Lohmueller et al., 2003). However, one alternative 
to this theory is that while there are indeed many alleles of relatively small effect 
segregating for a given trait, they are very rare at each trait-related locus. This would 
make detection of such variants much more difficult. 
 
As previously stated, where there have been successes in mapping genes involved in 
complex disease, the genes uncovered have typically been rare high risk variants. 
This means that at the population level these alleles explain little of the total disease 
prevalence. In the context of public health, this can be expressed conveniently as the 
population attributable fraction (PAF), which can be thought of as the proportion of 
the disease that would be eliminated if the risk factor were removed. The PAF for 
rare high risk alleles in complex diseases is normally less than 10%, for example over 
150 rare high risk alleles have been identified for Alzheimer’s disease, but the 
combined PAF for all of these is less than 5% (Carlson et al., 2004). It is thought that 
common modest risk variants may contribute a much greater PAF to common 
complex disease than rare high risk alleles due to their higher frequency in the 
population (Risch and Merikangas, 1996). This explains why these genes are so 
important to find from a public health perspective, and why small to modest effect 
disease genes are what geneticists are now trying to map. With recent advances in 
both theoretical and technological fields, the potential for detecting such genes has 






As previously noted, linkage studies to determine the location of trait-affecting genes 
are not new. However, after the discovery of microsatellites and SNPs, and the ability 
to rapidly and efficiently score them, linkage scans became far more commonplace. 
As a consequence of their increasing popularity, there was also a great increase in the 
number and type of study design and the testing used to detect possible linkages. 
Initially, linkage was performed on binary phenotypes using family-based methods 
designed to trace the inheritance of specific trait-related alleles through a pedigree, 
and these methods typically required an explicit model of inheritance to be specified. 
Subsequently, less stringent tests were formulated, and later, tests which searched for 
linkage with quantitative traits, and which operated at a population level. 
 
The common uniting feature amongst all these tests for linkage is the underlying 
assumption that the same disease-related allele is physically linked to the same 
marker allele in all “affected” individuals within the same family (or in the case of 
quantitative traits, in all related individuals occupying one extreme of the phenotypic 
distribution). Note that for most methods the specific marker allele linked to the 
disease predisposing allele may be different across families, so long as within 
families it is the same. This implicitly assumes that the trait and marker loci are 
closely linked enough that recombination between them is rare. Indeed, this is a 
crucial aspect of linkage studies, as no linkages can be detected if there are too many 





Linkage analysis was initially only widely used for analysis of binary traits in the 
form of diseases in families within which the disease was segregating. To test for the 
presence of linkage, segregation of disease is correlated with markers of known 
location throughout the genome, hence determining an approximate region containing 
a disease locus. Classically, evidence for linkage is assessed via the lod-score, which 
requires specifying a mode of inheritance (i.e., whether the trait is inherited in a 
dominant or recessive manner) and estimating the recombination fraction between 
marker and trait loci using recombination events observed in the data. The 
recombination fraction, θ, is typically small when loci are physically close to one 
another and there are therefore very few recombination events (tending towards zero 
as the frequency of recombination drops), and is large (up to a maximum of 0.5) 
when the loci are a large distance apart. A value of 0.5 indicates the loci are acting 
statistically independently of one another, which is typically the case for loci many 
mega-bases (Mb) apart or on different chromosomes. 
 
Since this method requires the definition of mode of inheritance and specification of a 
number of parameters, it is often referred to as parametric (or model-based) linkage 
analysis. Other than the mode of inheritance of the trait, some of the other parameters 
needing specification are the trait and marker allele frequencies in the population and 
the penetrance of the trait. Penetrance refers to the probability that an individual 
exhibits the trait phenotype given a trait-causing genotype at the locus. Apparent 
incomplete penetrance (when the probability of exhibiting a phenotype is less than 
one despite carrying the susceptible genotype) can occur due to a number of reasons, 
 21 
although some of these reasons are recognised as unique phenomena themselves. 
Trait heterogeneity is one of these; if several different combinations of disease genes 
can all be responsible for causing a disease but no single gene alone, then individuals 
can display the trait phenotype without having the same genotypes at any given trait 
locus. Trait heterogeneity can also cause other problems for linkage studies if each 
gene can itself be entirely responsible for causing disease. In this case the penetrance 
of each disease gene is in fact one, although not every individual exhibiting the 
disease will possess the same genotype at any one of the disease loci. There is also 
the related phenomenon of phenocopies, whereby individuals (even within the same 
family) may exhibit the same trait due to different, and not necessarily genetic, causes 
(Forabosco et al., 2005). 
 
After specification of the model the recombination fraction is estimated using 
maximum likelihood, and the value of the recombination fraction that maximises the 
likelihood is given as the best estimate of its true value. Significance is determined by 
the maximum lod-score, which is the log10 ratio of the maximum likelihood score and 
the likelihood score at θ = 0.5 (corresponding to the null hypothesis of no linkage). 
Traditionally, a lod-score of 3.3 is used to demonstrate significant linkage at the 
genome-wide level, corresponding to a p-value more extreme than 0.0001 (Lander 
and Kruglyak, 1995). 
 
While this type of analysis has proven successful in the past to detect trait loci, 
particularly in Mendelian disease, there are a number of problems with parametric 
linkage analysis. The major problem pertaining to this type of linkage analysis relates 
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to the uncertainty with which the underlying genetic architecture of the disease under 
study can be predicted. The necessity of parametric linkage analysis to define a given 
mode of inheritance and set model parameters, while making the test extremely 
specific, also make it sensitive to errors in these parameters. Although testing a model 
specified with the correct parameters would have more power to detect linkage, in 
reality it is hard to know what these correct parameters are, and specifying the wrong 
mode of inheritance or setting inaccurate parameters can make it extremely difficult 
to detect linkages. It has been shown that linkage analyses are sensitive to the degree 
of dominance, although less so to the allele frequency estimates (Clerget-Darpoux et 
al., 1986). Consequently, there are also a range of other linkage methods that are non-
parametric (or model-free) in nature, and these can be much more powerful in 




Model-free methods of linkage analysis rely on the concept of identity-by-descent 
(IBD) sharing of alleles amongst relatives. Two alleles are said to be IBD when they 
both descend from the exact same ancestral allele in a common ancestor when traced 
back through a pedigree. Two alleles which are identical from a molecular point of 
view (for example, two “A” bases) but not definitively descended from the same 
ancestral allele are termed identical-by-state (IBS). Note that alleles that are IBD are 
always IBS, but the reverse it not necessarily true. Affected relatives will share alleles 
IBD at disease-causing and surrounding loci more often than expected by chance 
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alone, and by using markers this information can be used to find the disease-causing 
alleles. 
 
The first, and still one of the most commonly used, non-parametric tests for linkage is 
the affected sib pairs (ASP) test (Penrose, 1935). The ASP design tests if there is a 
significant increase in the average observed IBD sharing between each pair of 
affected sibs in the sample at each marker in the study. Across a sample of sib pairs 
the average expected IBD sharing at a given locus is 50%, and a significant increase 
over this amount indicates linkage between the marker and the gene contributing to 
the cause of the disease. There are now many other tests based upon the ASP design 
which allow for more complex situations. For example, some analyses allow a more 
generalised family structure and are now capable of including complex pedigrees, i.e., 
pedigrees containing multiple generations and inbreeding loops (where it is possible 
to trace a route in the pedigree between two individuals, and return back to the first 
individual by a different route). Other ASP design extensions allow missing data, and 
some allow data from multiple markers to be used simultaneously (Forabosco et al., 
2005). 
 
While non-parametric tests have the advantage of not having to specify large numbers 
of parameters, they do suffer from having to discard relevant information, for 
example by leaving out unaffected relatives from the analysis. As a result, there are 
occasions where a correctly specified parametric test will out-perform non-parametric 
methods, but in general it is now commonplace for non-parametric methods to be 
used. One advantage of non-parametric methods is that often large pedigrees with 
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multiple affected individuals (favouring classical linkage analysis) are hard to find, 
and therefore collecting many smaller families with two affected sibs is a more 




As with linkage analysis of binary traits, family data are the focus of methods 
designed to analyse quantitative traits. The first wide-spread linkage method used for 
the analysis of quantitative traits was Haseman-Elston regression (Haseman and 
Elston, 1972). This method is still in use, and has also been the foundation for various 
extensions and numerous other methods which are based on the same idea. The 
original Haseman-Elston regression utilises sib-pairs and looks for a correlation 
between estimated IBD sharing of the sibs and the squared trait difference between 
the sibs. Under the null hypothesis of no linkage the slope of the regression line is 
zero; any significant departures from this should be negative in sign since squared 
trait difference should increase as IBD decreases, thus the test is one-sided (Feingold, 
2001). 
 
Extensions to the original Haseman-Elston regression method include allowing more 
distantly related pairs of individuals to be used in an analysis (Amos and Elston, 
1989), and also to allow using many different types of relative pairs in the same 
analysis (Olson and Wijsman, 1993). Some variations of the test alter the dependent 
variable; instead of using the squared trait difference between a pair of relatives, an 
alternative function of the trait values is used. For example, using the mean-corrected 
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trait product as the dependent variable yields a better estimate of the effect of the 
locus than simply the squared trait difference (Feingold, 2001). Other alterations of 
the method adopt a more selective approach in the samples used. Two manifestations 
of this sort of test use sibling pairs in the study only if together they exhibit either 
extremely concordant (at either extreme of the distribution) or discordant trait values. 
By selecting such individuals at the extremes of the distribution, the power of the test 
can potentially be increased since the difference in the amount of IBD sharing 
between pairs at different ends of the distribution (in the concordant pair analysis), or 
between the discordant pairs, will be maximised. 
 
There is also another class of linkage method used primarily for analysing 
quantitative traits (although applications to binary traits are possible), called variance 
components (VC) analysis. VC analysis models the phenotype in such a way that it is 
decomposed into segments accounting for different parts of the total trait variation. 
Typically these components are a random QTL variance component modelled by an 
IBD matrix (which is specific to a given location), a variance component pertaining 
to the remainder of the polygenic effects, and a non-genetic (environmental) variance 
component. It is usually assumed that these components have no covariance (Amos 
and de Andrade, 2001). Maximum likelihood is used to evaluate the model under the 
null hypothesis of no linkage and the alternate hypothesis of linkage, and a likelihood 
ratio test (LRT) is used to accept or reject the null hypothesis (Blangero et al., 2001). 
This test is performed at incremental steps along the genome to find the most likely 
QTL position (Blangero, 2004). VC analysis is more powerful than Haseman-Elston 
regression when the trait being analysed is normally distributed, and has the 
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significant advantage of being able to analyse family data from large pedigrees, and 
not rely on specific relative pairs. However, type I errors (false positives) are inflated 
when the trait is not normal (Feingold, 2001). 
 
While VC analysis and other linkage techniques have proved extremely useful for 
detecting high risk variants, linkage tests do not have sufficient power to detect small 
to moderate effects, certainly not less than 10% of total phenotypic variance 
(Forabosco et al., 2005).  This is because power to detect effects of a given magnitude 
is a function of sample size, and for smaller effects the sample size required to reach 
significance is far beyond that generally available to collect within families, or even 
across multiple families. This is especially the case for late onset diseases such as 
Alzheimer’s, although to some extent this problem can be offset by using an age-of-
onset quantitative phenotype instead. Additionally, in most studies there are not 
enough recombination events within families to be informative for densely packed 
SNPs, therefore dense maps provide little extra information and sparse marker maps 
are deemed sufficient. However, using sparse marker maps for linkage has a different 
consequence - typically the confidence intervals for putative QTL span hundreds of 





After the initial success of linkage studies, it was evident that less had been 
discovered about the genetics of common complex diseases (and traits in general) 
than was expected. In an influential piece of work in 1996 it was demonstrated using 
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binary phenotypes that with realistic effect sizes, linkage studies did not have 
sufficient power to detect loci using the sorts of sample size that were feasible (Risch 
and Merikangas, 1996). In the same paper it was also demonstrated that by using a 
different approach, that of association studies, power was much greater to detect 
genes of smaller effect size than it was for linkage. Association tests show greater 
potential for identifying the modest risk genes that are most likely to be involved in 
controlling common complex human disease. 
 
Association is fundamentally different to linkage in its concept, although both 
techniques rely on markers in close proximity to QTL in order to detect their 
presence. Where linkage requires the same marker allele and QTL allele to remain 
together in related affected individuals, the same is not necessarily true for 
association. In essence, association hypothesises that the marker being tested is 
actually the causative variant affecting the trait, and assesses the statistical evidence 
across the population to support this theory. The technique was originally applied as a 
direct test for association of variants in a candidate gene type approach, where likely 
genes were sequenced and markers were tested for association with the disease 
(Kruglyak, 1999). In reality however, it is extremely unlikely that the causative 
variant happens to be one of the typed markers being tested. 
 
In order to detect QTL, association studies rely on a phenomenon known as linkage 
disequilibrium (LD) between the tested marker and a causal variant. While this is also 
true for linkage studies, for association the LD must be present at a population level, 
not only a family level (which is trivial for close loci as a consequence of direct 
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transmission from parents to offspring). Unsurprisingly then, in general association 
studies are performed population wide, and make no special attempt to sample 
multiple related individuals. Indeed, sampling related individuals in population-based 
studies can cause additional complications for analysis, as will be discussed 
subsequently. Some tests for association do exist in which the basic unit is a nuclear 
family, although these still depend on LD between the marker and causative locus at a 
population level. Examples of these are the transmission disequilibrium test (TDT), 
quantitative transmission disequilibrium test (QTDT) and family-based association 
test (FBAT). For the remainder of this Thesis, the focus will be study designs which 
utilise population-based data, therefore these family-based association methods shall 
not be discussed further. 
 
As will be described more fully in due course, the reliance upon population-wide LD 
means a denser marker map is required to perform association studies. Consequently, 
when an abundance of new markers were made available through sequencing projects 
such as HapMap (The International HapMap Consortium, 2005), and more efficient 
genotyping methods became available, this caused a shift in study design. Where 
previously linkage studies were targeted to one or a small number of specified genes, 
the advent of association sparked a progression to use all of the new information 
provided, rather than specific parts. Hence association studies became truly genome-
wide and inspired a move towards indirect testing, hoping to detect QTL anywhere in 
the genome by virtue of LD, rather than the traditional direct testing (Collins et al., 
1997). Indirect association has the benefit of requiring no prior assumptions about the 
genomic location of disease-influencing variants, and is therefore innately appealing 
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Linkage disequilibrium refers to the non-random association of alleles between two 
loci, causing certain alleles to appear together more often than would be expected by 
chance alone. There are many population genetic factors that can create LD between 
loci – genetic drift, selection and mutation for example – but unless sustained by a 
force such as selection, LD will decay over time. This decay of LD between loci 
occurs as a consequence of recombination, and since recombination happens more 
frequently between loci further apart, in general LD persists longer between more 
closely linked loci. Between very tightly linked loci it is possible for LD to persist for 
many generations without being eroded, but LD can also exist over much longer 
regions, and it is not unknown for LD to persist even through recombination hotspots 
(The International HapMap Consortium, 2005). 
 
Linkage disequilibrium technically exists between any number of loci considered 
jointly, although usually only pairwise measures of LD are considered. Given that the 
majority of SNP loci have only two alleles, a single LD measure is enough to capture 
all LD information present at those loci, although for loci with more alleles there is an 
LD statistic for each combination of alleles. LD is measured using the coefficient of 
linkage disequilibrium, known as D. For two biallelic loci, A (with alleles A and a) 
and B (with alleles B and b); 
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D   =   pAB   -   pApB 
where pAB is the frequency of the AB haplotype in the population, and pA and pB are 
the population frequencies of the A and B alleles. In this case, where the loci are 
biallelic, the coefficient of linkage disequilibrium, D, between all alleles is the same 
(i.e., DAB = Dab = -DAb = -DaB), therefore no subscript is required. If D is equal to zero 
then no LD exists between those loci, and the alleles are therefore behaving 
statistically independently of one another (Slatkin, 2008). 
 
The coefficient of linkage disequilibrium, D, is not the best descriptor for the level of 
LD between two alleles, although the two other measures of LD more frequently used 
are both derived from D. The first of these is D’, which is the ratio of the observed 
value of D to the maximum value of D possible given the allele frequencies. D’ 
ranges from minus one to one, tending away from zero as the level of LD between 
alleles increases. The sign attached to a D’ value reflects whether the alleles are in 
coupling or repulsion (i.e., more often found on the same chromosome together, or on 
opposite chromosomes), and it is the absolute magnitude of D’ that reflects the level 
of LD. D’ is particularly useful to detect recombination, since it only has the value 
one if at least one of the four possible haplotypes is not present, indicating that 
recombination has not occurred. The second other measure of LD is called r2 and this 
has a value between zero and one. R2 is the squared statistical correlation between 
two alleles, and this property of r2 is one reason why in general it is used more often 
than D’, since it provides an indication of which SNPs are highly correlated and can 
therefore be used as proxies for each other (often called tag SNPs). r2 is also more 
sensitive to the allele frequencies at the two loci than D’, as r2 can only be one when 
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both alleles have the same frequency. The importance of the ability of SNPs to serve 
as proxies for each other shall be discussed in greater detail subsequently. 
 
LD is essential for successful association studies because when testing markers for 
association, even those from within candidate genes, it is highly probable that none 
will be a causative locus. However, the estimated effect size of a tested marker is a 
function of both the true effect of the causative QTL and the level of pairwise LD that 
exists between the marker and this QTL (Blangero, 2004). With this being the case 
and due to the fact that LD decays with distance, a much denser marker map is 
required for association compared to linkage. As stated previously, the HapMap 
project was responsible for cataloguing a large proportion of the common human 
genetic variation world-wide (four distinct populations were analysed), and 
discovered a large number of novel SNPs which could be exploited in association 
studies. 
 
The International HapMap Consortium genotyped over one million SNPs in 269 
samples in the first pass (The International HapMap Consortium, 2005), and at the 
second pass over 3.1 million SNPs in 270 samples were genotyped (The International 
HapMap Consortium, 2007). Interestingly, for the European samples in the study, the 
common SNPs (minor allele frequency ≥ 0.05) had a mean maximum r2 – that is the 
mean of all SNPs’ maximum LD value with another SNP – of 0.96 to any other typed 
SNP, and even the rare SNPs (minor allele frequency < 0.05) had a mean maximum r2 
of 0.79. This illustrates how each SNP in the genome is generally well tagged by at 
least one other SNP, and it is likely that many others do so almost as well. It was 
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estimated that to capture the variation from all common SNPs in Phase II of the 
HapMap project with an r2 of ≥0.8, only slightly more than 500,000 SNPs would be 
needed. If HapMap has done a sufficient job of capturing most of the genome-wide 
SNP variation present, this means that almost all the common SNP variation in 
humans is tagged with on average 80% efficiency in just half a million SNPs (The 




With the availability of a larger number of SNPs to analyse and their greater power 
compared to linkage, association studies began to be utilised for binary traits. The 
degree of precision afforded by the much greater number of markers used in 
association enabled studies to fine-map QTL to regions of 5-10Kb or less once a 
putative QTL had been initially detected using linkage. However, as opinions on the 
likely nature of QTL began to change, association studies became more attractive as 
an alternative, not just supplementary, way to analyse data. Just as with linkage, there 
are now association methods for analysing both categorical (in most circumstances 
with human data this means binary) and quantitative traits. 
 
Population-based association of binary case-control phenotypes requires careful 
selection of an appropriate dataset. Unlike in linkage and family-based association, a 
single or multiple affected probands across several families are not sufficient for an 
analysis. Ideally, hundreds or even thousands of unrelated affected individuals and an 
equal number of carefully selected matched controls are required to perform an 
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analysis. Usually the number of affected individuals with data available is the limiting 
factor on the sample size of the study, but having as many as possible is crucial since 
power is partly determined by sample size. Controls should be matched as closely as 
possible to cases for factors such as age, sex, ethnicity, socio-economic status and 
other relevant variables (for example smoking) for the study. Failure to select 
appropriate controls may results in spurious associations. 
 
The classical way of assessing evidence for association with a binary trait is by using 
case-control data in a contingency table, where rows and columns are tested against 
the null hypothesis of statistical independence. This can be performed using a 
genotype model which produces a 2x3 contingency table, or as is more usually the 
case, by using a 2x2 table and assuming an additive model for allele action. It is also 
possible to specify a fully dominant / recessive mode of inheritance and test this in a 
2x2 contingency table. The additive test is the one most frequently used, and 
essentially states that the heterozygote risk is expected to be intermediate between the 
two homozygote risks. A Pearson one degree of freedom (df) test can then be used to 
test for association. One problem with this test is that it assumes Hardy-Weinberg 
equilibrium (HWE) in cases and controls combined, which may not hold. However, a 
way around this is to use the Cochran-Armitage test instead, which also assumes an 
additive mode of action for the locus but does not assume HWE (Balding, 2006). 
 
A slightly more complex way to analyse case-control data is using logistic regression. 
Logistic regression uses the logit transformation to assess the log odds of disease, and 
can perform either a 2df genotype test or a 1df additive test. Significance is tested via 
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a likelihood ratio test to compare the full model (with a SNP effect) with the reduced 
model not containing a SNP effect. One benefit of logistic regression is that it is 
extremely flexible and models can be specified in a way that tests much more specific 
alternative hypotheses (for example, for dominance or for an interaction). Logistic 
regression can also be extended in order to fit covariates in the model which may not 
be of direct interest themselves but that need to be accounted for, such as age or sex 
for example. Similarly, multiple SNPs may be fitted in the model simultaneously, and 
a general test of their overall association can be performed. In the simplest case, 
logistic regression models are equivalent to the simpler contingency table counterpart, 
however the additional benefits afforded by logistic regression makes it a very useful 




In order to dissect complex traits, researchers are turning more and more to the 
analysis of quantitative phenotypes. With the advent of association analyses, 
techniques have had to be developed to deal with this demand. Typically, the method 
of analysis used on quantitative data is simple linear regression, where the SNP 
marker can be specified as either a linear covariate (i.e., a 1df test where the effect is 
additive), or as a fixed effect where each genotype has its own unique effect on the 
trait. In this case, each genotype can be tested individually in a 1df T-test, or a global 
F-test for association of all genotypes can be performed. Just as with Haseman-Elston 
regression and logistic regression, additional “nuisance” covariates and fixed effects 
can be fitted in the model to better fit the data. A two-sided T-test can be used to test 
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the effect of the marker in the additive model, or an F-test for the genotypic model, a 
significant result rejecting the null hypothesis of no association. 
 
An alternate but related method of analysis to regression is analysis of variance 
(ANOVA). This partitions the variance due to each factor in the model and performs 
an F-test to assess the null hypothesis that the amount of variance attributable to any 
given factor is equal to zero. The F-statistic produced for a genotype effect using this 
test should be the square of the T-statistic produced for the corresponding genotype 
using linear regression. As with regression, additional factors not of primary interest 
may be included. Both linear regression and ANOVA require that trait residuals are 
normally distributed, and usually means the trait is approximately normally 
distributed itself. If a trait is not normally distributed, or there is difficulty obtaining 
normal residuals, a transformation of the data can be performed in an attempt to solve 
this problem (for example, a log-transformation or square-root transformation). 
 
As with the analysis of binary traits by association, the norm nowadays is to 
interrogate the whole genome by testing a vast array of SNP markers. While this 
method is exhaustive in its search for association, it also introduces something which 
had never been a serious problem until now; multiple testing. Multiple testing is not 
the only issue pertaining to genome-wide association studies (GWAS) however, as 
there are a number of other matters which also require consideration. Some of these 
issues relate initially to study design, but also have ramifications for both the analysis 
of data and subsequent interpretation of the results. As this thesis is concerned with 
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using association methods to detect QTL in complex traits, many of these issues are 




Issues concerning the design and analysis of GWA studies can be decomposed into 
matters concerning the study population, marker panel selection, method of analysis, 
interpreting the results and replication of any positive findings. There are very few 
definitive solutions to these issues however, and the literature is divided on the best 
way to perform a GWAS. Nevertheless, a number of standard procedures have arisen, 
and while not necessarily ideal, they are broadly recognised as the most acceptable 




“Study population” refers more specifically to the population from which the samples 
for the study were taken, since it is rare that data from the entire population will be 
collected. There are a number of considerations regarding the study population, and 
one of the most important of these when designing a GWAS is sample size. This 
problem is clearly not unique to association studies, but it is a crucial consideration 
nonetheless. In general, the larger the study the more power there will be to detect 
genes of small to modest effect, and while the cost of a study scales linearly with the 
number of samples, this is not the case for power. Having too few samples will 
severely under-power a study to the extent that any putative associations will be 
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suspect unless the effect size is extremely large, because power to detect small to 
moderate effects will be negligible. Consequently, it is important to reach an 
appropriate trade-off between the cost of the study and an acceptable power to detect 
effects of a given magnitude. 
 
Another important consideration for population-based association studies is ensuring 
that samples are a randomly selected subset of the population as a whole (to the 
extent possible - cases for disease studies are obviously selected based on being 
affected). Unless specified by adding terms into the model, samples are considered 
independent, so selecting individuals that are related may introduce covariances to 
both phenotype and genotype that cause spurious results. It is also important that the 
demographic history of the population is known. In modern society, particularly in 
the developed world, it is common for many different populations to become 
admixed. Hidden population admixture can lead to false positives in GWA studies if 
both the allele frequencies and incidence of disease differ between recently admixed 
populations. 
 
The study population also affects the choice of SNP marker panel. Although choice 
of marker panel will be discussed further in the next section, it is important to 
emphasise here that it is critical the panel used to analyse a study population was 
designed with that population in mind. For example, using a panel in which SNPs 
were selected to tag an Asian population for analysis of data from a European 
population would not be optimal. This is because SNPs can vary in minor allele 
frequency and patterns of LD between populations. If SNPs selected on the panel 
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were identified in a population with a different history to the study population, then it 
is likely that some will not even segregate in the study population. Additionally, some 
SNPs missing from the panel may no longer be captured by LD for the study 




A major reason for the increasing prevalence of association studies is the increase in 
availability of relatively cheap and fast-throughput SNP genotyping platforms. 
However, the choice of marker panel for a GWAS is very important. One reason for 
this has already been described, however there are several more. New high-
throughput technologies are enabling ever more SNPs to be genotyped on a single 
panel, but even so the cost of GWA still scales with the number of SNPs that are 
typed. Unlike with sample size where in general more is better, and money is usually 
the limiting factor, for SNPs there is a different trade-off. Due to the reliance of 
association on LD, a relatively dense marker map is required. This is because LD 
decays quickly over large distances and the aim is to capture as much genetic 
variation in the genome as possible. Preferably, good genomic coverage would be 
achieved with as few markers as possible however, to avoid generating an excess of 
redundant information which would exacerbate the problem of multiple testing. When 
r2 between neighbouring SNPs is high, one SNP captures almost all variation at the 
other, therefore only one of them needs to be typed. However, LD is not uniform 
across the genome and in some places the variation can be reliably captured with a 
fraction of the number of markers of other places. The ideal SNP panel would 
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therefore have an enrichment of SNPs in regions where LD is typically quite low, and 
be slightly more sparse where LD is high. 
 
Even so, there is still a somewhat arbitrary choice of what level of LD on average is 
acceptable, in order to capture as much genotypic variation as possible. For example, 
requiring that at least one SNP on the panel has a minimal r2 of 0.7 with each SNP not 
included will not provide as much power as if an r2 of 0.8 was used, because power is 
partly a function of LD between the marker and causative locus. However in the latter 
case, many more SNPs would have to be included. As already mentioned (and will be 
discussed in more detail shortly), the major drawback of simply including all or most 
segregating SNPs in the analysis is the multiple testing burden this imposes on the 
study. 
 
There is a variety of options of SNP panel to choose from. Two of the leading 
manufacturers of SNP chips are Illumina (www.illumina.com) and Affymetrix 
(www.affymetrix.com), both of which offer several different panels depending on the 
level of SNP coverage required. A typical panel includes upwards of 300,000 SNPs, 
although there are now chips which contain 500,000 and even up to a million SNPs. 
The companies also offer different panels depending on the population under study; 
for example there are different SNP chips for use in European and African 
populations. Of the two companies, only Illumina selects its SNPs based on 
maximising the overall variation captured by the SNPs and reducing redundancy. 
Affymetrix initially produced panels based on enzyme restriction sites, and 
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subsequently filled these panels with an essentially random selection of SNPs spaced 




The majority of association studies use population-based data rather than family data, 
or at least operate under the assumption that each individual is independent, i.e., 
unrelated. In reality this is not always possible, and also ignores the fact that if 
ancestors are traced back far enough, any two people are related. In studies where 
known family members are included, or some other sort of population structure or 
relatedness is expected, there are ways to account for this in the analysis. If 
unaccounted for, hidden population stratification (or cryptic relatedness as it is also 
known) can cause spurious associations, just as with using admixed populations. 
 
There are a number of ways in which either known relationship information or cryptic 
relatedness can be accounted for. Where known relationships exist, the typical 
method is to use a relationship matrix to fit a random polygenic term into a regression 
model. This accounts for the genome-wide covariances between relatives and allows 
a test to be performed for association at a specific marker. The relationship matrix for 
this method is based upon expected values of IBD sharing for each type of relative 
pair; for example, full sibs are expected to share on average 50% of their genome 
IBD, and this value decreases for more distantly related pairs of individuals. At any 
given locus however, the actual proportion of alleles shared IBD between full sibs 
can be zero, one or two with probabilities 0.25, 0.5 and 0.25. This means that the 
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estimated amount of IBD sharing over multiple loci will be wrong 50% of the time. 
While using a relationship matrix derived in this manner is on average correct, purely 
by chance the amount of alleles actually shared IBD by two full sibs across the 
genome may vary considerably, leading to inaccurate estimates of genome-wide IBD. 
 
Inaccurate estimates of genetic relatedness can lead to incorrect results that generate 
false positives and obscure true positives, both of which want be minimised in GWA 
studies. There is an alternative, more accurate, way to estimate genetic relatedness 
between individuals that may be more suitable. Genome-wide marker data can be 
used to give an estimate of relatedness across the genome by averaging marker 
similarity at each individual locus. This is not entirely straightforward however, since 
only IBS between individuals is actually observed, and IBD must be inferred. This 
impacts upon accuracy, but while these methods inevitably introduce some degree of 
error, programs do exist that make reasonable estimates of true IBD sharing from 
dense marker data. 
 
Another way of dealing with cryptic population relatedness is to use something called 
genomic control (Devlin and Roeder, 1999). Genomic control makes no attempt to 
account for relatedness between individuals in the tests, but instead induces a post-
hoc adjustment to p-values produced from the tests. This is because the effect of 
population substructure on the test statistic should be constant throughout the 
genome, hence test statistic inflation due to substructure is the same for all markers 
(Bourgain and Genin, 2005). To account for this, observed p-values from a genome-
wide scan are plotted against the expected p-values from the null hypothesis on a Q-Q 
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plot. If there is a general inflation of all observed p-values from the genome-wide 
scan this indicates that cryptic relatedness exists in the population. To adjust for this, 
a deflation factor known as λ is calculated as the ratio of the median expected p-value 
to the median observed p-value. All p-values are then multiplied by this deflation 
factor, thus adjusting the results for the presence of population structure. 
 
One other technique for removing problems associated with either population- or 
pedigree-based relatedness is to identify groups of individuals using clustering 
approaches. A similar approach is principle components analysis (PCA), which is a 
data reduction technique that attempts to assign individuals into a number of groups 
based on covariances at marker loci. The principle components (PCs) can then be 
used as factors in a regression analysis so that phenotypic covariance caused by these 




Although some methods of analysing data are more widely used than others, there is 
no consensus upon which is best. In all likelihood, the best method for any given 
dataset will vary depending on a number of unknown factors such as the number of 
underlying QTL present and their frequency and effect sizes. However, one aspect 
that remains constant in the majority of GWA studies is that SNP data are 
interrogated one SNP at a time. Generally, the same test is performed on each SNP in 
a stepwise fashion along the genome, until the entire SNP panel has been used. This 
is undoubtedly the simplest way of analysing GWAS data, and has been moderately 
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successful to date. However, this may not necessarily be the most effective way of 
using the data, and there are a number of interesting alternatives. 
 
All alternatives of using a single SNP to analyse GWAS data naturally involve using 
more than one SNP at a time to test for association. The theory behind performing 
association with multiple SNPs is that more SNPs may better tag a causative variant 
which exhibits low LD to typed SNPs. If no single SNP has high r2 with a causative 
variant then single SNP analyses will fail to detect the QTL unless power is very high 
due to other factors such as sample size. However, QTL may well be in high LD with 
certain combinations of alleles at multiple nearby loci. Specific combinations of 
alleles inherited together on the same chromosome are known as a haplotype, and the 
existence of LD causes some haplotypes to become more frequent than would be 
expected based solely on the frequencies of their SNPs. Fundamentally, the idea 
behind using multiple markers in association studies is to attempt to locate QTL by 
virtue of identifying haplotypes conferring higher or lower risk to disease. 
 
While all alternate methods for GWA studies use multiple SNPs, the way in which 
the multiple SNPs are used determines the differences between them. The simplest 
way of using multiple SNPs is to incorporate more SNPs into the regression model, 
analogous to the way extra covariates and fixed effects are fitted for example. The 
only difference is that unlike the covariates these extra SNPs are of interest, and can 
be tested individually in 1df or 2df tests (depending whether the SNPs are 
parameterised for an allelic or genotypic test), or globally in a F-test of all SNPs in 
the model. Adding large numbers of SNPs into multiple regression models can cause 
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problems however, since each SNP added takes up an additional degree of freedom 
for performing a global test of association. It is possible to avoid over-
parameterisation of the model by implementing a step-wise procedure that determines 
which SNPs should be kept and which left out. Step-wise procedures are defined as 
either forwards or backwards depending on whether SNPs are added (forwards) or 
removed (backwards) from an initial model. SNPs are accepted or rejected from the 
model based on a model comparison metric such as the AIC (Akaike’s Information 
Criterion), and in this way the optimal model can be found. 
 
Fitting multiple SNPs in models like this only tests the marginal effects of each of 
SNP, that is, the main effect each SNP has individually on the trait. Most SNP effects 
are expected to be main effects, however, some genetic effects are epistatic in nature. 
“Epistatic effects” (or epistasis) refers to effects which are the consequence of an 
interaction between two (or more) loci. To detect epistasis using multiple regression, 
interaction terms must be explicitly added to the model and tested. While there is only 
one interaction term for two SNPs (using an additive model), the number of possible 
interactions increases rapidly as the number of SNPs increases. In GWA studies 
epistatic effects are usually ignored at least initially, since the number of two-way 
interactions possible given the number of SNPs in a typical GWAS is prohibitively 
large, and even more so for interactions involving larger numbers of SNPs. 
 
Another more sophisticated method of using multiple SNPs to test for association is 
haplotype analysis. This is no easy task however, and there are many things to think 
about when considering using haplotypes for a GWAS. Not least of these is obtaining 
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haplotypes in the first place, since only single-locus genotypes are generated from 
SNP panels, not multilocus haplotypes. While there are technologies available to 
obtain haplotypes directly from DNA samples, these are extremely expensive and 
therefore generally not a favoured choice for most GWA studies. An alternative way 
to obtain haplotypes is to use a statistical algorithm which estimates haplotypes and 
their frequencies in the study population from the genotypes. Although these 
algorithms inevitably introduce some level of error into the data, some programs are 
able to generate very accurate estimates of the haplotype structure of the population. 
One suite of such programs that was originally based on the Expectation 
Maximisation (EM) algorithm (Excoffier and Slatkin, 1995) is PHASE, fastPHASE 
and warpPHASE (Stephens et al., 2001). 
 
Once haplotypes are obtained, a decision regarding the method of analysis must be 
made. To some extent this may also be reliant upon the algorithm that was used to 
generate the haplotypes, since different algorithms provide different outputs. Some 
algorithms give only the most likely haplotype pair for each individual for example, 
while others give the probability of each possible haplotype for each individual. Both 
the type of analysis performed and the interpretation of results are dependent on the 
data that are available from the haplotyping algorithm. Regardless of the type of data 
provided, there is a wealth of different options for how this data can be used. One 
particularly pertinent issue is how to deal with rare haplotype classes for example. 
From a statistical standpoint it is preferable to remove rare classes prior to analysis, 
but it is far from clear that this is the optimal way of dealing with these classes. 
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Haplotypes provide a very interesting and potentially powerful new way to look at 
GWAS data, yet thus far they are little used and questions remain regarding their 
application. Where haplotypes have been used in the literature it is sparingly, often as 
a last resort, and with sub-optimal analysis methods. One of the aims of this project 
was to investigate genome-wide data using haplotype approaches, and as a result a 
much more detailed discussion of haplotypes and their application to GWA studies 




The explosion in availability of genome-wide SNP data has undoubtedly been 
beneficial for attempting to identify loci influencing quantitative traits. However, it 
has also brought with it a problem of its own. By testing many more SNPs for 
association, the nominal 5% significance threshold is no longer appropriate to ensure 
an acceptable type I error rate at the genome-wide level. Where a single test might be 
considered significant if it exceeds a nominal p-value threshold of 0.05, performing 
more than one test requires this threshold to be altered. If no adjustment is made, then 
as the number of tests performed increases, it is increasingly probable that one will 
report a significant association by chance alone. For example, when performing 100 
tests with a nominal p-value of 0.05, the expectation is that a total of five tests would 
reject the null hypothesis by chance even if no association was present. 
 
The solution frequently used in the literature to the problem of multiple testing is to 
adopt a Bonferroni correction to the nominal p-value. This involves dividing the level 
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of significance required by the total number of independent tests performed, and 
yields a point-wise threshold appropriate for genome-wide significance. So, in the 
example above with 100 tests requiring an overall p-value of 0.05 for significance, 
the p-value required to show significance for an individual test would be 5x10-4. The 
Bonferroni correction is a useful tool to assess significance of genome-wide results, 
however it is not perfect. The problem is that it assumes all tests are independent, 
however this assumption is clearly violated in the case of SNPs due to the presence of 
LD. This results in the correction being too stringent, i.e., the p-value required for 
significance being too small, and therefore the number of type II errors (false 
negatives) in the results increases. As power is defined as one minus the false 
negative rate, clearly power is reduced by inflated type II error. 
 
In practice, while the Bonferroni correction is useful as a guideline for the level of 
significance required to indicate true association, the significance threshold is often 
relaxed somewhat when interpreting GWAS results. However, this produces 
uncertainty regarding exactly how small a p-value must be in order to be considered a 
potential true association. Small QTL effect sizes may cause genuine signals to have 
non-significant p-values, and contrastingly, highly significant results may be entirely 
spurious, therefore unequivocal conclusions about which associations are real can be 
hard to draw. 
 
There is another way to determine significance for genome-wide analyses, although 
this also has disadvantages. Permutation analysis can be used to construct an 
empirical distribution of the test statistic under the null hypothesis of no association. 
 48 
This is achieved by permuting phenotypes with respect to genotypes in such a way 
that the LD structure remains intact, but any association between genotype and 
phenotype is broken. A genome-wide scan is then performed on the permuted data, 
and the most significant result is stored. Data is permuted a large number of times so 
that a distribution of the most extreme result is created, which can then be used to set 
a genome-wide significance level for the real data. While this method is very robust, 
it is extremely computationally intensive due to performing what amounts to 
thousands of genome-wide scans. Therefore it is more usual for the imperfect but far 




One of the major problems of any linkage or association study is knowing whether 
results exceeding the significance threshold are genuine associations. Rarely is an 
associated SNP located in the intron of a relevant gene for the trait under study, or 
code for a non-synonymous mutation. Most putative associations are to SNPs not in 
genes or even necessarily close to genes, and even if they are it is not immediately 
clear why the gene would affect the trait under study. To make results such as these 
more reliable, it is necessary to replicate them in an independent study. This is not 
always trivial, since there is not always a study population available to replicate the 
finding in. If no alternative study population currently exists, then the options are to 
either wait for a suitable study to commence, or spend more money genotyping a 
whole new study population. 
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Even when there is a population in which to attempt replication, results are not 
always positive. Generally a much reduced significance threshold (typically 0.05) is 
acceptable to act as replication of a putative association, but often even then the 
replication fails. If this is the case then, assuming the replication study was well-
powered enough to detect the effect, it is probable that the finding was a false 
positive. One other possible explanation for failed replication is that the effect is real, 
but that it is unique to the population it was discovered in. This could be due to either 
a founder effect, or random genetic drift causing the frequency of the mutation to 
increase in the discovery cohort. Either of these would result in there being little 
chance of replication, and is therefore likely to be of limited relevance to other 
populations, since the variant will be extremely rare or not present at all. 
 
If replication is successful, there is a much greater chance that the finding is a real 
genetic effect. However, in many respects this is just the beginning; the next task is to 
identify the causal variant and discover how this mutation mediates an effect on the 
phenotype. This task is made easier if the association is discovered in or near a 
candidate gene or gene rich region, although even so it is unlikely to be fast or cheap. 
To identify the causative mutation requires sequencing individuals in the study at the 
associated locus to ascertain what variation is segregating in the population within the 
region of interest. As sequencing is relatively expensive, it is of paramount 
importance to select which regions are of most interest to examine more closely. 
However, if the original finding is located in a gene desert it is hard to know how to 
follow the association up since there are no good candidate regions for sequencing. A 
possible exception to this is if the variant falls in what appears to be a regulatory 
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region, although in this case it can be hard to determine which gene or genes are 
being regulated. 
 
After identification of the causal variant, the next task is to elucidate how the 
mutation is affecting the phenotype. This can involve complex pathways that take 
years to fully understand, highlighting the fact that identification of QTL via 
association studies is only the first step, and there remains much work to be done 
subsequent to the discovery. The manner in which a project proceeds at this point is 
largely dependent upon the funding and resources available to the project, and 




This Thesis is concerned with detecting QTL using genome-wide association studies 
in human populations. A typical GWAS now entails hundreds or thousands of 
individuals and several hundred thousand SNP markers, and usually the traits of 
interest are disease endpoints, or intermediate phenotypes thought to play major roles 
in disease aetiology. The next chapter of this Thesis describes the analysis and results 
of such a study performed in a Croatian isolate population. The most interesting of 
the findings in this initial scan, a highly significant association between a region of 




The remaining two analysis chapters in this Thesis move away from using traditional 
methods to analyse GWAS data. Instead the focus moves towards looking at 
alternative methods of using genotype data in a GWAS, and in the fourth chapter 
several different multiple marker methods are used to analyse simulated data. The 
performance of these methods is compared and contrasted with that of traditional 
single SNP analysis. Subsequently, in chapter five, all these methods are applied to a 
subset of the data that were analysed in chapter two, to see how the methods compare 






Common complex diseases currently represent the primary health burden in the 
Western world (Zondervan and Cardon, 2004). Consequently, there is much interest 
in identifying novel genes involved in controlling these diseases. Early successes in 
mapping disease genes were typically achieved using highly-structured family based 
linkage designs (Forabosco et al., 2005), however more recently genome-wide 
association (GWA) studies have become the method of choice for determining the 
genetics behind multifactorial disease. This is for a number of reasons, the foremost 
of which is the recent improvement in SNP typing technology and the development of 
methods to quickly analyse genome-wide data. Additionally, a recent change in 
philosophy regarding study design means that quantitative intermediate phenotypes 
conferring increased disease risk to disease, as opposed to clinical disease endpoints 
themselves, are now more often the focus of study than was initially the case. This is 
not to say that direct disease association is not still popular however (see for example 
The Wellcome Trust Case Control Consortium, 2007). 
 
Intermediate phenotypes affecting disease generally have higher heritabilities and are 
less complex than the disease they are a risk factor for, therefore it is thought that 
disease loci will be detected more readily through analysis of these intermediate 
phenotypes than the disease. The change of emphasis towards analysing intermediate 
phenotypes reflects the shifting opinion regarding the likely nature of genes involved 
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in common complex disease - instead of being determined by a single dominant high-
penetrance gene, these diseases are the result of combinations and interactions of 
numerous genetic and non-genetic factors. 
 
This chapter describes the analysis and results from a typical genome-wide 
association study (GWAS). Data for this project were supplied by a large European 
collaboration involving a number of different study populations. The population used 
in this study is from a Croatian island in the Adriatic Sea off the Dalmation coast. A 
variety of phenotypes were measured and analysed, ranging from those contributing 
to disease risk, to those of a more purely academic interest, and to those necessary for 
accurate analysis of the data (i.e., covariates that may required to adjust the 
phenotype, such as alcohol intake). Data were analysed using a novel software 
package, GenABEL, in the statistical program R, which was designed to analyse 
GWA data in the presence of pedigree structure within the population. There were a 
number of interesting results produced in this study, at least one of which was worthy 




It is becoming relatively common for association studies to use genetic isolates as the 
study population. Genetic isolation simply means that the population is closed (there 
is very little or no migration into the population), and has been so since its founding 
some number of generations in the past. As a consequence, isolated populations 
generally have longer stretches of LD present in the genome (Shifman and Darvasi, 
 54 
2001), since there are a limited number of founder chromosomes. Also, isolated 
populations often have fewer generations since founding (leading to less 
recombination), and have no new genetic variation introduced other than by mutation, 
which itself is a very rare event. Long stretches of LD such as those exhibited by 
individuals from isolated populations are very useful for association mapping because 
they make it possible to detect causative variants with more distant SNPs - although it 
can make fine-scale localisation of the causative variant more difficult. 
 
Assuming panmixis (i.e., random mating within the population), genetic isolation also 
eliminates the problem of population stratification, which is one great advantage over 
using populations which are potentially admixed for GWA studies. Another 
advantage of isolated populations is that there is expected to be much less trait 
heterogeneity, i.e., a specific mutation influencing a particular trait is likely to be 
present in all individuals showing increased (or decreased) trait value (Bourgain and 
Genin, 2005). This is due to the fact that only a subset of all loci affecting any given 
quantitative trait (QT) will be segregating in the population founders, and if by 
genetic drift one of these loci reaches an appreciable frequency in the descendant 
population, all descendents showing an increase / decrease in the trait are likely to be 
identical by descent (IBD) for the same QTL, by virtue of common descent from the 
same ancestor. The probability of genetic drift raising the frequency of a QTL to a 
level where it is easier to detect is higher for isolated populations due to the relatively 
small size of the founder population (Kruglyak, 1999). Instead, if the disease was a 
consequence of a mutation within the population since the founding, genetic drift 
could still cause the allele to become frequent, however in this situation it may be 
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difficult to replicate the association as the same mutation may not be present in other 
populations. Nevertheless, it may still highlight an involvement of previously 
unknown pathways or genes in the trait. 
 
One further advantage of using genetic isolates is that individuals from these 
populations often have shared environmental exposures as a consequence of similar 
natural environments, diet and lifestyle choices influenced by their culture. Shared 
environments cause a reduction in the residual environmental variance usually 
associated with quantitative traits in more urban, admixed populations, and also 
reduce the proportion of trait variance attributable to gene-by-environment 
interactions. This can improve the signal-to-noise ratio for genetic effects by 
effectively increasing the heritability of traits in these populations (Heutink and 
Oostra, 2002). There have been many examples of successful studies using isolated 





The collaborative project of which the dataset analysed here is part is called 
EUROSPAN, and is comprised of five isolated study populations; these came from 
Croatia, Orkney, Sweden, Italy and the Netherlands. In addition to performing 
association analyses for these populations, EUROSPAN aimed to compare properties 
of the isolated populations. EUROSPAN was funded by the EU, and a portion of this 
money went to fund the genotyping of the Croatian part of the project, called 
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CROAS. The Medical Research Council (MRC), the University of Zagreb and the 
Institute for Anthropological Sciences (Zagreb) all provided additional funding. Also 
involved in analysis and processing of the data were the University of Edinburgh, the 
MRC Human Genetics Unit (Edinburgh), Public Health Sciences (Edinburgh), the 
University of Zagreb, the Institute for Anthropological Sciences (Zagreb) and 
genotyping labs in Germany.  
 
Croatia has become a focal point for genetic studies into QTL mapping and 
inbreeding in recent times as a result of harbouring many genetically isolated 
populations. There are a total of 1,185 islands along Croatia’s Adriatic coastline, 
although only 67 are inhabited. The inhabited islands have been isolated for many 
generations, and have very little migration between themselves or the mainland, 
making them perfect for association analyses. One island in particular was identified 
as a good candidate on which to perform genetic analyses; the island of Vis. The 
main aim of the CROAS project was to identify QTL involved in susceptibility to 






Participants in this study were mostly residents of two large villages on the Croatian 
island of Vis, although some participants also came from smaller villages on the 
island. The two main villages on this island are called Komiza and Vis, and 
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population sizes of these villages at the time the project commenced were 1,523 and 
1,776 respectively. All participants in the study were volunteers, and had given 
informed consent. Volunteers were a mixture of families and single individuals with 
no known relatives (referred to as singletons henceforth). In this way, a total of 1,062 
of the adult population of Komiza (N = 584) and Vis (N = 478) – approximately 65 - 
70% of the total adult population – were recruited to take part. These individuals 
ranged from 17 to 90 years of age. 
 
Detailed pedigrees were constructed for the study population using both historical 
family records collected during the fieldwork, and parish registers containing 
genealogical records dating back to 1838 and covering the period up to 1950 (the 
earliest records detail a couple born in 1838 and 1851 respectively). The largest 
pedigree joined 481 participants in a pedigree encompassing 7,242 individuals, with 
another 138 individuals comprising a further 58 small pedigrees of between three and 
13 individuals (the larger pedigree was subsequently split as some links were un-
informative for analysis). Pedigree reconstruction was performed before this PhD 
project commenced. Dr. Ozran Polasek and Dr. Ivana Kolcic of the University of 
Zagreb undertook reconstruction of the large pedigree. A total of 412 individuals 




Phenotyping was performed before this PhD project commenced. Fieldwork was 
carried out over two summers, May 2003 for Vis, and May 2004 for Komiza. During 
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this time, fasting blood samples were taken (20ml EDTA either for DNA extraction 
or liquid nitrogen storage of 2x0.5ml aliquots for future transformation; 4.5ml citrate 
for clotting factors and 10ml clotted blood for serum biochemistry), and plasma and 
serum were rapidly frozen and stored at -70˚C in 200µl aliquots using standardised 
sample handling procedures. A number of biochemical traits were recorded from 
these samples. Volunteers were also asked for their clinical histories and given 
questionnaires, in addition to having anthropometric and physiological measures 
taken. All traits measured, along with a brief description and an abbreviation used to 
refer to each trait, are shown in Table 2.1. Of the original 1,062 individuals, 1,031 
had data successfully recorded. 
 
 
TRAIT DESCRIPTION / UNIT ABBREV. 
Ankle Brachial Pressure 
Index 
Lowest of ankle pressure measure 
divided by highest of  brachial pressure 
measure 
ABPI 
Albumin Serum albumin Measured in g/l Albumin 
Body mass index Weight (kg) divided by the square of height (m) BMI 
Brachial circumference Measured in Mm Brach Cir 
Brachial width Measured in Mm Brach Wid 
Systolic pressure at 
brachialis left Measured in mm Hg Bra L 
Systolic pressure at 
brachialis right Measured in mm Hg Bra R 
Calcium concentration Measured in mmol/l Calcium 
Cholesterol Measured in mmol/l Cholesterol 
Cholesterol ratio Total cholesterol divided by HDL cholesterol Chol ratio 
Cortisol concentration Measured in nmol/l Cortisol 
Creatinine Measured in mmol/l Creat 
Ddimer Measured in ng/ml Ddimer 
Diastolic blood pressure Measure in mm Hg Diast 
Systolic pressure at dorsalis 
pedis left Measured in mm Hg Dor L 
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Systolic pressure at dorsalis 




Extracted from personality 
questionnaire using factor analysis. 
Described in Ivkovic et al, 2007. 






Extracted from personality 
questionnaire using factor analysis. 
Described in Ivkovic et al, 2007. 






Extracted from personality 
questionnaire using factor analysis. 
Described in Ivkovic et al, 2007. 
Personality and individual differences 
42: 123-133. 
Fev 
Fibrinogen 1 Measured in Zagreb (antibody method) g/l Fib1 
Fibrinogen 2 Measured in Glasgow (clotting factor assay) g/l Fib 2 
General health 
questionnaire  GHQ 
Glucose Measured in mmol/l Glucose 
High density lipoprotein Measured in mmol/l HDL 
Height Measured in m Height 
Hip circumference Measured in mm Hip Cir 
Hip-waist ratio Hip circumference (mm) divided by waist circumference (mm) Hip-Waist 
Low density lipoprotein Measured in mmol/l LDL 
Pulse pressure Difference between systolic and diastolic blood pressure PulseP 
Reactance From bioelectrical impedance analysis React 
Resistance From bioelectrical impedance analysis Resist 
Biceps skinfold thickness Measured in 1/10th mm Skin B 
Triceps skinfold thickness Measured in 1/10th mm Skin T 
Subscapular skinfold 
thickness 1/10
th mm Subscap 
Suprailiac skinfold 
thickness 1/10
th mm Suprail 
Systolic blood pressure Measured in mm Hg Syst 
Systolic pressure at tibialis 
posterior left Measured in mm Hg Tib L 
Systolic pressure at tibialis 
posterior right Measured in mm Hg Tib R 
Tissue plasminogen 
activator Measured in ng/ml Tpa 
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Triglycerides Measured in mmol/l Trigly 
Uric acid Measured in mmol/l UA 
von-Willebrand factor Measured in IU/dl vWF 
Waist circumference Measured in mm Waist Cir 




Genotyping was also performed before this PhD project commenced. Genotypes of 
each of the study participants were taken using the Illumina genotyping platform 
HumanHap300-Duo Genotyping BeadChip. This chip contains 317,503 tag SNPs, 
with a high density of SNPs in areas of the genome within 10Kb of a gene or 
evolutionarily conserved region, and approximately 7,300 non-synonymous SNPs 
(www.illumina.org). Of the original 1,031 individuals successfully phenotyped, 986 




Genotyping rates for both SNPs and individuals were calculated, and SNPs or 
individuals with <90% call rate were removed from analysis. This was to ensure poor 
quality or contaminated DNA (in the case of low genotype call rate per individual), 
and unreliable SNPs (in the case of low SNP call rate) were not used in the analyses. 
There was a total of 17 individuals removed from the study due to a poor genotyping 
rate, and the number of SNPs removed was 9,552. 
 
Table 2.1 List of traits analysed, with the units they were measured in and a brief description 
where necessary, and their abbreviation.  
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A detailed investigation into the genetic structure of the study population was 
performed to ascertain whether any genetic stratification existed between inhabitants 
of the two villages involved in the study. The program STRUCTURE (Pritchard et 
al., 2000), was used to perform this analysis, which was carried out by Dr. Caroline 
Hayward at the MRC HGU in Edinburgh. STRUCTURE allows the user to determine 
the number of sub-populations to be formed from the data using the parameter “k”. 
By gradually increasing the number of sub-populations it is possible to establish 
which individuals / groups are more genetically distinct. Results from this analysis 
indicated that genetic stratification was present within the study population, and this 
broadly corresponded to the individuals of Komiza and Vis clustering into groups 
representing their respective villages. In addition to this, it was also discovered that 
there were three individuals who failed to cluster with any other samples. These three 
successively emerged as singletons as k was increased until the two groups 
corresponding to villages resolved themselves at k = 5. As these three individuals 
were unable to cluster they were treated as genetic outliers, and were removed from 
further analysis. Two of these individuals were also present in those found to have 
poor call rate, therefore a total of 966 individuals remained in the analyses after 
quality control. The total number of SNPs retained for the analysis was 307,951. 
 
One further alteration was also made to the genotypic data before analysis, and this 
was to remove very rare genotypes for each SNP. With a total of 966 individuals in 
the analysis it was decided to remove (i.e., set to missing) genotypes with less than 10 
occurrences in the data (a frequency of ~0.01). This was performed because rare 
genotypes can erroneously inflate the magnitude of an effect estimate (particularly for 
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a genotypic test) if coupled with an extreme phenotype, due to the small sample sizes 




A total of 44 traits were analysed, all of which were quantitative. Before analysis, 
basic checking of the phenotypic data was performed. Distributions of the traits 
analysed were investigated, and where they were found to be non-normal, 
transformation was performed in an attempt to produce trait normality. Table 2.2 lists 
each trait analysed and shows which transformation was used, if any. 
 
TRAIT TRANSFORMATION FIXED EFFECTS / COVARIATES 
RANDOM 
EFFECTS 





Albumin Natural logarithm Age*Sex  
BMI Natural logarithm Age*Sex  
Brach Cir N/A 
Age*Sex 
BMI 










Bra L N/A Age*Sex BMI  
Bra R N/A Age*Sex BMI  





Cholesterol Natural logarithm Age*Sex BMI  
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Creatinine N/A Age Sex  
Ddimer Natural logarithm Age*Sex BMI  
Diast Square root Sex BMI  










Epqe N/A Age*Sex  
Epqn N/A Age Sex  























HDL N/A Age Sex  
Height N/A Age Sex  
Hip Cir N/A Age Sex  
Hip-Waist Rank transformation to normality Age*Sex  
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React Rank transformation to normality Age*Sex  
Resist N/A Sex BMI  
Skin B N/A Age Sex  
Skin T N/A Age Sex  







Syst Natural logarithm Age*Sex  





















Uric acid Square root Age*Sex BMI  
vWF Natural logarithm Age  
Waist Cir Natural logarithm Age*Sex Maternal ID 
Weight Natural logarithm Age Sex Maternal ID 
 
Table 2.2 Table showing all fixed effects, covariates and random effects fitted for each of the traits 
analysed. Transformations performed for traits are also indicated. A random polygenic effect 
accounting for relatedness, and a fixed effect accounting for population stratification are fitted for 
all traits, and are therefore omitted from the table. Age*Sex indicates that age, sex and an age-by-






The method of analysis for this study was a new technique called Genome-wide 
Rapid Association using Mixed Model And Regression (GRAMMAR – Aulchenko et 
al., 2007). This is a three-step technique designed to greatly reduce the computational 
time required to perform genome-wide association analyses in the presence of 
relatedness in the population. The first step involves analysing the data under a model 
including all relevant fixed effects and covariates, and a term for the polygenic 
variance that is modelled using a relationship matrix. The relationship matrix contains 
information on expected identity-by-descent sharing estimated from the pedigree. The 
vector of residuals calculated from this stage of the analysis is then used in the next 
step as the dependant variable in simple linear regression. Each SNP is tested as a 
fixed effect in a two degrees of freedom (df) genotypic test, or a covariate in a 1df 
additive allelic test, and p-values are recorded. In the final step, all SNPs with p-
values exceeding some pre-determined threshold are selected to perform the full 





Step one of GRAMMAR was carried out using ASReml (Gilmour et al., 2002). Traits 
were analysed under the following mixed model; 
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yi  =  µ + Σj βj cji + Gi + ei* 
 
where yi is the phenotype of the ith individual, µ is the mean, βj are the effects 
associated with the covariates and each level of the fixed effects, cji is the value of the 
jth fixed effect or covariate for the ith individual, Gi is a random polygenic effect for 
the ith individual, and ei* is the residual error term for the ith individual. It is the vector 
of residual error terms that is used in the second step of the analysis. The specific 
fixed effects and covariates included for each trait was dependent upon which were 
significant at the 5% level. Some traits also fitted an additional maternal 
environmental random effect since the shared environment induced by a similar 
upbringing in full-sib families can cause additional trait covariance. Details of the 
covariates and fixed / random effects fitted for each trait are in Table 2.2. Heritability 




The vector of residual errors from the first stage of the analysis was used as the 
dependant variable in simple linear regression with the following model; 
 
   ei*  =  µ + kgi + ei 
 
where ei* is the residual of the ith individual obtained from the previous step, µ is the 
mean, k is the additive effect of an allele (additive allelic model), or fixed effect of a 
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genotype (genotypic model), gi is the genotype of the ith individual, and ei is the 
residual error term for the ith individual. This part of the analysis can be carried out 
rapidly using the library GenABEL (Aulchenko, 2007) in the statistical software R (R 
Development Core Team, 2006). 
 
The score test performed for each SNP is as follows; 
, 
 
where g is the vector containing allelic or genotypic values (depending on whether it 
is the 1df or 2df test), E[g] is the expectation, superscript T represents the transpose 
of the vector and ê is a normally distributed error term. GenABEL calculates 
significance based on determining the empirical distribution of the score test through 
permutation (Aulchenko et al., 2007). 
 
Due to the use of residuals corrected for polygenic variation from the first stage of the 
analysis, the test statistic for each SNP is deflated below what it should be (i.e., made 
less significant). This is a consequence of factoring out some of the SNP effect with 
the random polygenic effect, however the magnitude of this decrease can be 
estimated using genomic control, which is also implemented in GenABEL. Observed 
p-values from the GWAS are plotted on a Q-Q plot against expected values from 
under the null hypothesis. The deflation factor, λ, is taken as the median value of the 
observed distribution divided by the median value of the null distribution, and 
corrected p-values are calculated as the product of the original p-values and λ. 
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Normally, where genomic control is used to correct for the presence of cryptic 
relatedness, λ takes on a value greater than one since the observed p-values are too 
small (i.e., more significant). However in this case there is a general inflation of 
observed p-values, therefore λ is less than one, and the p-values are adjusted 
downwards. Once the factoring out has been accounted for, a threshold is needed to 
determine which SNPs are significant enough to follow up with the more time-
consuming full model in GRAMMAR step three. Although the Bonferroni-corrected 
significance threshold for 307,951 SNPs is 1.62×10-7, for this study an initial 
threshold was set at 1×10-6 since in practice the Bonferroni correction is likely to be 




For the third stage of GRAMMAR, SNPs exceeding an arbitrary threshold (in these 
analyses set to 1×10-6) are analysed using the full model. This consists of all the 
appropriate covariates and fixed effects for that trait along with the random polygenic 
effect, but also includes the SNP effect. This is equivalent to the “gold standard” 
measured genotype (MG) approach. The model is; 
 
yi  =  µ + kgi + Σj βj cji + Gi + ei 
 
where all terms in the model are as previously described. This part of the analysis can 







The most appropriate model for each trait was determined by finding the fixed 
effects, covariates and random effects that were significant at the 5% level. For each 
trait, only those covariates with a biologically plausible explanation affecting the trait 
were tested. Table 2.2 shows the model fitted for each trait, in addition to any trait 
transformations that were performed. Table 2.3 provides a brief summary of how 




EFFECT NAME FIXED EFFECT / COVARIATE DESCRIPTION 
Alcohol Fixed effect 
Three categories; 
- No alcohol or less than RDA 
- Drinks over RDA in one type 
of alcohol 
- Drinks over RDA in two 
types of alcohol 
*RDA is intake of 0.5l beer, 0.2l of 
wine/bevanda, or 0.3l of hard liquor 
Smoking Fixed effect 
Five categories; 
- Never smoked 
- Former smoker, stopped for 
over five years 
- Former smoker, stopped for 
less than five years 
- Current smoker for less than 
10 years 
- Current smoker for over 10 
years 
 70 
Carbohydrate index Covariate Number (5-25) calculated from five questionnaire questions 
Healthy food 
consumption Covariate 
Number (6-30) calculated from six 
questionnaire questions 
Physical activity Covariate 
Number (1-4, at 0.5 intervals) 




Number (1-16) from one 
questionnaire question 




Heritability estimates were calculated during the first stage of GRAMMAR. A total 
of eight traits had a heritability that was not significantly greater than zero: ABPI, 
Brach Wid, Bra R, Calcium, Cortisol, Creat, GHQ and HDL. Significant heritabilities 
ranged from 0.179 (standard error 0.101) for Diast1, to 0.970 (standard error 0.067) 
for height. All heritability estimates with their standard errors and p-values can be 
found in Table 2.4. 
 
TRAIT HERITABILITY S. E. P-VALUE 
ABPI 0.109 0.112 0.166 
Albumin 0.662 0.091 2.98×10-8 
BMI 0.459 0.108 1.12×10-4 
Brach Cir 0.770 0.094 1.11e-12 
Brach Wid 0.166 0.100 0.051 
Bra L 0.296 0.108 3.68×10-3 
Bra R 0.166 0.106 0.059 
Calcium 0.101 0.106 0.169 
Cholesterol 0.187 0.103 0.037 
Chol ratio 0.203 0.102 0.024 
Cortisol 0.080 0.108 0.233 
Creat 0.047 0.093 0.309 
Table 2.3. Fixed effects and covariates, and how they were calculated for use in analyses. 
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Ddimer 0.290 0.097 1.64×10-3 
Diast 0.179 0.101 0.040 
Dor L 0.250 0.112 0.014 
Dor R 0.354 0.113 1.26×10-3 
Epqe 0.390 0.103 9.04×10-4 
Epqn 0.263 0.112 0.022 
Fev 0.305 0.106 1.69×10-3 
Fib 0.314 0.122 6.04×10-3 
Fib 2 0.311 0.118 4.94×10-3 
GHQ 0.113 0.102 0.136 
Glucose 0.594 0.108 2.45×10-7 
HDL 0.090 0.097 0.176 
Height 0.970 0.067 ~0 
Hip Cir 0.503 0.106 3.73×10-6 
Hip-Waist 0.335 0.106 1.11×10-3 
LDL 0.209 0.106 0.020 
PulseP 0.383 0.107 3.02×10-4 
React 0.273 0.110 7.55×10-3 
Resist 0.265 0.096 7.55×10-3 
Skin B 0.915 0.072 1.27×10-14 
Skin T 0.614 0.097 1.89×10-7 
Subscap 0.848 0.075 ~0 
Suprail 0.671 0.094 2.19×10-10 
Syst 0.237 0.107 0.026 
Tib L 0.328 0.116 3.07×10-3 
Tib R 0.284 0.115 7.76×10-3 
TPA 0.323 0.107 1.59×10-3 
Trigly 0.275 0.134 4.15×10-3 
Uric acid 0.389 0.105 3.62×10-4 
vWF 0.621 0.099 7.14×10-9 
Waist Cir 0.230 0.131 0.020 





Vast quantities of results were produced in this GWAS since each trait was tested at 
307,951 SNPs, for each of two models (additive and genotypic). Consequently, only 
results exceeding the significance level of 1×10-6 are presented. This is slightly more 
relaxed than the Bonferroni corrected threshold of p ≤ 1.62×10-7, although as already 
Table 2.4.Table showing heritabilities and standard errors for each trait. 
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noted, Bonferroni corrections tend to be too stringent due to the assumption of 
independence of SNPs. For an initial look at the results, it is justifiable to consider 
slightly less significant results since there may be a strong signal just short of 
reaching Bonferroni significance. The results from step two of GRAMMAR are 
shown in Table 2.5. Results from the additive model have been corrected using 
genomic control as discussed previously. A number of results from the additive 
model provide evidence for putative QTL for a variety of traits. In particular, there 
are strong signals of associations with uric acid on chromosome 4, vWF on 
chromosome 9, and creatinine on chromosome 5. At this stage, these associations are 
the most convincing due to very high significance for at least one SNP, and the 
presence of multiple other SNPs supporting the associations at these loci. 
 
 
ALLELIC MODEL GENOTYPIC MODEL TRAIT 
SNP name Chr P-value SNP name Chr P-value 
rs6974152 7 1.29×10-7 rs6448326 4 1.01×10-13 
rs2899046 4 1.62×10-7 rs10502942 18 1.37×10-13 
   rs7649544 3 2.54×10-10 
   rs1159851 1 4.71×10-10 
   rs9873442 3 4.96×10-10 
Brach Cir 
   * List truncated by 34 * 
rs904554 11 ~0 rs6656902 1 ~0 
rs17067136 8 4.23×10-12 rs6534405 4 ~0 
rs2131002 4 3.27×10-11 rs10484941 6 ~0 
rs7950298 11 1.41×10-8 rs10795659 10 ~0 
rs613836 1 2.50×10-8 rs10905409 10 1.11×10-16 
Brach Wid 
* List truncated by 11 * * List truncated by 521 * 
Bra R rs7786279 7 5.28×10-7    
Chol ratio rs10875171 1 1.68×10-7 rs10875171 1 1.00×10-6 
Cortisol rs10826151 10 1.57×10-7 rs10826151 10 8.18×10-7 
rs3734061 5 3.18×10-14 rs13103146 4 ~0 
rs11959439 5 3.24×10-9 rs11959439 5 ~0 
 
rs1911216 14 9.80×10-8 rs3799884 6 ~0 
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rs2153527 1 1.88×10-7 rs9472810 6 ~0 
rs2301472 1 2.34×10-7 rs7378011 4 1.11×10-16 
Creat 
* List truncated by 8 * * List truncated by 212 * 
rs2022309 1 5.63×10-7    Ddimer 
rs6585454 10 9.60×10-7    
Dor L    rs4126472 10 7.71×10-7 
rs1925324 1 9.53×10-7 rs11652164 17 6.07×10-7 Fev 
   rs238342 13 8.90×10-7 
Fib 2 rs11695082 2 7.98×10-7    
   rs7315833 12 4.62×10-7 HDL 
   rs1441541 5 6.51×10-7 
   rs17135557 7 8.64×10-10 
   rs11766744 7 4.91×10-7 
Hip Cir 
   rs677214 1 4.93×10-7 
Hip-Waist    rs3843354 3 1.13×10-7 
rs2319188 3 5.57×10-7 rs2180621 6 2.01×10-7 Resist 
   rs2319188 3 7.79×10-7 
   rs9842344 3 1.77×10-8 
   rs10011689 4 6.53×10-8 
   rs13013285 2 8.29×10-8 
   rs405970 20 8.75×10-8 
   rs6017819 20 9.37×10-8 
Tib L 
   * List truncated by 8 * 
   rs9379722 6 2.93×10-8 
   rs12583158 13 3.20×10-8 Tib R 
   rs1405040 10 3.56×10-8 
rs737267 4 1.22×10-9 rs737267 4 2.21×10-8 
rs13129697 4 6.06×10-9 rs13129697 4 9.54×10-8 
rs6449213 4 1.36×10-8 rs6449213 4 1.69×10-7 
rs1014290 4 2.02×10-8 rs1014290 4 2.50×10-7 
rs13131257 4 2.42×10-8 rs13131257 4 3.56×10-7 
Uric acid 
* List truncated by 1 *    
rs657152 9 ~ 0 rs657152 9 ~ 0 
rs505922 9 ~ 0 rs505922 9 ~ 0 
rs630014 9 6.95×10-11 rs630014 9 3.90×10-10 
rs8176749 9 3.98×10-9 rs8176749 9 8.08×10-8 
rs8176746 9 5.62×10-9 rs8176746 9 1.09×10-7 
vWF 
* List truncated by 4 * * List truncated by 1 * 
rs4954723 2 3.97×10-7 rs4954723 2 6.90×10-7 Waist Cir 
   rs4347759 2 7.64×10-7 
Weight rs2633254 2 3.07×10-7    
 
Table 2.5 Table showing p-value and chromosome from step two of GRAMMAR for all SNPs more 
significant than 1×10-6. Where “~ 0” is displayed, the actual figure was too small for GenABEL to 
report. Where the list is longer than five SNPs for any trait/model combination, the list is truncated, 
and the number of missing SNPs is indicated. 
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Figures 2.1 - 2.3 show results for the specific trait / chromosome combinations 
mentioned above. Physical distance (Mb) is plotted on the x-axis and -log10 p-value 
on the y-axis. Figure 2.1 shows results from analysis of uric acid on chromosome 4. 
There is a clear signal for association around 11Mb into the chromosome, as five 
SNPs exceed Bonferroni significance, the most significant of which (rs737267) with 
a p-value of 1.22×10-9. There are also a number of supporting SNPs in the region that 
do not quite reach this level of significance, but lend credence to the more significant 
results. Figure 2.2 shows the vWF results on chromosome 9. The most obvious peak 
is at around 135Mb, and is supported by a total of six SNPs exceeding Bonferroni 
significance (two marked in red on the figure due to p-values of approximately zero 
from R), and there are also a couple of smaller peaks at 6Mb and 81Mb that may be 
worth examining closer. Results of chromosome 5 for creatinine are displayed in 
Figure 2.3. The most significant hit is an isolated SNP around 151Mb into the 
chromosome. There is also a cluster of three SNPs falling to either side of 120Mb, 
two of which are close to Bonferroni significance and the third of which exceeds it. 
This peak at 120Mb looks promising, although the evidence is less conclusive than 







It is often difficult to interpret associations consisting of only a single SNP, such as 
the one to rs3734061 at 151Mb on chromosome 5 mentioned above (Figure 2.3). 
While it is possible they represent true signals, there is a greater chance of the finding 
Figure 2.1 Results for chromosome 4 for uric acid. Results are from a 1df allelic test using 
step two of GRAMMAR. The red line indicates Bonferroni significance. 
Figure 2.2 Results for chromosome 9 for vWF. Results are from a 1df allelic test using step 
two of GRAMMAR. The red line indicates Bonferroni significance. The two red points at 
133.17Mb and 133.18Mb correspond to p-values set to zero by R. 
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being either spurious or artefactual than for loci where multiple SNPs show 
association. This is because common SNPs like those on the panel used for this study 
usually have at least moderate LD to other nearby SNPs, and consequently two typed 
SNPs in moderate to high LD are expected to tag a third variant (i.e., a QTL) almost 
as well as each other. An association where no flanking SNPs show at least 
suggestive significance thus has a higher chance of being false. It should be noted that 
multiple close false positives or a single true positive may occur depending on the 
local LD structure, however the probability of this occurring is smaller. The most 
likely cause of an artefactual association is poor genotype calling, whereby the calling 
algorithm used to assign genotypes to individuals from allelic intensity data performs 
badly. Intensity data for this study were unavailable, therefore it was not possible to 
verify that this was the case for the association to creatinine on chromosome 5. 
However, in this case, LD to SNPs nearby rs3734061 was low (highest r2 was 0.152 




Figure 2.3 Results for chromosome 5 for creatinine. Results are from a 1df allelic test using 




In addition to peaks consisting of at least one significant SNP and a number of 
suggestive SNPs such as those mentioned above, there are numerous cases of well-
supported associations where none of the individual hits reach Bonferroni 
significance. In these situations it could be worth investigating further as the 
associations may still be real, however these associations would not be a top priority. 
Accordingly, the most promising results from the additive tests show evidence for a 
QTL on chromosome 4 affecting uric acid levels, a QTL on chromosome 9 affecting 




Results for the genotypic model are from 2df tests for overall association of each 
SNP. Initially, it appears that there are numerous positive results from the genotypic 
model. However, for two traits in particular – Brach Wid and Creat – the number of 
significant SNPs for the genotypic test begins to look suspicious. In the most extreme 
case, that of brachial width, there are a total of 526 SNPs with a p-value of less than 
1×10-6. This is clearly inflated in comparison to the number of hits for the vast 
majority of traits. The only other trait to have such an extreme number of significant 
results is creatinine, totalling 217, which is also remarkably high. Figure 2.3 shows 
the additive model results for creatinine on chromosome 5, therefore the same trait 
and chromosome combination was selected to illustrate a typical example of the 
results obtained for creatinine and brachial width using the genotypic model. This is 
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shown in Figure 2.4. Given that the only difference in Figures 2.3 and 2.4 is the 




In addition to the number of associations for these traits, another factor decreasing the 
likelihood of their validity is how scattered the hits are across chromosomes. In 
Figure 2.4, there are several places where Bonferroni significance is surpassed, 
however there are no well-supported peaks. The strongest convincing signals are at 
around 100-125Mb and 150-170Mb, as these do have multiple suggestive SNPs. 
There is also a SNP at 119Mb represented by a red point (again, due to a limitation of 
R) on Figure 2.4, further validating that peak. However, since the reliability of these 
results is questionable no strong conclusions can be based upon them. 
 
The strange results mentioned above are restricted to just creatinine and brachial 
width, suggesting that there is some phenomenon affecting only these two traits. For 
Figure 2.4 Results for chromosome 5 for creatinine. Results are from a 2df genotypic test 
using step two of GRAMMAR. The red line indicates Bonferroni significance. The red point 
at 119.43Mb corresponds to a p-value set to zero by R. 
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example, the genotypic model had the same top five SNPs (in the same order) on 
chromosome 4 for uric acid, and also the same associated SNPs on chromosome 9 for 
vWF, as the additive model, therefore there is reason to believe that the genotypic test 
can perform well. There are also a number of other traits for which the genotypic test 
looks to have identified interesting associations. There is evidence for associations to 
Hip Cir, Tib L and Brach Cir for example, as seen in Figures 2.5 - 2.7. The hip 
circumference results from chromosome 7 (Figure 2.5) show a putative association 
100Mb into the chromosome. There is a single SNP above Bonferroni significance, 
and this SNP has a p-value three orders of magnitude beyond the threshold. In 






Figure 2.5 Results for chromosome 7 for hip circumference. Results are from a 2df genotypic 




Figure 2.6 shows the Tib L results for chromosome 20. There is a peak with three 
SNPs exceeding Bonferroni significance standing above the background noise around 
44Mb into the chromosome. There are also a number of peaks above background 
noise on the short arm of chromosome 20, although these fall well short of 
significance. The final graph (Figure 2.7) shows the Brach Cir results from 
chromosome 1. Here, the most prominent peak is at 67Mb, with four hits more 
extreme than the Bonferroni threshold. There are no additional suggestive SNPs in 
the flanking region, but the four hits themselves provide good evidence for 
association. There is also a suggestive peak consisting of three SNPs at around 98Mb, 
and another one at 202Mb where one SNP almost reaches Bonferroni significance. 
 
Figure 2.6 Results for chromosome 20 for systolic pressure at tibialis posterior left. Results 








A mini follow-up on brachial width and creatinine was performed to investigate the 
strange results from the genotypic model more closely. Genotypic analysis for these 
traits was repeated, however on this occasion a more stringent limit on the proportion 
of observations in each genotype class for each SNP was imposed. This was to 
eliminate the possibility that a large proportion of significant SNPs were produced 
due to sensitivity of the score test to SNPs with an extremely rare genotype class. 
Where previously SNPs with a rare genotype count of less than 10 were set to 
missing, a new threshold of 50 was set (a frequency of approximately 0.05), and 
genotypic analysis was then performed as described in the methods. 
 
Figure 2.7 Results for chromosome 1 for brachial circumference. Results are from a 2df 
genotypic test using step two of GRAMMAR. The red line indicates Bonferroni significance. 
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Figure 2.8 shows the results for creatinine on chromosome 5 from the new analysis. 
On this occasion, unlike the previous genotypic analysis for this trait / chromosome, 
there are no results reaching Bonferroni significance. Results from the new analysis 
are very different from those in Figure 2.4 for example, with the most extreme –log10 
p-value reaching just under five, and the results now appear similar to the genotypic 
analysis results for most other traits. No significant associations for either creatinine 
or brachial width were found in the new analysis of these traits however. 
Interestingly, there is also no evidence in Figure 2.8 to support the significant 
associations on chromosome 5 for creatinine with the additive model (Figure 2.3). 
This does not necessarily mean the significant results from the additive model are 
false positives however, since the genotypic test will have reduced power compared 




Figure 2.8 Results for chromosome 5 for creatinine. SNPs with one genotype class with less 
than 50 occurrences are removed from the dataset (set to missing). Results are from a 2df 




Brachial width and creatinine were both traits whose residuals (i.e., trait value after 
correcting for polygenic effects and other covariates) were not normally distributed, 
and for which it was difficult to find a transformation leading to normalisation of the 
residuals. Figures 2.9 and 2.10 illustrate the distribution of the residuals produced 
from GRAMMAR step one for Brach Wid and Creat respectively. Figure 2.11 shows 
the residuals produced for uric acid, as a comparison. Although regression is thought 
to be fairly robust concerning trait distribution, normality is nevertheless an 
assumption of the regression model fitted in step two of GRAMMAR. Therefore it 
would be interesting to see if a combination of rare genotype classes and poor trait 








Figures 2.9 - 2.11 Distributions of the brachial width, creatinine and uric acid residuals 
from GRAMMAR step one. 
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The frequency of the rare genotype class for each of the top five hits (genome-wide, 
not only chromosome 5) from the Creat genotypic tests was recorded. All five SNPs 
had a rare genotype class with frequency less than 0.05 (the maximum was 0.018). 
Five SNPs matched for chromosome were then selected from each of three different 
categories of rare genotype class; 0.05 - 0.1, 0.1 - 0.2, and over 0.2. For each of the 
20 SNPs in total, permutation analyses were performed with respect to two traits; the 
non-normally distributed creatinine residuals, and the normally distributed uric acid 
residuals. In each case, SNP genotypes were permuted with respect to phenotypes 
10,000 times. Permutations across SNPs were performed independently to avoid 
correlations between SNPs due to LD (since some SNPs are located on the same 
chromosome). Simple linear regression was performed for each SNP in R for each of 
the permutations, and the p-value resulting from the F-test for an overall SNP effect 
was recorded. 
 
Table 2.6 shows results from these analyses, along with basic descriptors of the SNPs 
selected. The categories the SNPs were divided into are defined in the third column in 
the table. The fourth and fifth columns show the means of the F-statistic over the 
10,000 permutations for each SNP for creatinine and uric acid respectively. The 
overall mean for a given category of SNPs is in bold beneath the individual SNP 











rs13103146 0.1057 0.01708 1.043 0.990 
rs7378011 0.1066 0.01751 1.013 1.003 
rs11959439 0.0928 0.01116 1.066 0.990 
rs3799884 0.1325 0.01421 1.031 1.015 
rs9472810 0.1210 0.01124 1.057 0.988 
   1.042 0.997 
rs11727494 0.2650 0.07005 0.995 1.006 
rs6828802 0.2670 0.07411 1.027 1.004 
rs10076494 0.2819 0.08722 0.979 1.014 
rs7756332 0.3063 0.09635 1.007 0.995 
rs6596860 0.2444 0.05386 1.007 1.001 
   1.003 1.004 
rs7682616 0.3373 0.12255 1.007 1.013 
rs7666919 0.2969 0.10480 1.001 0.996 
rs7446851 0.2915 0.10153 1.006 1.004 
rs6932895 0.3316 0.11055 1.001 1.005 
rs727056 0.4190 0.17591 0.997 1.009 
   1.002 1.005 
rs10027536 0.4815 0.24820 1.007 1.018 
rs7665922 0.4770 0.28208 1.000 1.003 
rs4956987 0.4959 0.25922 0.997 1.023 
rs1540771 0.4613 0.21261 0.998 1.009 
rs6937708 0.4505 0.22914 0.996 1.012 
   1.000 1.013 
 
 
The expectation of an F-statistic with two and (effectively) infinite degrees of 
freedom is one. The most striking result is how high the overall F-statistic mean is for 
SNPs with a rare genotype frequency (<5%) when analysed for creatinine. At 1.042, 
it is by far the highest overall mean, and the discrepancy between this overall mean 
and the overall mean for the same five SNPs analysed for uric acid is the biggest 
discrepancy of all four categories. A T-test indicates that the mean of 1.042 is 
Table 2.6. Results for the 20 SNPs used for permutation analysis to assess effects of trait 
distribution and genotype class on regression analysis. The table shows SNP name, MAF, rare 
genotype frequency and the means of 10,000 permutations with respect to each of creatinine and 
uric acid. Numbers in bold represent the overall mean for that genotype class (i.e., a mean of 
50,000 permutations). The four groups of five SNPs correspond to different categories of rare 
genotype class frequency, and within each five SNPs the first two are from chromosome 4, the 
third is from chromosome 5 and the last two are from chromosome 6. 
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significantly different from one (p = 1.97×10-5). The only other overall mean which 
was noticeably higher was for the >20% rare genotype frequency category analysed 
with uric acid, at 1.013. This is the only other overall mean that is also significantly 
different from the expected F-statistic of one (p = 0.003). 
 
Two-sample T-tests were used to determine whether the overall means were 
significantly different from one another between categories. When considering 
creatinine, three of the six possible comparisons yielded significant differences, and 
these were all when comparing the <5% rare genotype class to the others. The p-
values for comparison of means of the <5% class with each ascending frequency class 
are 3.9×10-4, 2.2×10-4 and 7.6×10-5 respectively, showing that the mean for this class 
is significantly higher than the means of all other classes. None of the other 
comparisons for creatinine are significant. The same tests for the uric acid results 
produced one significant result at the 5% level, for the comparison of the <5% and 




Ensembl (Hubbard et al., 2007) was used in an attempt to identify candidate genes for 
each trait in the regions suggesting associations in the results. All hits for uric acid 
fell within a gene called SLC2A9 (also known as GLUT9). This gene is a member of 
the solute carrier family 2, which is a facilitative glucose transporter family. There are 
two transcripts of SLC2A9, one having a shorter N-terminus and different start codon. 
This shorter transcript is known as GLUT9deltaN. 
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As was the case with uric acid, all vWF significant hits fell within the same region. 
This region is located very close to the ABO blood group gene. It is already well 
documented that the ABO gene has a significant effect on vWF levels (Souto et al., 
2000), therefore our results replicate that association. The SNP panel used in this 
study does not include the polymorphism known to cause the difference in blood 
group, although it is likely that this is where the signal originates, and that the 
significantly associated SNPs in this study are in high LD with it. 
 
Interestingly, the top hit for creatinine on chromosome 5 (the lone SNP around 
151Mb into the chromosome) codes for a non-synonymous mutation in coding 
sequence. The change occurs in the FAT2 gene, the second human homolog of the 
Drosophila fat gene, which encodes a tumour suppressor essential for controlling cell 
proliferation during Drosophila development. The mutation is a transition from G to 
A, which causes the amino acid change of proline (P) to serine (S) (a conservative 
change, as both amino acids have neutral side chain charges). The protein is a 
member of the cadherin superfamily, and most likely functions as a cell adhesion 
molecule, controlling cell proliferation and playing an important role in cerebellum 
development. At this stage it is hard to see a link between creatinine and the FAT2 
gene, since creatinine is largely an indicator of renal function. The other significant 
result for creatinine on chromosome 5 involve SNPs not in the vicinity of any genes. 
There are no genes for over 400Kb in either direction of the hit SNP, effectively 
ruling out the possibility of cis effects between these SNPs and genes that may affect 
creatinine. The possibility of these SNPs tagging a variant involved in long-distance 
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gene regulation remains, however this would be hard to confirm without extensive 
research. 
 
Both SNPs for the hip circumference significant result fall within the gene EMID2. 
This gene encodes a collagen alpha-1 chain precursor protein thought to be involved 
in both biological processes and cellular component activities. How this would relate 
to hip circumference is hard to see at this stage. Similarly, for Tib L the top hits 
appear to be located in a gene called Zinc Finger Protein 663, and there is limited 
information on the proposed function of this gene, therefore it is unclear whether an 






Of the 44 traits analysed, 36 had heritabilities significantly different from zero. 
Significant heritabilities are important because they confirm that a significant 
proportion of trait variation is controlled by additive genetic effects, meaning it 
should be possible to identify the underlying genetic factors. Higher heritabilities 
indicate more genetic control of the trait relative to environmental (or non-genetic) 
sources of variation, which could mean either more genes involved than in traits with 
a lower heritability, or that the genes involved have larger effect sizes. Either way, 
appropriately powered GWA studies have a better chance of detecting QTL for traits 
with high heritability. It is also encouraging to note that many heritabilities reported 
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here are similar to those cited in the relevant literature, for example height 




There were not many SNPs reaching the Bonferroni corrected genome-wide 
significance level after analysis at step two, i.e., analysing residuals. This may partly 
be a consequence of “factoring out” some of the SNP effect due to the method of 
analysis, but genomic control should largely correct for this. It is more likely that 
failure to detect many associations is a consequence of low power for this study. 
Analysis was performed out on approximately 966 individuals (the exact number 
varies across traits due to differing patterns of missing data), however, considering 
that around 500 of these are in pedigrees the effective sample size is considerably 
less, since related individuals cannot be classed as independent. As a result, it seems 
likely that power is limited to detect very small effects in this study. 
 
This study did detect some significant results however, of which the uric acid and 
vWF results were the most exciting. After analysis using GRAMMAR step two, the 
most significant hit for vWF was assigned a p-value of approximately zero by R, and 
that for uric acid was 1.22×10-9. Both these associations were supported by numerous 
flanking SNPs also exceeding Bonferroni significance. This outcome is expected due 
to higher levels of LD between physically close SNPs, since SNPs in high LD will 
generally tag the same causative variant. For example, two of the SNPs showing 
strongest support of the top SNP for uric acid, rs13131257 and rs6449213, had 
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pairwise r2 of 0.83 and 0.79 with rs737267 in this dataset. If there were no SNPs in 
high LD with either the causal variant or the primary tagging SNP, then no supporting 
flanking SNPs would be present, however this is less likely for physically close 
common SNPs. Single significant SNPs can also be a consequence of artefacts such 
as poorly called genotypes, and these are likely to explain some instances of 
individual SNPs exhibiting a low p-value. 
 
The fact that the vWF hits were almost certainly due to the already known association 
between vWF and the ABO blood group system meant that these results were no 
longer of primary concern for further investigation. Although there is a slight 
possibility that the effect on vWF is enhanced by another variant located very close to 
the ABO gene, this is unlikely. Contrastingly, the gene that the UA hits fall within has 
no previous links to uric acid metabolism, but does look like a suitable candidate due 
to its transporter-like function. Combined with a very strong association signal, this is 
a strong candidate to follow up in a replication study. 
 
Both results above came from the additive model, however there was also a 
promising result for hip circumference from the genotypic test. The top hit is three 
orders of magnitude smaller (i.e., more significant) than the required Bonferroni 
significance threshold of 1.62×10-7, and two other SNPs at this locus are also 
suggestive. However, these results are more difficult to interpret in light of the nature 
of hip circumference as a trait, since it can be thought of as a composite measure of 
two other underlying traits – bone structure and fat around the hips. It is possible that 
bone structure around the hips is under evolutionary pressure in women due to child-
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birth for example, and both composite measures are correlated with hip 
circumference. Hip fat is likely to be under both genetic and environmental control, 
and gene-by-environment interactions are also likely to be involved. Consequently, 
hip circumference is likely to be under similar genetic control to other weight / fat 
measures such as waist circumference, weight, biceps and triceps skin fold thickness 
and BMI, however there was no concordance in the results for any of these traits. 
There were no SNPs near significance for these traits on chromosome 7. As a result, 
although the hip circumference results would be followed up more extensively in due 





The investigation into the effects of non-normal trait distribution and different rare 
genotype classes was very instructive in interpreting certain results from this GWAS. 
There was statistically significant inflation in the mean of the test statistic for SNPs 
whose rare genotype frequency was under 0.05 when analysed for a trait that was 
non-normally distributed. The majority of the data for the Creat distribution (Figure 
2.10) falls below a certain threshold, with a relatively small number of higher outliers 
that exceed this. With this distribution, it is possible that over a large number of SNPs 
in which one of the three genotypes is rare, by chance all or most of the rare 
genotypes may be present in the high outliers. This would cause a spurious 
association between that genotype and the trait. The same SNP analysed under an 
additive model would not necessarily be found to be associated because of the large 
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number of alleles in heterozygotes that are present in individuals with lower trait 
values. 
 
Results of the permutation appear to validate this hypothesis, with the test statistic on 
average being approximately 0.04 higher for SNPs with the lowest rare genotype 
frequency class. If these 20 SNPs comprised the entire dataset (as might be the case if 
they were part of a candidate gene study for example), a Bonferroni significance 
threshold of 0.0025 would be set. Performing 200,000 permutations for the trait 
(10,000 each for 20 SNPs) would mean that an expected number of 500 tests would 
be found significant purely by chance. Of the 200,000 permutations for creatinine, 
there were 1,881 tests that exceeded the 0.0025 threshold, almost 1,400 more than 
expected, of which 1,350 were SNPs in the <5% rare genotype category. In each of 
the three remaining categories (in ascending order of rare genotype frequency) the 
number of hits exceeding the threshold is 296, 171 and 64 respectively. Interestingly, 
applying the Bonferroni corrected threshold used in this GWA study (1.62×10-7), 
there would be 221 SNPs found significant, with only one of them not being in the 
<5% rare genotype frequency category (this one is in the 5-10% category). 
 
In comparison, results from performing permutations on uric acid are much more 
similar to the expectation. Of the 200,000 tests, only 523 are found significant, where 
by chance 500 are expected, and of those the breakdown is 116, 132, 142 and 133 in 
ascending rare genotype frequency class order. There appears to be a slight reduction 
in the number of hits reaching 0.0025 in the rarest genotype frequency class 
compared to the other three categories. With creatinine, the number of hits exceeding 
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0.0025 gets smaller as the frequency of the rare genotype increases, corresponding to 
the decreased chance that most of the rare genotypes will be paired with a high trait 
value. Compared with the 221 hits found with creatinine, there would be no results 
significant at the Bonferroni level when analysing uric acid. 
 
These results indicate that when there is one rare genotype class the test for 
association of genotypes fitted in a regression model is not reliable, although this is 
also clearly tied in with having a trait that is not normally distributed. Trait normality 
is one of the assumptions made when using regression models, however regression is 
generally considered fairly robust to this assumption. Nevertheless, there is also a 
slight increase in the number of significant hits found in Creat and Brach Wid even 
using the additive model compared to other traits, although this is nothing like that 
seen for the genotypic model. Clearly the genotypic test is far more sensitive to the 
distribution of the trait than the additive model. With this in mind, it may not be 
worth using the genotypic model for poorly distributed traits. Other potential 
solutions are removing SNPs with very extreme rare genotype frequencies (as 
opposed to setting only the rare genotype to missing), or treating traits distributed in 
this way slightly differently. For example, it may be better to consider creatinine and 








Data for this GWAS were analysed using a new technique for analysing genetic data 
in the presence of a pedigree, called GRAMMAR. This involves adjusting raw trait 
values for all relevant covariates, fixed effects and random effects before testing each 
SNP in a simple linear regression model. GRAMMAR is many orders of magnitude 
faster on a genome-wide scale than the gold standard measured genotype approach; 
the estimated time taken to complete a GWA scan using the measured genotype 
approach is in the region of 2.5 years for each trait (Aulchenko et al., 2007). In this 
study, computational time for analysis (up to step two) of each trait did not exceed ten 
minutes. The compromise made to enable this increase in speed was a slight decrease 
in power to detect QTL effects, due to removing some of this effect along with the 
polygenic variation in step one. This is largely corrected for by using the method of 
genomic control however, which accounts for cryptic relatedness and population 
substructure (Devlin and Roeder, 1999). Since effect of population substructure on 
the test statistic is constant throughout the genome, test statistic inflation due to 
substructure is the same for all markers (Bourgain and Genin, 2005). The principle is 
the same when removing polygenic variation, only in this case the test statistic 
experiences deflation rather than inflation. After correction, SNPs can be selected for 
analysis under the full measured genotype approach which will not suffer from test-
statistic deflation. Given the time penalty for analysing every SNP with MG, 
GRAMMAR is a much more feasible alternative. 
 
Considering the relatively few associations found during this GWAS so far, it may be 
valid to question the suitability of these data to association analyses as opposed to 
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linkage. The limited sample size and the fact that many participants are related means 
that these data are not ideally suited to an association study, however it should be 
noted that a recent study suggests that loss of power due to the latter is minimal 
(Visscher et al., 2008). Additionally, the data are even less suited for linkage 
analyses, since there are even less individuals (than the 966 available for association) 
that form part of a pedigree. Considering that power to detect small to moderate effect 
sizes is far greater in an association framework (Risch and Merikangas, 1996), GWA 
is thus justified as the best method of analysing this dataset. This project would 
clearly benefit from an increase in the number of participants however, and this was 
achieved over the summer of 2007, when a further 1,000 individuals from the island 
of Vis were recruited. 
 
One aspect of this GWAS that proved successful was the use of intermediate 
quantitative phenotypes to analyse instead of clinical disease endpoints. This is 
reflected in the uric acid findings, as high uric acid levels, or hyperuricemia, is a 
common feature in individuals suffering from gout (although not all people with 
hyperuricemia go on to develop gout), therefore it is possible that the putative QTL 
identified in this study will also increase risk of gout. This shows how SNPs 
identified by analysis of an intermediate phenotype may provide information that is 
relevant to disease, and indicates that prospects for detection of QTL underlying 








In the previous chapter a genome-wide association study (GWAS) finding multiple 
significant hits on chromosome 4 affecting uric acid levels was reported. In total five 
SNPs exceeded the Bonferroni-corrected nominal p-value threshold of 1.62×10-7. 
These SNPs were identified using step two of the GRAMMAR procedure outlined in 
the second chapter (section 2.2.6.3), and all fell within introns of the same gene, 
SLC2A9. These results were particularly appealing to follow up not only due to their 
genome-wide significance, but also because SLC2A9 is part of a known solute carrier 
family of genes. Although originally reported as a transporter of glucose (Phay et al., 
2000), SLC2A9 is nonetheless a gene that provides a biologically plausible reason for 
containing SNPs affecting uric acid level. Uric acid is considered to be of great public 
health significance due to the link it has with many prevalent population diseases (see 
for example, Heinig and Johnson, 2006), further enhancing this finding as one worth 
investigating. 
 
The first stage in following up these SNPs is to perform a full measured genotype 
(MG) analysis for each of the significant SNPs, as implemented in step three of 
GRAMMAR. Assuming these results validate the original findings, other 
considerations may then be taken into account to investigate further. This could 
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include a closer inspection of appropriate covariates and fixed effects to fit in the 
model for example, or extrapolating the findings to other related traits. Performing a 





Uric acid is the end product of purine metabolism in humans and the great apes. It is 
produced via oxidation of oxypurines by xanthine oxidase, which in other mammals 
is then further oxidised by the enzyme uricase into allantoin. Loss of hepatic uricase 
activity by humans and the great apes has therefore lead to uniquely high uric acid 
levels compared to other mammals, being around 200-500µmol/L as opposed to 3-
120µmol/L. The American Medical Association considers a range of between 3.6 
mg/dL (~214µmol/L) and 8.3 mg/dL (~494µmol/L) to be normal for humans. 
 
Uric acid is important to study because it has been implicated in numerous afflictions 
of public health significance. Low uric acid levels have been associated with multiple 
sclerosis (Toncev et al., 2002), while high levels have been implicated in kidney 
stones (Heinig and Johnson, 2006), Lesch-Nyhan syndrome (Luo et al., 2006; Nyhan, 
2005) and cardiovascular disease (Heinig and Johnson, 2006). Gout is the condition 
most often associated with uric acid however (Seegmiller et al., 1963), where high 
uric acid levels, also known as hyperuricemia, greatly facilitate its onset. Gout is a 
type of arthritis that most commonly affects the big toe, but can also affect other 
joints - such as the ankle, heel, instep, knee, wrist, elbow, fingers and spine - causing 
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excruciating pain. Approximately 10% of individuals with hyperuricemia go on to 
develop gout, and >90% of subjects with gout have diminished fractional excretion of 
uric acid (FEUA) (Graessler et al., 2006). Given that 5-25% of the human population 
have impaired renal excretion leading to hyperuricemia (Becker and Jolly, 2006), it is 





All SNPs implicated in affecting uric acid levels from the initial genome-wide 
association (GWA) scan are found either within introns of the SLC2A9 gene, or 
slightly 5’ of it. SLC2A9, also called GLUT9, has previously been documented as a 
glucose transporter, and belongs to a family of genes known to be carriers of glucose 
and other solutes. Another gene within the solute carrier gene superfamily, SLC22A12 
(encoding URAT1), is a known urate transporter (Enomoto et al., 2002). There have 
also been reports of SLC2A9 being expressed in human (Augustin et al., 2004) and 
mouse (Keembiyehetty et al., 2006) kidney tubules, further strengthening the link 
between the hit SNPs, uric acid and SLC2A9. 
 
The SLC2A9 gene codes for two transcripts; the longer version of the gene is 
approximately 214Kb long, (9,718,140 – 9,504,117; 4p16-p15.3) with 13 exons, 
whereas the shorter version, known as GLUT9deltaN, has a shorter N-terminus and 
only 12 exons, spanning 195.3Kb (9,699,382 – 9,504,117; 4p16-p15.3). Both forms 
of the gene are transcribed in a 5’ – 3’ direction. Of the five SNPs exceeding 
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Bonferroni significance for uric acid in our study, all were found within introns 3-7 of 
the SLC2A9 gene. One of the aims of performing further studies into the region of 
interest is to narrow the search and draw more definite conclusions about the location 





The first step in following up the significant uric acid results is to use the MG 
approach (as implemented in GRAMMAR step three), as this provides more accurate 
estimates of significance and effect size for the polymorphisms tested (Aulchenko et 
al., 2007). In this step, SNPs are analysed with uric acid as the dependent variable, as 
opposed to residuals from a polygenic model as performed previously. Greater 
consideration of appropriate fixed effects and covariates was taken at this stage, to 
ensure that the best model to fit the data was used.  
 
Assuming the MG results were significant, the next stage would be to look more 
closely at the associated SNPs in the context of the gene in question, and attempt to 
fine map the location of the causative polymorphism. Viewing the LD structure 
among the associated SNPs, using software such as HaploView (Barrett et al., 2005) 
for example, is one way of interrogating the locus to identify the QTN. Another way 
to help define the associated region is to test multiple SNPs. Accounting for the 
variation explained by one SNP may entirely remove the signal of association at other 
nearby SNPs if they all tag the same causal variant. However, due to the stochastic 
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nature of LD it is possible that two SNPs not in LD with each other may each be in 
partial LD with the causative QTN. Using the strength of signal of numerous 
secondary SNPs may therefore help to refine the likely location of a QTN. 
Accounting for significant SNPs may also detect secondary, independent associations 
at the locus, if any exist. 
 
Also of interest is whether the same SNPs are associated with other medical 
conditions or diseases that may be connected in some way to urate metabolism. For 
example, uric acid may have a role to play in the epidemiology of another more 
complex disorder, therefore SNPs explaining variation in uric acid would also have a 
diluted effect on this other trait. One obvious possibility in the case of uric acid is 
gout, however another possibility is the metabolic syndrome. Evidence for 
association to more complex phenotypes would be harder to obtain however, since 
the effect of these SNPs is small even on the uric acid scale, and could conceivably be 
orders of magnitude smaller when considering more complex diseases, due to the 




Any positive GWAS results must be replicated in order to ensure that they are not 
spurious. Without successful replication it is impossible to know whether significant 
results are true or false positives, and this impacts upon the credibility of the results. 
It may be the case, for example, that interesting results pertain to effects unique to 
that particular study population, and are absent or greatly diminished in other 
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populations. In this regard, one of the great strengths of population isolates becomes a 
potential weakness, since alleles that have risen in frequency in an isolate may be at 
lower frequency and hence harder to replicate in other populations. However, since a 
replication study is not burdened a by stringent multiple testing correction, the 
relaxed significance threshold generally facilitates successful replication of true 
positive results. 
 
The EUROSPAN collaboration, of which this project was part, has five GWA studies 
running in tandem, and one of these was used as a population in which to replicate the 
uric acid findings. These population data were collected on the island of Orkney, off 
the north coast of Scotland, and are therefore also from an isolated population. In 
addition to this, a German population collected as part of a case / control study of 






GRAMMAR step three (i.e., the measured genotype approach) was used for the 
follow-up analyses. The exact model for analysis at this stage is shown below - see 
chapter two sections 2.2.6.1 - 2.2.6.4 for description of terms.  
 
yi  =  µ + kgi + Σj βj cji + Gi + ei 
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Covariates and fixed effects included in the model remain unchanged from those used 
in step one of GRAMMAR, which were age, sex, BMI and an age-by-sex interaction. 
In total, 26 SNPs in SLC2A9 were analysed using this model. Of these 26 SNPs, five 
were the SNPs exceeding Bonferroni significance from the original analyses, and two 
were SNPs that were located within SLC2A9 but fell marginally short of the this 
significance level. These seven SNPs are located on a stretch of DNA encompassing 
17 SNPs on the Illumina platform, therefore the remaining SNPs followed up were 
the intervening SNPs plus some extending past the outermost of the original seven in 
either direction. A likelihood ratio test (LRT) was used for each SNP to test whether 
an additive or genotypic model fitted the data better (twice the difference in log 
likelihood is chi-square distributed with d.f. equal to the difference in parameters 
estimated). All SNPs were found to act in an additive manner, as in the initial 




HapMap data were used to obtain the level of LD surrounding SLC2A9 in the 
European (CEU) population. These data were also used in conjunction with the 
HaploView software (Barrett et al., 2005) to visualise regions of LD within and 
around the gene. HaploView allows the choice of either r2 or D’ to present the LD 
structure, since they are indictors of slightly different things. R2 is a correlation 
measure that takes into account factors such as the age of mutation and the frequency 
of mutation and recombination, whereas D’ is primarily a measure of whether 
 104 
recombination has occurred since it is only ever less than one if all four haplotypes 
between two (biallelic) markers are present (Slatkin, 2008). Both measures range 




The use of multiple markers should elucidate a clearer picture of the genetic 
architecture of the effect on uric acid. It is possible that the effect is caused by a 
single QTL, and this is the hypothesis that has been tested so far in the analyses. 
However, it is also possible that the effect is a consequence of more than one QTL, 
and is instead due to small cumulative effects from multiple causal loci in the 
SLC2A9 gene, either all found on one “high risk” haplotype, or on numerous genetic 
backgrounds. One way to test whether there is an effect over and above that of a 
single SNP is to fit multiple SNPs in a multiple regression model, thus determining 
whether any variation exists in uric acid that is not fully explained by the first SNP in 
the model. Using this approach could also help to fine-map the location of a QTL, as 
previously explained. 
 
Multiple regression was performed for numerous combinations of the five SNPs 
exceeding Bonferroni significance in the original analyses, in order to determine 
whether any effects near the top SNPs were due to a secondary, independent, 
mutation at the locus, and to help fine-map the location of any QTN. Should any 
secondary QTN with low r2 to the hit SNP exist, these independent effects would be 
detected (assuming the presence of tagging SNPs and requisite power to do so) 
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regardless of whether the top SNP was adjusted for, since the top SNP does not 
correlate with these other markers. However, after adjusting nearby SNPs for the 
variance explained by the hit SNP, any strong signals remaining may indicate the 
presence of a secondary QTN, or help to better define the location of a single QTN. 
Using only five SNPs also helped to control the number of tests to some degree. For 
example, if all seven highly significant SNPs were considered, there are 42 possible 
ways in which any two of the seven SNPs could be fitted (accounting for both 
orientations of the two SNPs in order to test each SNP in the presence of the other), 
therefore allowing greater numbers of SNPs in the model would result in an 




Due to the known link between uric acid and gout, individuals in the dataset suffering 
from this disease were identified from the records collected initially. This is because 
individuals suffering from gout are likely to be on medication that would include 
urate-lowering drugs. In addition to treatment for gout, other types of medication also 
have an effect on uric acid concentration, including those taken for cardiovascular 
disease for example, therefore individuals using these were also identified. The major 
uric acid lowering drug found to be taken by individuals in the study was Allopurinol, 
which is used as a treatment for gout. 
 
Including individuals with environmentally (i.e., drug) altered uric acid levels in the 
analysis would not be optimal, since no term in the model accounted for this. This 
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would affect the analysis by reducing power and hence making any association harder 
to find, since those who would have high uric acid levels due to genetics instead have 
a much lower trait value. It is possible to fit a fixed effect for treatment / non-
treatment, but this would not capture the situation fully since there is no way to know 
whether there was a different reaction to the drugs among different people (i.e., gene-
by-drug interactions), or any dose-dependent effects, and this method would also 
class all uric acid lowering drugs as the same. Assigning each drug a different level of 
fixed effect is an alternative, although this solution still fails to account for any gene-
by-drug interactions or dose effects. The only way in which this information can be 
modelled is with time-series data that record of the change in uric acid level of 
individuals pre and post drug taking. 
 
In total 174 of the original 1,031 individuals with phenotypic information were 
removed from the analyses due to using medication known to affect uric acid levels, 
since no more preferable way of dealing with them could be found. Most of these 
individuals had also been excluded on the basis of the quality control described in the 
previous chapter however, therefore only 20 additional individuals were removed. 
After removing the additional individuals that were on urate-altering medication there 
was a total of 946 individuals (400 males and 546 females) to perform the analyses 
on, although the exact number varied between SNPs due to missing genotypes. 
 
One interesting thing that came to light in the follow up analyses was that there were 
drastically different effect sizes estimated for the top SNPs for men and women. 
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Consequently, the model was changed to include a sex-by-SNP interaction term for 




The SNPs associated with uric acid were tested for association with other traits 
potentially linked to it. Some traits analysed at this stage were not quantitative, and 
others that were recorded as quantitative had well-defined thresholds in medical 
literature with which to dichotomise them, therefore these traits were analysed as both 
quantitative and binary phenotypes. For example, diastolic blood pressure is 
dichotomised at 90mmHg, and systolic blood pressure is dichotomised at 140mmHg 
in the medical literature. Binary traits included gout and the metabolic syndrome. 
 
For traits that were binary, the method of analysis used was Fisher’s Exact Test, or 
where numbers were too large, a 2x2 contingency table (assuming additivity) and chi-
square approximation. Only those individuals who are “unrelated”, namely founders 
and singletons (individuals for whom no information exists to connect them to other 
members of the dataset) were used. This was to prevent potential inflation of the test 
statistic due to phenotypic correlations between family members that may be present 
due to polygenes or shared environmental factors. The quantitative phenotypes were 
analysed in the same way as for the rest of the quantitative traits (QTs) during the 
GWAS, i.e., tests were performed using step three of GRAMMAR on the raw trait 
data, including a random effect accounting for polygenic variation in the model. 
 108 
Details of traits analysed, transformations used and covariates / fixed effects fitted 
can be found in Table 3.1. 
 
TRAIT TRANSFORMATION COVARIATES / FIXED EFFECTS 
Gout (Binary) N/A None 
Metabolic Syndrome – IDF 
(Binary) N/A None 
Metabolic Syndrome – ATP 
(Binary) N/A None 
Creatinine (QT) None None 
Diastolic BP (Binary) N/A None 
Diastolic BP (QT) Square Root Sex BMI 
Systolic BP (Binary) N/A None 
Systolic BP (QT) Natural Logarithm Sex*Age 
Brachial – left (QT) Natural Logarithm Sex*Age LogBMI 
Brachial – right (QT) Natural Logarithm Sex*Age LogBMI 



















The Orkney population used as a replication cohort was also collected as part of the 
large EUROSPAN collaboration to which the CROAS project belongs (see chapter 
Table 3.1 Additional traits analysed for association to the SLC2A9 SNPs. Transformations used, 
and all covariates and fixed effects are also given. 
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two, section 2.1.2). Orkney Complex Disease Study (ORCADES) is an ongoing 
family-based, cross-sectional study with data collected from the isolated Scottish 
archipelago of Orkney, off the north coast of Scotland, and was supported by the 
Scottish Executive Health Department and the Royal Society. Genetic diversity in 
this population is decreased compared to Mainland Scotland, consistent with the 
historically high levels of endogamy. Data for participants aged 18-100 years, from a 
subgroup of ten islands, were taken for this study. Fasting blood samples were 
collected and over 200 health-related phenotypes and environmental exposures were 
measured in each individual, including uric acid. In total the study genotyped 758 
individuals and phenotyped 1,048 individuals, however after genotypic quality 
control (individual call rate threshold of 98%), there were 719 individuals with both 
genotypic and phenotypic information recorded. All participants gave informed 
consent and the study was approved by Research Ethics Committees in Orkney and 
Aberdeen. 
 
The model used for the Orkney population was the same as that for the Croatia 
population. Individuals taking medication affecting uric acid were similarly removed, 
and the sex-by-SNP interaction was included. Six of the top seven SNPs from the 
original study had been genotyped in the ORCADES project (rs733175 was not 
genotyped in this population), therefore these were selected as replication SNPs. In 
total there were 719 individuals in the analyses; 317 males and 402 females. 
 
One further population used as a replication was a German cohort initially sampled 
for use in research into FEUA. FEUA is the main risk factor for hyperuricemia, 
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therefore this dataset should be well suited for positively replicating the SLC2A9 
SNPs. Additionally, since 90% of subjects with gout have below normal FEUA 
(Graessler et al., 2006), this phenotype may be one step closer to gout than uric acid 
is, and replicating the association may more strongly implicate these SNPs in 
affecting gout. The dataset consists of 349 German subjects with low FEUA (≤6.6%), 
and 255 controls matched for ethnicity with normal FEUA (≥7.4%), therefore the trait 
is binary, unlike uric acid. These data were analysed for the same six SNPs as were 
replicated in the ORCADES dataset, using logistic regression with age, sex and BMI 






Results from the full model can be found in Table 3.2, which also shows the minor 
allele frequency, effect size and direction of effect of the SNPs. Effect estimates 
given in the table indicate the effect of substituting a minor allele for a major allele. 
There is clearly evidence for a QTL affecting uric acid at this locus. The ordering of 
SNPs in terms of significance changes slightly from the reduced model (i.e., step two 
of GRAMMAR), but these changes are minimal and all five SNPs originally 
exceeding genome-wide significance are still highly significant. The SNPs are 
slightly more significant than they were in the reduced model; for example the p-
value for the most significant SNP, rs727367, decreases from 1.22×10-9 to 1.12×10-10. 
This effect is expected as a result of the “factoring out” effect mentioned earlier, 
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whereby some of the SNP effect is lost in the original analysis due to modelling of 
the polygenic effects. Many SNPs failing to reach genome-wide significance still 
show moderate association; of the 19 extra SNPs tested, six of the non genome-wide 
significant SNPs reach significance at the 0.1% level, and four more do at the 5% 
level. 
 
SNP MAF EFFECT (S.E) P-VALUE 
rs4697693 0.319 0.21 (0.115) 0.067 
rs2280204 0.115 0.21 (0.170) 0.197 
rs2280205 0.488 0.23 (0.105) 0.026 
rs4697695 0.326 -0.41 (0.112) 2.73×10-4 
rs10805346 0.473 0.47 (0.107) 1.03×10-5 
rs3733591 0.119 -0.39 (0.162) 0.016 
**rs13129697** 0.369 0.64 (0.104) 6.02×10-10 
rs881971 0.453 -0.44 (0.105) 2.34×10-5 
**rs737267** 0.297 0.70 (0.109) 1.12×10-10 
rs4447863 0.435 -0.49 (0.102) 1.00×10-6 
rs12498956 0.490 0.44 (0.104) 2.6×10-5 
rs4505821 0.203 -0.17 (0.133) 0.194 
**rs13131257** 0.269 0.66 (0.113) 3.86×10-9 
rs6849736 0.069 0.32 (0.225) 0.153 
rs4502681 0.060 0.30 (0.238) 0.201 
**rs6449213** 0.246 0.69 (0.114) 1.54×10-9 
**rs1014290** 0.316 0.64 (0.107) 1.97×10-9 
rs6845554 0.468 0.36 (0.106) 7.79×10-4 
rs6827754 0.466 0.35 (0.106) 8.38×10-4 
rs6820230 0.254 -0.15 (0.125) 0.238 
rs10939663 0.277 -0.37 (0.118) 1.58×10-3 
rs9291645 0.238 -0.20 (0.127) 0.112 
**rs733175** 0.285 0.61 (0.110) 4.02×10-8 
rs7683832 0.081 0.14 (0.209) 0.490 
rs2241469 0.196 -0.13 (0.134) 0.322 





Table 3.2 Results for each of the 26 follow up SNPs in SLC2A9. SNPs are ordered as they 
would be found moving along the chromosome in a 3’ to 5’ direction. Minor allele frequency, 
effect size and p-value are given for each SNP. Analysis was performed using step three of 
GRAMMAR. P-values are from two-sided T-tests, and effects are on square root of uric acid 
scale. SNPs exceeding suggestive significance (1×10-6) from step two of GRAMMAR are 
shown in bold, and are marked by asterisks.  
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In general, the minor allele is associated with a decrease in uric acid levels, however 
for one of the SNPs, rs4447863, the minor allele associated is with an increase in uric 
acid levels, opposite to the direction of the effect for all other SNPs. The minor allele 
frequency for this SNP is slightly higher than that of the rest. The average minor 
allele frequency of the main seven follow-up SNPs is 0.316, and that of the remaining 
SNPs is 0.287. A t-test reveals that there is no significant difference in minor allele 
frequency (MAF) of the seven top SNPs compared to the remaining 19 (p = 0.491), 
although with such a small number of SNPs a significant difference would be hard to 
detect. A significant difference may have indicated that SNPs at a higher MAF better 
tag the QTN in general, suggesting the QTN may also have higher MAF. 
 
The MAF and effect sizes of the SNPs that were followed up are displayed 
graphically in Figure 3.1. Initially, it does not appear that there is a narrow minor 
allele frequency band unique to the significant hits - while the six SNPs with effects 
in the same direction all have reasonably similar MAF, other nearby SNPs also with 
similar MAF do not reach genome-wide significance. For example, five of the top 
seven hits have a MAF of between 0.269 and 0.316, however the three SNPs just 3’ 
of rs733175 have MAF within or only slightly below this range, and do not have 
particularly significant results. However, for these three SNPs the effect is in the 
opposite direction, meaning the allele associated with decreasing uric acid has 
frequency one minus the MAF. Therefore in general, it would seem that alleles 
associated with decreasing uric acid and that have a frequency of approximately 0.3 
are most highly associated. Interestingly, for a stretch of 11 consecutive SNPs starting 
at the 3’ end, including four genome-wide significant SNPs, the effects of 
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neighbouring SNPs are in opposing directions, i.e., the effect direction of the minor 
allele for each consecutive SNP changes. It is around this stretch of 11 SNPs that 
three of the top four significant hits can be found, and many intervening SNPs also 




Figure 3.2 shows the patterns of pairwise linkage disequilibrium (LD) between SNPs 
located in and around the SLC2A9 gene, taken from the CEU HapMap data using 
HaploView. Bright red colouration represents a D’ of one, meaning that no 
recombination has been observed between the two markers. Above the LD plot in 
Figure 3.2 is a display of the locations of all typed SNPs on our panel, and above that 
is shown the short and long isoforms of SLC2A9 from the Ensembl genome browser 
Figure 3.1 Effect size (in square root uric acid in mmol/L) and minor allele frequency of 
significant and non-significant SNPs along the SLC2A9 gene on chromosome 4. Effect 
size is for substitution of one minor allele for one major allele. Asterisks indicate SNPs 
exceeding 1×10-6 in the follow-up analysis using step three of GRAMMAR. 
 114 
(Hubbard et al., 2007). There are 13 and 12 exons respectively in the long and short 




All significant SNPs fall within introns 3-7 of the long isoform (2-6 of the short 
isoform), with the exception of rs733175 that is in the 5’ UTR. The seven most 
significant SNPs are labelled numerically on the graph in order of significance, and 
SNP names are provided in the figure legend. The two most significant SNPs are 
found within the same LD block, and a highly significant third SNP (rs4447863) is 
immediately 5’ of it. This is shown in close up in Figure 3.3, where coloration 
represents D’ (reddest being D’ = 1) and the number represents r2. The r2 value for the 
CEU HapMap population is 0.7, where in the Croatian dataset the value is 0.73. 
Figure 3.2 LD blocks in the SLC2A9 gene. Red indicates high D', white indicates D' of zero. 
All typed SNPs are displayed immediately above the LD plot, and the main seven SNPs 
followed up are labelled in order of significance. SNPs are labelled as follows; (1) rs737267, 
(2) rs13129697, (3) rs1014290, (4) rs6449213, (5) rs13131257, (6) rs733175, (7) rs4447863.  The 
two transcripts of the SLC2A9 gene are shown above the SNP locations.  
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Similarly, r2 between rs737267 and rs4447863 is 0.34 in HapMap and 0.36 in the 




Figure 3.4 shows the associated region and -log10 p-values for all typed markers using 
the SNP Annotation and Proxy Search tool (Johnson et al., 2008). This also uses CEU 
HapMap data to display pairwise r2 between all SNPs all the top SNP, represented by 
the shade of red. This figure shows that the top seven SNPs are all in moderate to 
high LD, but that the SNPs flanking these seven show reduced association with uric 
acid. Overlaid on the plot is the recombination rate in this region of the genome, 
which clearly indicates that to either side of the main association (at around 9.3Mb 
and 9.8Mb into chromosome 4) there is an increase in recombination. No SNPs reach 
a -log10 p-value of three past these recombination hot-spots, which strongly suggests 
that the causative variant is located somewhere within these bounds. Two other genes 
Figure 3.3 Plot from HaploView showing LD in D' (colour) and r2 (number) for the LD block 
containing the most significant SNP. Two other of the top seven SNPs are also shown in the 
plot. 
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flanking SLC2A9 and within the boundary defined by the recombination hot-spots are 
WDR1 (WD repeat-containing protein 1) in the 5’ direction, and DRD5 (dopamine 
receptor D5) past the 3’ end. SNPs in both these genes show weak association with 
uric acid. 
 
In order to determine how the strength of association changed across the follow-up 
SNPs relative to the top hit rs737267, -log10 p-values were plotted against r2 to 
rs737267 (calculated for this dataset). This is shown in Figure 3.5. The figure shows 
that there is a clear increase in the strength of association as r2 to rs737267 increases, 
and the correlation between r2 and -log10 p-value was 0.93. This suggests that there is 
a single effect being detected at this locus, since none of the other p-values are 
particularly larger than expected, given their r2 to the top SNP. This evidence 
therefore implies the presence of a single QTN, and that rs737267 is the SNP that 
best captures the variation explained by this QTN. 
Figure 3.4 Plot showing the association within the SLC2A9 gene using the SNP Annotation 
and Proxy Search tool. All typed SNPs within this region shown. Colour of each SNP 
indicates r2 with the top SNP rs737267. Overlaid on the graph is an estimate of the 







Table 3.3 shows the results from fitting two of the top SNPs in a multiple regression 
framework. For each two-SNP model, both orientations of SNPs were tested, because 
after correcting for the effect of one SNP, secondary, independent associations may 
be identified for the other. Orientation 1 shows results where the more significant of 
the two SNPs from the original analyses was fitted first in the model. Eight of the 10 
tests in orientation 1 have non-significant p-values for the second SNP, and the other 
two have p-values significant at the 5% level. The p-values for the first SNP are not 
identical to those for that SNP when analysed alone since slight differences are 
produced due to differing patterns of missing data when combining data from more 
than one SNP. P-values for the second SNP are largest (i.e., least significant) when 
the top SNP, rs737267, is fitted first in the model. 
Figure 3.5 Correlation between the -log10 p-value of SNPs within SLC2A9 and their LD with 
the top SNP rs737267. 
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ORIENTATION 1 ORIENTATION 2 SNPs FITTED IN 
MODEL SNP1 SNP2 SNP1 SNP2 
rs737267 rs13129697 1.14e-10 0.174 4.01e-10 0.038 
rs737267 rs6449213 2.00e-10 0.313 2.83e-9 0.013 
rs737267 rs1014290 1.10e-10 0.137 3.81e-9 0.003 
rs737267 rs13131257 1.15e-10 0.777 3.58e-9 0.009 
rs13129697 rs6449213 1.05e-9 0.031 2.84e-9 0.010 
rs13129697 rs1014290 6.22e-10 0.271 3.42e-9 0.033 
rs13129697 rs13131257 5.97e-10 0.099 5.26e-9 0.008 
rs6449213 rs1014290 1.53e-9 0.145 3.62e-9 0.052 
rs6449213 rs13131257 1.57e-9 0.325 5.57e-9 0.064 
rs1014290 rs13131257 1.81e-9 0.037 3.49e-9 0.018 
 
For orientation 2, where the order of the SNPs has been reversed and the more 
significant SNP is fitted second, in eight of the 10 tests the second SNP is significant 
at the 5% level at least. The top SNP, rs737267, is always at least significant at the 
5% level when fitted second, and for all tests where the SNPs are arranged in 
orientation 2, the second SNP is more significant than when those SNPs were in 
orientation 1. This suggests that all SNPs are tagging the same variant, but that one is 
doing so more effectively (i.e., rs737267). Since there was little suggestion of 




Table 3.4 shows results from using the final model with which the seven follow-up 
SNPs were analysed. The sex-by-SNP interaction was significant at the 5% level (at 
Table 3.3 Results from fitting two markers in a multiple regression. The two SNPs fitted in each 
case are given in the table, and results are shown for both orders the SNPs could be arranged in 
for that pair. Orientation 1 refers to the order given in the first column of the table, and 
orientation 2 gives the reverse order. P-values are from an F-test with 1 and effectively infinite 
degrees of freedom. 
 119 
least) for the five most significant SNPs. For rs733175 and rs4447863 the interaction 
term is not significantly different from zero. A 5% significance level is appropriate to 
test for the interaction because it is a specific hypothesis test performed on seven 
SNPs only. The effect sizes for substituting a minor allele for a major allele are also 
shown in Table 3.4. Effect sizes for all SNPs are much larger for females than males, 
and the p-values are also far more significant. The largest effect size estimate for the 
females was 0.962, for rs737267. Interestingly, the effects in females are so striking 
that the SNPs would not have been found significant in a GWA scan if only the males 
had been used – for three SNPs the p-value doesn’t exceed 0.05, and even the most 
significant only reaches 0.014. In contrast, the most significant of the p-values for the 
women was 9.76×10-12. For all SNPs, results from the females alone produces p-
values more significant than with the sexes combined. 
SNP N EFFECT (S.E) P-VALUE SNP*SEX INTERACTION 
390 0.358 (0.162) 0.027 rs737267 521 0.962 (0.141) 9.76e-12 0.004 
399 0.314 (0.154) 0.041 rs13129697 542 0.880 (0.133) 3.84e-11 0.004 
394 0.332 (0.174) 0.056 rs6449213 545 0.938 (0.146) 1.46e-10 0.007 
400 0.360 (0.162) 0.026 rs1014290 546 0.844 (0.137) 8.25e-10 0.020 
400 0.317 (0.166) 0.056 rs13131257 546 0.930 (0.147) 2.28e-10 0.005 
400 0.409 (0.166) 0.014 rs733175 544 0.751 (0.143) 1.36e-7 0.110 
399 -0.303 (0.154) 0.050 rs4447863 539 -0.625 (0.130) 1.51e-6 0.101 
 
Table 3.4 Results showing individual sex effects, p-values and the sex-by-SNP interaction p-values 
for the SLC2A9 SNPs analysed for uric acid in the Croatian population. The top line for each 
SNP corresponds to the males and the bottom one to the females. Effects are for substitution of 




Results for each SNP analysed for the alternate traits are in Table 3.5. With 14 traits 
and seven tests for each trait, if independence over all SNPs and traits was assumed 
then the appropriate significance level derived through a simple Bonferroni correction 
would be approximately 5×10-4. There are no p-values that reach this level of 
significance, therefore it would appear that there is no association between these 
SNPs and any of the uric acid related traits. This is notable in the case of gout, given 
the known links between uric acid and the disease.  
TRAIT rs737267 rs13129697 rs6449213 rs1014290 rs13131257 rs733175 rs4447863 
Gout 0.176 0.122 0.256 0.292 0.166 0.320 0.663 
MS (IDF) 0.806 0.146 0.301 0.066 0.215 0.237 0.560 
MS (ATP) 0.018 0.009 0.039 0.012 0.019 0.020 0.265 
Creatinine 0.497 0.688 0.597 0.934 0.566 0.649 0.904 
Diastolic 
BP (binary) 0.671 0.348 0.791 0.632 0.357 0.920 0.493 
Diastolic 
BP (QT) 0.694 0.300 0.854 0.536 0.270 0.355 0.666 
Systolic BP 
(binary) 1.000 0.888 0.420 0.549 0.354 0.254 0.597 
Systolic BP 
(QT) 0.867 0.712 0.968 0.888 0.767 0.778 0.879 
Brachial 
(left) 0.308 0.075 0.418 0.220 0.249 0.146 0.955 
Brachial 
(right) 0.483 0.186 0.409 0.275 0.301 0.097 0.670 
Dorsal 
(left) 0.111 0.052 0.230 0.291 0.053 0.919 0.367 
Dorsal 
(right) 0.094 0.064 0.171 0.239 0.035 0.240 0.710 
Tibial (left) 0.154 0.073 0.285 0.271 0.048 0.504 0.373 
Tibial 
(right) 0.151 0.047 0.236 0.228 0.063 0.263 0.480 
 
Table 3.5 Table showing p-values for each SNP tested for each of the extra traits. P-values 
significant at the 5% level are shown in bold. 
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Interestingly however, six SNPs reach the 5% significance level when analysed for 
the ATP measure of the Metabolic Syndrome. At a 5% significance level, the 
expectation for 98 tests would be that five were significant purely by chance, 
however it is unlikely that these would be concentrated on the same trait. The fact 
that there is an enrichment of SNPs reaching 5% significance within this trait (six of 
the nine p-values that are below 0.05 are for ATP Metabolic Syndrome) may be 




Results from analysis of the SLC2A9 SNPs in the Orkney population are shown in 
Tables 3.6 and 3.7. Table 3.6 shows the overall test for association, without the sex-
by-SNP interaction term fitted in the model, and Table 3.7 shows the results for when 
this interaction is included. 
 
SNP EFFECT (S.E) P-VALUE 
rs737267 0.175 (0.050) 5.00e-4 
rs13129697 0.193 (0.045) 1.72e-5 
rs6449213 0.211 (0.048) 1.33e-5 
rs1014290 0.204 (0.052) 7.74e-5 
rs13131257 0.262 (0.057) 4.50e-6 




These tests positively replicate the results found for uric acid in the Croatia 
population, as all SNPs are highly significant for the overall test, albeit in a different 
order of significance. The tables show the effects produced by substitution of a minor 
Table 3.6 Table showing effect sizes and p-values for the SLC2A9 
Uric Acid hit SNPs in the Orkney population. Effects are for 
substituting one minor allele for a major one. 
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allele for a major allele, therefore in all cases except that of rs4447863, the effects of 
the SNPs in both populations are in the same direction (the major allele in both 
populations is associated with the higher uric acid level). With rs4447863, it is the 
minor allele in the Croatian dataset, but the major allele in the Orkney dataset that 
causes the increase in uric acid. This can be explained by the fact that the same 
nucleotide is the minor allele in one population, but the major allele in the other. This 
is a consequence of the allele frequency for this particular SNP being much closer to 
0.5 than the other significant SNPs. 
 
SNP N EFFECT P-VALUE SNP*SEX INTERACTION 
313 -0.006 (0.072) 0.936 rs737267 390 0.324 (0.066) 8.22×10-7 
5×10-4 
315 0.064 (0.070) 0.358 rs13129697 392 0.273 (0.056) 9.58×10-7 0.016 
313 0.024 (0.070) 0.726 rs6449213 393 0.356 (0.062) 1.13×10-8 
2×10-4 
317 0.085 (0.076) 0.267 rs1014290 397 0.292 (0.061) 1.0×10-5 0.034 
315 0.050 (0.080) 0.529 rs13131257 395 0.454 (0.077) 2.86×10-9 
2×10-4 
313 0.056 (0.061) 0.352 rs4447863 393 0.226 (0.053) 1.71×10-5 0.030 
 
The sex-by-SNP interaction in the Orkney population is significant at the 5% level (at 
least) for all SNPs replicated, so this term was included in the model. Three of the 
sex-by-SNP interactions are more significant than for the Croatian population, 
exceeding the 0.1% threshold. Similarly to the Croatian population, fitting the sex-by-
SNP term for the Orkney population enhances the size of effect in women and 
Table 3.7 Results showing individual sex effects, p-values and the sex-by-SNP interaction p-values 
for the SLC2A9 SNPs analysed for uric acid in the Orkney population. The top line for each SNP 
corresponds to the males and the bottom one to the females. Effects are for substitution of one 
minor allele for one major allele. 
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reduces it in men. However, for those SNPs where the interaction is significant in the 
Orkney population, the difference in p-value between males and females is far more 
extreme, and none of the p-values for association in the males is significant even at 
the 5% level. The effect sizes of the association in absolute terms for the women are 
much smaller than the effect sizes found in the Croatian population, the largest being 
0.454 (0.077) for rs13131257 compared with 0.962 (0.141) for rs737267. 
 
Results of the replication analysis in the German cohort of individuals with reduced 
FEUA are presented in Table 3.8. A sex-by-SNP interaction was not significant at the 
5% level for any of the SNPs and was therefore omitted. Again there is positive 
replication of the SNPs implicated in the initial GWAS, as all SNPs are significant at 
the 5% significance level. Unlike for the Orkney replication, in this dataset the major 
allele of rs4447863 was found to decrease uric acid, therefore all SNPs have direction 
of effect in agreement with the initial findings. 
 
SNP EFFECT (S.E) P-VALUE 
rs737267 0.480 (0.158) 0.002 
rs13129697 0.515 (0.154) 0.001 
rs6449213 0.425 (0.170) 0.012 
rs1014290 0.448 (0.160) 0.005 
rs13131257 0.457 (0.163) 0.005 







Table 3.8 Effect sizes and p-values for the SLC2A9 uric acid hit SNPs in the 
German cohort, collected as part of a study into fractional excretion of uric 






The full model results for uric acid clearly provide strong evidence for an association 
on chromosome 4, as a total of six SNPs from the full measured genotype approach 
exceed the Bonferroni threshold for genome-wide significance. The association is 
strongly supported by replication in two independent European populations, as six 
SNPs in both of these studies exceeded the 5% significance level at least. Direction of 
effect was in agreement for all SNPs with the German cohort, but differed for one 
SNP with the Orkney population. However, this SNP has a minor allele frequency 
approaching 0.5, therefore it is likely the difference represents the major allele in the 
Orkney study being the minor allele in the remaining two studies. 
 
The causal variant (or variants) is probably located within or very close to the 
SLC2A9 gene. Previous studies have identified the SLC2A9 gene product as 
belonging to a solute carrier family of proteins, and it has been reported as acting as a 
glucose transporter (Phay et al., 2000). Levels of linkage disequilibrium within and 
around SLC2A9 are consistent with the hypothesis that a causative variant may be 
tagged by one of the SNPs found significant in this study. One other interesting 
finding to report from this follow up is a significant sex-by-SNP interaction for the 






Results for the seven main uric acid SNPs followed up became slightly more 
significant once analysed under the full model. This is expected due to the partial 
factoring out of SNP effects by steps one and two of GRAMMAR. “Factoring out” 
refers to the loss of some of the variation pertaining to the SNPs tested in step two 
due to removing polygenic variation associated with the pedigree in step one. 
Genomic control can correct for this to some degree as it detects systematic inflation 
or deflation of the test statistic, however it has been suggested that the correction is 
conservative when used for this purpose. Given that all top hits experienced a 
decrease in p-value despite the application of genomic control after step two, it 
appears this is likely to be the case, although in absolute terms the changes are very 
small. 
 
The fact that there were multiple significant hits (five at Bonferroni significance, and 
in total 17 of the 26 followed up were under the 5% level) is highly suggestive of a 
real effect. Analogous to the way in which causative QTN are detected by the 
presence of genotyped SNPs in strong LD with it, correlations between marker 
genotypes may result in similar test statistics among these markers. Since many of the 
supporting hits for uric acid are at SNPs that have an r2 measure in the region of 0.7 
with the most significant SNPs, it is likely that they also tag the same causal variant 
reasonably well, thus reaching suggestive significance. The level of significance these 
SNPs reach ultimately depends on their own level of LD with the causative variant, 
which explains why there is variation in the strength of significance of the intervening 
and surrounding SNPs not identified initially in step two. 
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Further support in favour of the association being real is that of the seven SNPs 
brought forward from the initial analysis, six produced an effect on uric acid going in 
the same direction (i.e., the minor allele decreases uric acid). If many of the top hits 
had effects of the same magnitude but opposing direction then interpretation of the 
results would be more difficult. This is because for two markers in high LD, it is 
highly probable that the minor alleles are in coupling, not repulsion (this becomes 
more likely as MAF decreases, since rare alleles in repulsion never produce high r2), 
and should therefore both tag the same effect from the causative locus. If this is the 
case, it is therefore impossible for the two markers to disagree on the direction of 
effect. Given that the top SNPs associated with uric acid are in relatively high LD, 
with only moderate MAF (the mean of the top six hits is 0.297), it is to be expected 
that the effect directions are consistent. 
 
Despite the top six hits having the same effect direction however, the direction of 
effect does fluctuate for some consecutive SNPs, as seen in Figure 3.1. It follows 
from the previous paragraph that for this to be the case, SNPs with one direction of 
effect should either have low r2 with nearby markers of opposing direction estimates, 
or have a higher MAF. As can be seen using Figures 3.1 and 3.3, this is indeed the 
case. The most significant of the SNPs where the minor allele increases uric acid is 
rs4447863, which has a MAF of 0.435, and r2 with the three nearby SNPs with 
opposite direction (rs10805346, rs13129697 and rs737267 respectively) of 0.06, 0.38 
and 0.34. Similarly, for two other SNPs where the minor allele increases uric acid 
(rs4697695 and rs3733591) r2 values are also low; rs4697695 has r2 of 0.44, 0.20 and 
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0.16, and rs3733591 has r2 of 0.31, 0 and 0.08 to the three SNPs mentioned above. 
This means that the changes in direction of effect are not inconsistent with what may 
be expected and therefore do not bring the validity of the association into doubt. 
 
In addition to fluctuations in the direction of effect, the effect sizes also vary 
considerably between nearby SNPs. Again this is consistent with theory and is a 
consequence of changing allele frequencies at the typed markers, since estimated 
effect size is proportional to the level of r2 between the QTN and marker, and r2 itself 
is highly dependent upon both the frequency of each SNP and how close these 
frequencies are to one another. For example, the consecutive SNPs rs6820230, 
rs10939663 and rs9291645 all have negative effect estimates for the minor allele – 
i.e., the minor allele here is the uric acid increasing allele – and have a minor allele 
frequency of around 0.25 - 0.3 (Figure 3.1). Given that it appears the uric acid 
increasing allele has a much higher frequency than 0.3 (frequencies at the most 
significant SNPs suggest an allele frequency of ~0.7), r2 would be low between these 
three markers and the QTN. Consequently, effect sizes at these loci are smaller in 
magnitude. Correspondingly, for SNPs where the major allele increases uric acid, 
there is a clear relationship between the size of the effect and the allele frequency. 
SNPs with either a higher or lower allele frequency than the top six SNPs generally 
have smaller effect sizes. For example, SNPs rs6849736, rs4502681, rs6845554 and 
rs6827754 all have smaller effect sizes, and have minor allele frequencies different to 
the top SNPs (Figure 3.1), just as predicted. 
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Considering the genetic structure surrounding the SLC2A9 gene, the most likely 
location of the causative QTN is between the recombination hotspots flanking 
SLC2A9 in both directions (Figure 3.4). The presence of the hotspots causes a 
reduction in the level of LD between SNPs on opposing sides of the hotspot. Given 
that all significant SNPs are found within the recombination hotspots it is most 
probable that this is where the true causative variant lies. More specifically, Figures 
3.1 and 3.4, and Table 3.2 show that the strength of association tails off to either side 
of the main association (i.e., rs737367), suggesting that the causal mutation is most 





Results from the follow-up are suggestive of at least one QTL affecting uric acid 
within or near the SLC2A9 gene. Discussion has so far assumed the existence of only 
a single QTN, however it is plausible that more than one QTL is present. One way in 
which this would be possible is if the QTL were all in high LD with each other, as 
then the association would be detecting the effect of all of them. At one extreme it 
may be the case that a specific haplotype increased uric acid level due to a collection 
of QTL, meaning that results shown here tag the entire haplotype rather than an 
individual QTN. It is not necessary that the multiple QTN be on the same haplotype 
however. One way to help tease out individual effects from multiple QTL is by using 
multiple regression, fitting SNPs already found significant in the model as further 
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covariates and then looking for the significant effect of another SNP, and this was 
performed in the follow up investigation. 
 
In orientation 1, where the more significant of the two SNPs from the original 
analyses was fitted first in the model, there was little evidence to suggest that any 
additional SNPs contribute an independent effect to uric acid. Eight of the 10 tests 
have non-significant p-values for the second SNP, and the other two have p-values 
significant at the 5% level. It is not clear that these represent secondary loci however, 
as the level of significance is fairly low, and due to the nature of pairwise LD, the 
secondary-SNP associations are likely to be a consequence of LD between the second 
SNP and the causative variant that is left unexplained by LD between the first SNP 
and the causative variant. This is possible due to the complex nature of three-way LD, 
and is more probable where pairwise LD between the first and second SNPs is not so 
high, but the two pairwise LD measures between each SNP and the causative variant 
are both high. It is not possible to entirely rule out a second QTN, however a greater 
level of significance for the secondary SNP would be more convincing. In orientation 
2, where the order of the SNPs is reversed, most tests have the second SNP 
significant to at least the 5% level. This conforms to expectation if only one causative 
SNP exists however, given the fact that the SNP now second in the model has a larger 
effect on uric acid than the SNP fitted first. 
 
An additional use of the multi-SNP regression analysis was to help fine-map the 
location of a putative QTL (since in this case it appears there is only one at the locus). 
Results for secondary SNPs corrected for the top hit (rs737267) indicate that there is 
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very little of the effect on uric acid not explained by this SNP, as none of the p-values 
for the second SNPs in this scenario exceed 0.05. This is also the case for the second 
most significant SNP, which is located very close to rs737267 within intron seven of 
SLC2A9. The best interpretation of these results is that all significant SNPs are 
tagging the same causative variant, indicating that the causal QTN is in LD with all 
SNPs identified during the initial GWA scan, and rs737267 most of all.  
Consequently, close to intron seven is the most likely location of the QTL affecting 
uric acid. 
 
While there is no solid evidence to imply that there is more than one QTL influencing 
uric acid in this region, there does remain the possibility that multiple QTN exist in 
almost perfect LD with one another (and hence with the same LD with our markers). 
Without complete sequence information, this is extremely difficult to detect however. 
Likewise, it is not straightforward to identify the location of the QTN should the 
association consist of a single causative mutation. Sequencing would be the most 
effective way of getting down to the true causal variant, but this process is both time 
consuming and expensive to perform. 
 
One other potential use of multiple marker data that is not performed here is the 
construction of haplotypes to test for association. It would be interesting be see 
whether any high risk haplotypes exist in this population that better explain the 
variation seen at this locus than any of the individuals SNPs. A single QTL is likely 
to be found more frequently on one genetic background than others in regions of the 
genome exhibiting high LD, such as the uric acid associated region. This is especially 
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likely in a closed population such as the one analysed here, since there is no 
introduction of new genetic information through migration, and founder haplotypes 
can exist largely intact for many generations. Characterising any such haplotypes that 
exist in these data, and determining whether they would better tag the variation in uric 




The results in Tables 3.4 and 3.7 are conclusive in demonstrating that a sex-by-SNP 
interaction exists between the significant SLC2A9 SNPs and uric acid in both the 
Croatian and Orkney populations. There have been very few reports about such 
interactions in the literature, therefore this finding has potentially important lessons 
concerning the way future GWA studies are approached. For example, had the study 
initially been performed using the Orkney population, it is possible the association 
with uric acid would have been missed entirely, as no SNPs reached genome-wide 
significance when males and females were analysed jointly. Only after including the 
interaction in the model does the association become clear in the females. It is 
possible that past studies have missed genuine associations as a consequence of sex 
specific effects that are diluted when the sexes are analysed jointly. However, it does 
not make sense to include an interaction term in the model to begin with, as it reduces 
power to detect effects in the male and female subsets by effectively halving 
population size. Analysing each SNP twice, once with and once without the 
interaction term, is also unfeasible since the number of tests would double, further 
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compounding the multiple testing burden. One possible solution is to take SNPs at 
suggestive significance and fit those in a model with a sex-by-SNP interaction. 
 
This phenomenon of a sex specific effect is in itself very worthy of note, and is 
particularly interesting with regard to the known distribution of uric acid and gout 
among males and females. It is known that uric acid is higher in men (mean uric acid 
levels in the Croatia population for men and women were 362.74 and 273.22µmol/L 
respectively), as is the prevalence of gout. It is interesting to speculate therefore that 
the overall effect of SLC2A9 on gout may be small, given that high uric acid is a risk 
factor for gout and both high uric acid and gout incidence is higher in males, yet 
SLC2A9 has little or no effect on uric acid in males. This theory is supported by the 
fact that no association between gout and the SLC2A9 SNPs was found in the follow-
up analysis. 
 
More generally, it would be interesting to see how many traits were controlled (either 
partially or entirely) by genes with a sex-limited effect. It is possible this 
phenomenon is a feature of conditions in which there is an unequal distribution 
among the sexes, given it is known that gout, of which uric acid is a good indicator, 
has a higher prevalence in males than females. If this were the case, then intermediate 
phenotypes that are risk factors for sex-biased genetic conditions could be tested with 
a sex-by-SNP interaction to elucidate which genes are affecting them. This may be 
particularly useful for candidate gene approaches, where the interaction could be 





The vast majority of the traits connected to uric acid proved to have no significant 
associations with the SLC2A9 hit SNPs. This is not unexpected because the suggested 
links between uric acid and some of these traits are only considered tentative. 
Additionally, some of the extra traits were themselves a disease endpoint, and for 
these traits the effect sizes of the SNPs (assuming they do have an effect on the 
related trait) will be far smaller than any this study is powered to detect. This is 
because rs737267 explains only around 5% of the total variance in uric acid, and any 
effect on other related phenotypes or diseases is thus likely to constitute a smaller 
proportion of variance for these traits. 
 
One instance where the relationship with disease is not so tenuous is with gout, which 
has been strongly linked to uric acid for many years (Seegmiller et al., 1963). Both 
the initial uric acid association, and the subsequent replication in an independent 
cohort analysing FEUA (a stronger predictor of risk to gout) indicate that it is likely 
SLC2A9 also affects gout risk. The SLC2A9 SNPs clearly show no evidence of an 
association to gout in the Croatian population however, as the most significant p-
value was only 0.122 (Table 3.5). An association of this gene to gout was 
subsequently discovered in a study of 11,024 white individuals. A non-synonymous 
SNP within the gene, rs16890979, was associated with gout risk with a p-value of 
7×10-14, and an odds ratio of 0.59 per minor allele (Dehghan et al., 2008). 
 
The one exception where there was some evidence in the Croatian population to 
suggest the SLC2A9 SNPs were associated with one of the additional traits was with 
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the ATP measure of the Metabolic Syndrome. Here, six of the seven main SLC2A9 
SNPs were found associated at the 5% significance level. This would represent a very 
exciting finding if it were true, considering that the Metabolic Syndrome has been a 
difficult disease to characterise both genetically and epidemiologically, and even a 
concrete definition of the condition is hard to find. It must be noted however that 
none of the p-values exceeded the Bonferroni significance threshold, therefore the 






Since the conception of the genome-wide association study (GWAS), it has been the 
norm to analyse genetic data using each single SNP separately. This approach has 
clearly had some degree of success (Hirschhorn et al., 2002), and remains a robust 
way in which to interrogate the genome. However, recently there has been a greater 
focus on using SNP information in more complex ways in an attempt to increase 
power to detect QTL. The justification for this is that while analysing SNPs one at a 
time is currently the favoured method of analysis, it may not necessarily the best. 
Consequently, there is an increasing interest in using alternative methods to analyse 
genome-wide association (GWA) data which may have a better chance of detecting 
QTL, and these methods typically involve utilising more than one marker at a time. 
There are two broad categories that these methods fall into; those that use un-phased 






A haplotype can be defined as an ordered set of multi-locus genotypes such that the 
arrangement of alleles on each chromosome is known. The arrangement of alleles on 
a given chromosome is called its phase. For a haploid organism therefore, it is trivial 
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to determine the phase and haplotype (simply a matter of genotyping), but for diploid 
organisms such as humans, phase can be ambiguous with only genotype data if more 
than a single locus is heterozygous. The haplotype pair belonging to each diploid 
individual is collectively known as their diplotype. 
 
Haplotypes are the name given to specific combinations of alleles at a particular 
locus. While haplotypes may be present at equilibrium frequency (i.e., no more 
frequent than would be expected by chance, given the individual allele frequencies at 
markers comprising the haplotype), for nearby alleles it is more common that the 
alleles forming haplotypes display non-random association. This causes specific 
alleles to be found in combination more or less frequently than would be expected 
given their frequencies. As described earlier in this Thesis, non-random association of 
alleles is known as linkage disequilibrium (LD). Note that although LD between a 
pair of loci can exist over large distances on a chromosome, and that LD can even 
exist between loci on different chromosomes, this does not comprise a haplotype. 
Here we will consider haplotypes that are stretches of adjacent SNPs that collectively 
exhibit linkage disequilibrium. To better illustrate, consider three loci with genotypes 
A/C, C/T and A/G. There is a total of four ways these multi-locus genotypes could be 
arranged into haplotypes pairs, and a total of eight different haplotypes. The four 
combinations are: 
   A C A  A C G  A T A  A T G 
   C T G  C T A  C C G  C C A 
Note that with these three heterozygous loci there are 22 possible diplotypes, and 23 
possible haplotypes. In general, where n denotes the number of biallelic polymorphic 
loci, the number of possible diplotypes and haplotypes can be expressed as 2(n-1) and 
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2n respectively. Non-polymorphic loci have no effect on the number of possible 
haplotypes, since these will be consistent across all haplotypes in the population. The 
number of possible haplotypes in a population increases rapidly with the length of the 
sequence in question; by the time the number of polymorphic loci reaches 20, the 
number of possible haplotypes has grown to more than a million. In practice, 
although this number of haplotypes is possible, there are only a limited number that 




There are two distinct ways in which haplotypes may act to help detect QTL. The 
first of these is when a collection of SNP markers, through LD with causal variants, 
define a set of mutations that together create a “super-allele” that has a large effect on 
an observed phenotype (Schaid, 2004). For example, consider the situation below 
(which for simplicity makes the assumption that all individuals are homozygous at 
these SNPs): 
 
Individual 1   A G C  Case 
Individual 2   A G T  Control 
Individual 3   A G C  Case 
Individual 4   A A C  Control 
Individual 5   A G C  Case 
Individual 6   T G C  Control 
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By analysing these three SNPs one at a time, no association would be found with the 
trait (which in this case is a simple binary case/control phenotype). However, looking 
at all three SNPs simultaneously reveals that the cases all share the same AGC 
haplotype, which none of the controls have. 
 
This sort of situation may arise, for example, due to mutations in protein coding DNA 
regions - protein function often depends upon how the protein is folded, which in turn 
depends on the specific amino acid sequence (Clark, 2004). Multiple specific 
mutations within exons coding for a protein may therefore act jointly to affect protein 
structure, but have no effect on structure individually. By using only single SNP 
analysis on GWA data, it is possible that this type of association will be missed. One 
example of exactly this situation in humans is a gene affecting intestinal lactase 
activity (Hollox et al., 2001), therefore there are clear biological reasons why it may 
be important to study the effect of haplotypes (Schaid, 2004). 
 
The other way in which haplotypes may aid in GWA studies is by increasing 
statistical power to detect marginal effects of single causative QTL. The reason for 
this is that where a single marker may only capture a certain proportion of the 
variance of a nearby causative SNP, other nearby markers may capture variance not 
already explained by this first marker. A haplotype may capture all of this variation 
simultaneously by virtue of accounting for all first order, second order and any higher 
order interaction terms present between markers within the haplotype (Schaid, 2004). 
It has been shown that using two and three SNP haplotypes can increase the number 
of common SNPs tagged at an r2 of at least 0.8 by 25-100% (Pe’er et al., 2006). The 
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concept is similar to the example above, except that here the haplotype tags a single 
SNP variant contributing to the disease / trait rather than several SNPs working 
together to contribute. It is easier to envisage this situation by imagining a relatively 
young causative mutation being introduced to a population on some previously 
established haplotype background. Due to disparate allele frequencies, there will be 
little r2 at the population level between the causative SNP and any nearby SNPs, 
however the new mutation will be in strong LD with the specific set of alleles (i.e., 
haplotype) it arose on. 
 
The type of situation described above is more likely to be found when a causative 
mutation has been introduced by only one or a limited number of founders, and also 
where fairly few generations have passed since the introduction of the mutation. This 
is because fewer founders introducing the mutation means that a greater proportion of 
those carrying the mutation in the current generation will be identical by descent 
(IBD). Consequently, nearby regions surrounding the mutation in these individuals 
will also be IBD, and the individuals are therefore more likely to share common 
haplotypes. Similarly, the fewer generations back to the introduction of the mutation 
there are, the less chance there is for recombination to break down LD around the 
mutation. An isolated population is most likely to fulfil these criteria and for this 
reason may be a particularly suitable population for use of haplotype-based 
association methods (Bourgain and Genin, 2005). 
 
The argument about young variants influencing traits is one of the reasons why the 
common disease / rare variant (CD/RV) hypothesis is becoming more popular, since 
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all young mutations will also be rare without the presence of strong positive selection. 
There is also increasing evidence to suggest that rare variants contribute to common 
complex disease (see for example Crawford et al., 2004), and that common SNPs on 
current genome-wide SNP panels are not good at tagging them (Bodmer and Bonilla, 
2008). This is one area in which haplotypes should perform favourably when 
compared to single SNPs, since joint LD of SNPs in a haplotype background are 
more adept at capturing rare variation. If the CD/RV hypothesis is correct, then GWA 




While there are valid reasons to expect that analysing haplotypes may greatly help 
detect QTL, there are also situations in which haplotypes will never perform as well 
as a single SNP. In addition to this, there are a number of considerations and 
unresolved issues which can make haplotypes difficult to implement and therefore 
less attractive, thus explaining why haplotype analysis is not currently favoured as the 
method of choice in GWA studies. Some of the issues pertaining to haplotype 




There are a number of factors that determine the performance of haplotype-based 
analyses, and thus how well haplotype methods compare in efficiency and power to 
single SNP analysis. Foremost of these are the number of loci affecting a trait, the 
 141 
number of alleles at loci affecting the trait, the density of markers, LD between 
markers, LD between markers and QTL, and finally the allele frequencies of both the 
markers and the QTL (Schaid, 2005). These factors are discussed with reference to 
the recent literature in this section. It is important to note however, that the vast 
majority of relevant literature (and indeed this analysis) assumes that all trait loci are 
biallelic, but this may not always be the case. 
 
It has been shown that haplotype regression analysis is more powerful than single 
SNP regression when the number of haplotypes present is less than the number of 
(non-interacting) trait loci (Bader, 2001). Results from this study also imply however, 
that where there are only one or two QTL within a region, as expected most of the 
time, single SNP analysis will be more powerful. However, this study was performed 
under optimal conditions for single SNP regression, as the QTL themselves were 
included as markers for the analyses. Where this is the case (or if a SNP has r2 of one 
with a QTL), single SNP regression cannot be improved upon by adding extra 
markers because these add parameters to the model without adding new information. 
This highlights the importance of the role that marker-QTL LD plays in the relative 
efficiencies of single- and multi-marker methods. As pairwise LD between markers 
and the QTL drops, and tends towards the extreme of linkage equilibrium, haplotype 
analyses will become more strongly favoured (Bader, 2001). As already noted, one 
way for low LD to exist between markers and QTL is if the QTL is recent, although 




Another important factor for haplotype analysis is the level of LD present between 
markers. While r2 between SNPs is loosely correlated to their distance apart, patterns 
of LD can be complex, and the variance of pairwise r2 statistics is large for pairs of 
SNPs of equal distance apart. Ideally for haplotype analysis there would be moderate 
to high LD between markers comprising haplotypes, since the number of haplotypes 
increases as LD between markers decreases, until at linkage equilibrium there is the 
theoretical maximum number of haplotypes (2n for biallelic loci where n is the 
number of polymorphic loci). At this extreme, haplotypes only introduce noise into 
association tests at the cost of additional degrees of freedom. At the other extreme, 
with complete LD, there would only ever be two haplotypes and any association test 
would be equivalent to testing individual SNPs. More haplotypes means fewer 
degrees of freedom with which to test for association, and herein lies the trade-off 
with haplotype analysis. Extra variation captured by a model by using haplotypes 
must more than compensate for the extra degrees of freedom the haplotypes take up. 
This was illustrated in a power study of haplotype analysis under three different 
haplotypic distributions. In order to maintain power for the flat distribution (i.e., 
where each possible haplotype had equal frequency), sample size had to be 
dramatically increased (Schaid, 2004), illustrating that the distribution of haplotype 
frequencies is key to the power of the haplotype-based tests, and LD between SNPs is 
key to this haplotypic distribution. 
 
Allele frequency is another important issue for association studies, whether for single 
SNP- or haplotype-based analyses. One obvious reason for this is that statistically 
speaking it is not ideal to include low frequency classes in analyses (hence why rare 
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alleles are often removed from GWA studies by quality control), but additionally, 
allele frequency is closely linked to the r2 measure of LD. Loci with markedly 
different allele frequencies will have a smaller pairwise r2, and r2 can never be one 
unless allele frequencies are identical. Following from this, loci with different allele 
frequencies will have lower pairwise LD, and consequently there will be a greater 
number of underlying haplotypes. In regard to QTL detection, disparate frequencies 
of marker and QTL alleles has a direct impact on the ability to detect the QTL since 
marker-QTL r2 is correlated to power (Blangero, 2004). Frequently in the literature 
on simulated haplotype analyses, only very common QTL alleles are tested (for 
example Meuwissen and Goddard, 2000), which implicitly favours single SNP 
analysis, since SNP panels are generally designed to tag common SNP variants by 
inclusion of almost exclusively common SNPs. 
 
While there has been much work in elucidating how the above factors affect the 
relative efficiencies of single marker and haplotype methods, uncertainty still remains 
as to which methods perform best for GWA studies. This has lead to a tendency to 
overlook more sophisticated analysis methods, since the advantages are not well 
characterised, and it is generally faster and simpler to use single SNP regression. The 
above factors are not the only considerations involved in haplotype analyses however, 








The most obvious disadvantage of using haplotype methods to analyse genome-wide 
association data is that usually the haplotypes are all unknown, and must therefore be 
estimated from the genotype data first. While molecular methods to experimentally 
determine haplotypes from diploid DNA do exist (for example the long-range allele-
specific PCR method of Michalatos-Beloin et al., 1996), these methods are not widely 
utilised since they are expensive and generally low-throughput (Niu, 2004). 
Consequently, haplotypes are usually estimated using statistical methods, and there 
are a variety of these for estimating haplotype frequencies in either family-based or 
population-based studies. Family-based approaches, for example Merlin (Abecasis et 
al., 2002), are deterministic and can work well for small pedigrees and few SNPs, 
however larger and/or sparse pedigrees with high numbers of SNPs can cause 
problems both in terms of information to accurately phase all individuals (e.g., if key 
individuals are heterozygous and hence not informative), and also in terms of 
computational feasibility. Of particular concern for family-based haplotype 
reconstruction methods is that most make the assumption of linkage equilibrium 
between all markers, meaning that whenever phase is ambiguous, all potential 
haplotypes consistent with the genotypes are classed as equally likely (Niu, 2004). 
 
The simplest, and one of the most popular algorithms now used for population-based 
haplotype estimation, is the Expectation-Maximisation (EM) algorithm, developed in 
the 1970s (Dempster et al., 1977), and first applied to estimating population 
haplotype frequencies in 1995 (Excoffier and Slatkin, 1995). The EM algorithm 
entails a two-stage iterative procedure that gradually converges on the most likely 
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population frequencies for haplotypes observed in the study population. The 
haplotype frequency estimates are population-based, and therefore based on the 
assumption that all individuals in the sample are independent, i.e., unrelated. Related 
individuals can cause an upwards bias in the frequency of some haplotypes since 
haplotypes of related individuals are not independent. The original version of the EM 
algorithm had stringent limitations regarding both the number of individuals and the 
number of loci that could be phased simultaneously. This was because the algorithm 
started by enumerating all possible haplotypes from the data before dropping those 
that were unobserved, or observed at very low frequency. As already noted, only 20 
SNPs are required to take the number of possible haplotypes above one million, so 
the computation involved to enumerate all possibilities quickly becomes unfeasible. 
Later versions of the EM algorithm have been improved upon so that enumerating all 
possible haplotypes is no longer necessary, and frequencies are only estimated for 
haplotypes consistent with the observed data. 
 
There is also a large number of population-based haplotype estimation algorithms 
based on coalescent theory. One of the most popular implementations in this bracket 
of methods is a Bayesian program called PHASE (Stephens et al., 2001) which 
arrives at haplotype frequency estimates using Markov-chain Monte Carlo (MCMC) 
iterations. Later versions of this algorithm incorporate a useful “divide and conquer” 
feature that allows phasing of longer tracts of DNA than could previously be handled 
(Stephens and Donnelly, 2003). This technique is called partition ligation (PL), and 
works by subdividing the data into smaller segments and phasing these individually 
before re-joining the segments back to original length. Partition ligation was initially 
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introduced by Niu et al. (Niu et al., 2002), and was subsequently incorporated into 
many other methods. There is now a whole suite of Bayesian PL methods, and indeed 
a number of EM methods which also utilise PL (for example the “PLEM” method of 
Qin et al., 2002). 
 
The main drawback of any haplotyping algorithm is that inevitably some level of 
error will be introduced into the data. However, most of the more widely used 
algorithms manage to limit errors to a very small proportion of results. For example, 
Haplotyper (Niu et al., 2002) and PLEM (Qin et al., 2002), two of the recent partition 
ligation EM methods were compared in a simulation study, and were shown to have 
almost 100% accuracy in six different populations representing different haplotype 




Obtaining haplotypes is not the only consideration when using haplotypes for analysis 
of GWA data. For example, it is usually the case that some haplotype frequency 
estimates are extremely low (well below 0.05 for example), and when this is the case, 
it is not obvious how these rare classes should be treated, and nor is it clear what the 
most appropriate threshold is to declare a haplotype rare. From a statistical 
standpoint, it can be problematic to include rare classes in an analysis for two 
reasons. Firstly, rare data classes can lead to unreliable effect estimates and spurious 
positive associations, and secondly, a large number of rare haplotype classes use up a 
correspondingly large number of degrees of freedom with which to test for 
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association, thereby having a detrimental effect on the power of the haplotype test 
(Schaid, 2004). However, it is not clear that other ways of dealing with rare haplotype 
classes are superior. 
 
One of the alternative ways of dealing with rare haplotypes is to pool all rare classes 
and analyse these together, often as the base of comparison for all other haplotype 
classes. This approach is not optimal because potentially very large numbers of 
disparate haplotypes are being grouped together, and this may swamp any true effects 
of the mixed classes. Also, it makes sound interpretation extremely difficult if this 
“junk” bin is found to be associated with the trait. Another way to handle rare classes 
is to exclude them from analysis entirely, but this is unappealing because it may mean 
losing valuable information from the analyses. A slightly more sophisticated way to 
incorporate rare haplotype classes is to group all related haplotypes using a clustering 
algorithm (e.g., Morris, 2005; Li et al., 2006), although this may still homogenise 




The most variable aspect of haplotype-based tests is the method of analysis. Many 
different ways to analyse haplotype data have been proposed, however there is little 
consensus upon which is best. A typical method of analysis would involve a score test 
or some sort of regression of the trait onto an X-matrix consisting of the haplotypes, 
but even then parameterisation of the test can vary. The method will also vary 
depending on the exact nature of the haplotype data. Many haplotyping algorithms 
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produce both a best estimate of an individual’s haplotype pair (a “best-pair 
estimate”), and probabilities for each of the possible haplotype pairs per individual 
(Stephens and Scheet, 2005). Details of the analysis will vary depending upon which 
of these outputs is used. 
 
When best-pair estimates are used, there are two main ways in which this information 
can be utilised for testing the data. The first of these is to test each haplotype 
separately against one joined pool of all the remaining haplotypes. One problem with 
this is that the joined pool will consist of many heterogeneous haplotypes, and some 
of these may be similar to the tested haplotype, making an association both hard to 
detect and difficult to interpret. Not only that, but depending on the number of 
distinct haplotypes in the data, there may be a large number of tests performed, which 
must be corrected for in order to account for type I errors. Again, it would be possible 
to reduce the total number of tests performed in this situation by using a haplotype 
clustering algorithm. This use of best-pair estimates is best suited as a direct approach 
for when a particular haplotype is already suspected to have an effect on the trait. 
 
The second way in which best-pair haplotype estimates can be used is to fit all 
separate haplotypes individually in the model as fixed or random effects, and 
simultaneously estimate effects for all of them. Wald’s F-statistic, for example, could 
then be used as an overall test for association of all haplotypes on the mean trait 
value. The numerator degrees of freedom for this test is the number of haplotypes, 
therefore this technique also suffers from the problem of reduced power when the 
total number of haplotypes is high, as there may no longer be sufficient degrees of 
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freedom left to reject the null hypothesis. Another problem with this type of test is 
that as the number of haplotypes increases the test becomes rather general, since no 
single haplotype is implicated as being the cause of association. 
 
The strategies mentioned above are all based on using best-pair haplotype prediction 
for each individual. However, this makes the assumption that the best-pair prediction 
for each individual is known to be the correct diplotype, which may introduce 
substantial error into the data if the prediction is wrong. For example, given a 
situation where an individual has two potential diplotypes with probabilities 0.49 and 
0.51, the individual will always be assigned the diplotype that has 0.51 probability. 
Or, to consider an even more extreme example, if an individual has ten possible 
diplotypes each of approximately equal probability, the diplotype with the highest 
probability will be assigned to the individual with certainty, and no record of the 
uncertainty with which the diplotype was assigned is retained. 
 
Where information exists about the probability of each possible pair of haplotypes an 
individual might possess, a more complex regression model can be fitted allowing 
each individual to be a mix of many probabilities for different haplotypes. Haplotypes 
are fitted as linear covariates in this parameterisation, each individual having a vector 
of length n (n = number of haplotypes) giving the probability of possessing each 
haplotype. Again, overall significance of the haplotypes on the trait can be tested 
using Wald’s F-statistic. One disadvantage of this parameterisation is that no 





There has been extensive work over the last few years in an attempt to determine how 
haplotype methods perform compared to single SNP and multi-SNP genotype 
methods, and many novel haplotypic tests have consequently been proposed. Many of 
these methods were designed to detect loci affecting binary phenotypes in case-
control studies, however they can still provide valuable insights into what may be 
expected for quantitative phenotypes. The typical way to test for differential 
haplotype frequencies between case and controls is to use the EM algorithm to 
estimate haplotype frequencies, then calculate sample likelihoods in cases, controls 
and the pooled sample (L1, L2 and L3). The chi-square distributed likelihood ratio test 
statistic is then χ2 = -2 ln[L1/(L2L3)], with degrees of freedom given by the number of 
haplotypes minus one (Zaykin et al., 2002). Numerous alternative methods have now 
been suggested, and debate concerning the relative merits of using haplotypes 
compared to single marker analysis continues. Many of the methods that have been 
proposed for testing haplotypic effects in case-control studies are described in detail 
in Cordell, 2006, although this is not in direct comparison to how single SNP 
analyses perform. 
 
Considerable evidence from the literature exists to suggest that haplotypes can 
increase power to detect associations for binary phenotypes (e.g., Akey et al., 2001; 
Morris and Kaplan, 2002; Li and Jiang, 2005). Akey et al. point out that haplotype 
tests are more robust than single marker analyses because, where evolutionary forces 
(such as random drift and mutation) and varying degrees of initial marker-QTL LD 
act to increase the variability of observed pairwise LD between marker and disease 
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loci, simultaneous analysis of multiple markers as haplotypes can result in 
comparatively simpler patterns of LD (Akey et al., 2001). In the case of Morris and 
Kaplan, it was demonstrated that haplotype-based analyses are optimal for detecting 
disease susceptibility loci when multiple alleles are present at a single disease 
susceptibility locus (Morris and Kaplan, 2002), even though power will be below that 
possible if the locus was biallelic (Slager et al., 2000; Longmate, 2001). In this multi-
allelic situation, haplotypes do best when there is less LD between markers, therefore 
increasing the number of potential haplotypes, since this allows each disease locus 
allele to be present on a unique haplotype. 
 
Other case-control based studies have found that relative efficiencies of the 
contrasting methods are dependent upon the level of LD between markers, such that 
the optimal method varies (Nielsen et al., 2004), and yet others suggest that single 
SNP analyses, or analyses based on multiple SNP genotypes are always more 
powerful than using haplotypes (Chapman et al., 2003; Clayton et al., 2004). It is 
undoubtedly be the case that single SNP analysis will perform best when a single 
causative QTL is in extremely high LD with a typed SNP, for example. 
 
In other situations, It is also conceivable that multiple different SNPs each in partial 
LD with a given QTL with no strong tagging SNP will pick up extra marginal effects 
and hence perform better than any other method. In this latter case, it is unlikely that 
haplotype analysis would perform better, since many more degrees of freedom would 
be used to explain only a little more variance. However, it is also likely that in some 
situations a haplotype will be better able to characterise the variation present at a QTL 
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and hence capture the effect more efficiently than any single marker or set of 
unphased markers. The frequency with which this might be the case is one thing the 
literature is unsure of however, and furthermore is currently unable to address, given 
that haplotypes are relatively unused in GWA studies to date. 
 
More recently, there has been a plethora of association methods designed to use 
haplotypes to analyse quantitative phenotypes as opposed to binary ones. Once again 
there are no conclusions as to which method is definitively best, but there is yet more 
evidence to suggest that haplotypes can out-perform single SNP analysis. Often, 
where results suggest that single SNP analysis is uniformly best, it is not unexpected 
given that the parameters of the analysis strongly favour this outcome, for example by 
including the QTL as part of the tested marker set (Jannot et al., 2003), having high 
QTL minor allele frequency (Zhao et al., 2007), or by having extremely dense 
markers likely to be in high LD with the QTL (Grapes et al., 2004). These are all 
situations which would be ideal for QTL detection regardless of the method used, and 
therefore it seems reasonable to surmise that the majority of QTL falling into this 
category have already been found – the challenge remains to find QTL which have so 
far proven elusive however. 
 
There are many papers which have reported haplotypes increasing the power of an 
association test. One of the key factors in developing a good test for association is 
being able to take into account phase uncertainty from the haplotype prediction (in 
situations where phase is not already known). Only selecting the most probable 
haplotype pairs can cause substantial loss of information, particularly if LD is not 
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strong between the marker SNPs, since then confidence in the most probable pair is 
lower (Schaid et al., 2002). This loss of information introduces errors into the X-
matrix (haplotype scoring matrix) which in turn can lead to biased estimates of 
haplotypic effects (Zhao et al., 2003), and possibly inflate the error of estimated 
parameters (Tanck et al., 2003). It has been suggested that haplotype uncertainty is 
not as bad in family-based studies since there is often enough information to be 
accurate (Lee and Van Der Werf, 2005), however it has been found in population-
based association studies that simply assuming the most likely diplotype is true can 
have detrimental effects (Morris et al., 2004). 
 
Due to the importance of accounting for haplotype ambiguity appropriately, recent 
methods now explicitly model the probabilities of all possible haplotype pairs for 
each individual (Schaid, 2004). Many of these models have been shown to out-
perform single SNP analyses even when there is only a single QTL influencing a trait 
(e.g., Zaykin et al., 2002; Becker and Herold, 2009), and the relative performance of 
haplotypes compared to single SNP analysis should improve as the number of QTL 
loci increases (Bader, 2001). The vast wealth of existing data on which method of 
analysis is likely to work best for GWA studies only acts to highlight the truly 
complex nature of the underlying genetics, and emphasises the fact that as yet there 
are still very few concrete conclusions. Much work clearly remains to be done in 






In this chapter, several different methods for analysing GWAS data are compared; 
single SNP regression, multiple regression using three, five and seven SNPs, and 
haplotype analysis using windows of three, five and seven SNPs. These analyses 
should add to the current literature and help elucidate under which circumstances the 
respective methods perform best. In particular, a key aspect of these analyses was to 
explore how the different methods perform for QTL with rare minor allele frequency 
(MAF), something not investigated in the literature to date. In addition to assessing 
how the overall methods perform, these analyses should also give some indication 
about how differing window lengths for the multi-marker methods affects their power 
to detect QTL. 
 
In these analyses a single causative polymorphism at one locus was considered, 
which should be the most beneficial situation for single SNP analysis (Bader, 2001; 
Schaid, 2004). To determine which methods were performing best, “pseudo-traits” 
were created using real genotype data. This was achieved by removing one SNP at a 
time from the marker genotype data, and adding to the genotype value of the removed 
SNP a random number drawn from a normal distribution. The additional noise 
reduced the heritability of the “trait” and also made it more truly quantitative. Local 
SNPs were used in each of the statistical models in an attempt to detect the surrogate 
QTL (sQTL), and this was performed for each SNP along a whole chromosome. 
Comparing results from each of the different methods should help clarify the role 







The data used in this chapter were genotypes from chromosome 4 of the CROAS 
dataset introduced in chapter one. Using real genotype data meant that realistic 
patterns of genomic architecture were used (LD patterns, allele frequencies and 
haplotypes) rather than simulated IBD patterns and population genetic parameters 
(Hoggart et al., 2007). Quality control was performed such that SNPs or individuals 
with low call rate (<95%) were removed. Rare SNPs, i.e., those with a minor allele 
frequency below 0.05, were retained because these were of intrinsic interest to the 
study. Only founders and singleton individuals were used due to the fact that the 
haplotyping algorithm used for these analyses (PHASE) assumes all individuals are 
independent (i.e., unrelated). Including related individuals would therefore upwardly 
bias the population frequency of certain haplotypes due to sharing between family 
members. After quality control, the final dataset consisted of 17,022 SNPs and 453 




No “real” phenotypic data were used in these analyses. Instead, phenotypes were 
generated using the genotypes of SNPs that comprised the genotypic dataset. Each 
SNP used as a phenotype took the raw genotype score for each individual (i.e., 0, 1 or 
2 corresponding to number of a given allele), and added to this a random number 
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drawn from a normal distribution, in order to produce 70% noise. The added noise 
was calculated in the following way: 
 
    σ2noise = (1/0.3)σ2sQTL - σ2sQTL 
 
where σ2noise is the variance added corresponding to noise, and σ2sQTL is the variance 
of the sQTL genotypes. In this way, the heritability of the “trait” was reduced from 1 






The aim of this study was to compare the performance of several methods for 
analysing GWAS data in terms of their power and ability to capture trait variation. 
The methods compared were single SNP regression, multiple regression using three, 
five, and seven SNPs, and haplotype analysis using windows of three, five and seven 
SNPs. With 17,022 SNPs used as pseudo-traits, performing a genome-wide scan with 
all methods for each one was not feasible, and any significant results arising from 
SNPs on different chromosomes would only represent false positives anyway. 
Therefore to cope with the computational and time constraints, a test region of 100 
SNPs (50 in each direction) surrounding each sQTL was selected to perform analyses 
on. Since each sQTL required 50 SNPs to either side of it, this meant that the first 
sQTL was the 51st SNP of the dataset, and the last was the 16,972nd SNP, and 
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therefore the total number of sQTL was 16,922. Note that the total number of tests 
performed on the test region of each sQTL varied depending on the method used. For 
single SNP regression there was always exactly 100 tests, but with three-SNP 
multiple regression for example, only 98 tests were possible because that is the 




For each sQTL, simple linear regression was performed on each SNP within the 100-
SNP test region. The SNPs were coded as 0, 1, 2 or NA for missing, and were fitted 
as linear covariates, therefore the test was additive. No covariates or fixed / random 
effects were fitted. The sQTL was dropped from the set of test SNPs and therefore 
not tested. The model is as follows: 
 
    yi = µ + kgi + ei 
 
where yi is the phenotype for the ith individual, µ is the mean, k is the additive effect 
of an allele, gi is the genotype of the ith individual, and ei is the residual error term for 
the ith individual. A two-sided F-test was used to test the effect of the SNP, with one 
and n-2 degrees of freedom (df), where n is the number of individuals in the test. This 






Multiple regression was performed using a sliding window across the 100-SNP test 
region of each sQTL, moving forward a single SNP at a time. Regression models 
using windows of three, five and seven SNPs were used. This meant that different 
numbers of tests were performed for the sQTL over different window lengths, since 
the number of n-SNP windows possible within 100 SNPs decreases as n increases. 
The total number of tests performed for each sQTL was 98, 96 and 94 for multiple 
regression window lengths of three, five and seven respectively. As for SSR, sQTL 
were always dropped from the test region, and therefore never used in any of the 
windows. 
 
Again, SNPs were coded as 0, 1, 2 or NA for missing. SNPs were fitted as linear 
covariates, and no other covariates or fixed / random effects were fitted. The model 
is: 
 
    yi = µ + Σj kj gji + ei 
 
 
where kj now represents the effects of the jth SNP and gji is the genotype of the ith 
individual for the jth SNP. The test performed for each model was Wald’s F-statistic 
test, which tests for an overall association of SNPs with the sQTL. The F-test has n 
and N degrees of freedom, where n is the number of SNPs in the regression model, 
and N is the number of non-NA individuals minus n minus one. The multiple 
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regression methods are referred to as MR3, MR5 and MR7 respectively for window 




As with the multiple regression methods, haplotype analyses were conducted using 
three, five and seven SNPs. To perform haplotype analyses, haplotype estimates must 
first be obtained. This was carried out using the statistical software PHASE, which 
calculates not only the most likely diplotype for each individual, but also diplotype 
probabilities for all possible haplotype pairs. While the analyses themselves 
comprised of haplotypes consisting of three, five and seven SNPs, in order to ensure 
haplotypes were as accurate as possible, 11 SNPs at a time were phased, and 
haplotypes for the middle n were extracted for analysis. Each window of 11 
consecutive SNPs from the beginning to the end of the chromosome was haplotyped. 
In addition, extra windows were also haplotyped to account for situations where the 
window spanned an sQTL position. For each sQTL ten windows required dropping of 
the sQTL to haplotype. Consequently, the number of windows haplotyped was 
increased approximately ten-fold. 
 
In determining that 11 was the optimal number of SNPs to phase, a trade-off was 
made between the time taken to phase a single window of n SNPs and the accuracy of 
the estimates produced. 11 SNPs represented the best compromise as there was little 
difference in the frequency of the central seven-SNP haplotypes when using 11 SNPs 
to estimate them than from haplotypes estimated using longer windows. The 
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difference was even less so for haplotypes of length three and five SNPs. The 
increase in time taken to phase windows was not linear with number of SNPs, and 
became prohibitive above 11 SNPs. PHASE took approximately 41 seconds to run 
with 11 SNPs, therefore performing all the phasing required for these analyses would 
take 90 days for a single computer. However, increasing the number of SNPs phased 
each time to 13 would have increased this figure to over 195 days. Haplotyping 11-
SNP windows meant that for all haplotype methods there were 90 tests for each sQTL 
test region. This is because the last full 11-SNP window available within any 100-
SNP test region will encompass SNPs 90-100 (inclusive). 
 
Once haplotype estimates were obtained from PHASE, diplotype probabilities for 
each individual were used to calculate probabilities of each three, five and seven SNP 
haplotype for that individual. The probabilities for each individual / haplotype 
combination were calculated by summing the halved diplotype probabilities from a 
given individuals’ possible diplotypes. For example, consider the simplified situation 
below: 
 
Diplotype: 0 1 1 0 1 1 1 1 1 1 1 / 1 0 0 1 0 0 0 0 0 0 0  probability of 0.6 
Diplotype: 1 0 1 0 1 1 1 0 0 1 1 / 0 1 0 1 0 0 0 1 1 0 0  probability of 0.3 
Diplotype: 0 0 0 1 0 0 1 1 1 1 1 / 1 1 1 0 1 1 0 0 0 0 0  probability of 0.1 
 
This individual would have the following three-SNP haplotype probabilities: 
 
Haplotype: 1 1 1    probability of 0.45 
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Haplotype: 0 0 0    probability of 0.45 
Haplotype: 0 0 1    probability of 0.05 
Haplotype: 1 1 0    probability of 0.05 
All other population haplotypes:  probability of 0 
 
These probabilities would then be used to create a haplotype vector for each 
individual, where for each possible haplotype there was a non-zero probability, and 
for each haplotype not possible the probability was zero (so the length of the vector is 
equal to the number of haplotypes in the population for this window). In this way, for 
every 11-SNP window phased, each individual had one vector for each haplotype 
length of lengths “n3”, “n5” and “n7”, corresponding to the number of haplotypes in 
the population for haplotype lengths three, five and seven respectively, with each 
vector summing to unity. All haplotypes were kept, regardless of frequency. 
 
The haplotype probabilities for each haplotype were fitted in a regression model as 
linear covariates. No other covariates or fixed/random effects were fitted in the 
model. The model was identical to that shown for multiple regression, except that “j” 
now refers to haplotypes, not SNPs. The test performed on these data was Wald’s F-
statistic with numerator degrees of freedom equal to the number of haplotypes in the 
model, and denominator degrees of freedom equal to N (number of non-NA 
individuals) minus numerator degrees of freedom minus one. As already mentioned, 
this is only one of a number of ways that such haplotype data can be analysed, and is 
similar to the haplotype trend regression (HTR) method of Zaykin et al. (Zaykin et 
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al., 2002). The haplotype analyses are referred to as HL3, HL5 and HL7 respectively 




Analyses were conducted using in-house scripts written in the computer 
programming language Perl and the statistical software R programming language. 
Haplotyping via PHASE was called from Perl scripts, and relevant parts of the output 
from PHASE were then extracted. To perform the statistical tests, the scripts called R 
and used the regression function lm(). The proportion of variance explained from 
each model, along with the overall p-value for association, were recorded for each 
test performed for each sQTL. For example, for three-SNP multiple regression there 
were 98 tests per test region, and 16,922 test regions in total, therefore there were 
1,658,356 lines of results for this method. 
 
Both the p-value and the proportion of variance explained by the model were 
extracted, as these are both indicators of how well a method has performed. As the 
basis of comparison across methods, the p-value is the better statistic of the two, as 
this takes into account the fact that the methods have different numbers of 
parameters. In general, the more parameters there are in a model, the more variance 
will be explained, however it is not always the case that the model explaining most 
variance is the best (i.e., most significant) model. This is because a highly 
parameterised model may explain only slightly higher proportion of variance than a 
model with less parameters, but it will have less degrees of freedom to test with. This 
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is important, particularly in the haplotype analyses, because the total number of 
explanatory variables may be large; for example the theoretical maximum number of 
haplotypes with seven SNPs is 128. For this reason, using the p-value (or –log10 p-
value) provides a more appropriate comparison across methods than the amount of 




A heritability of 0.3 was decided upon based on permutation analyses to calculate the 
empirical distribution of the test statistic under the null hypothesis. Due to the 
computationally intensive nature of permutation analysis, and therefore the inherent 
time constraints, four methods were chosen on which to perform the permutations; 
SSR, MR3, MR7 and HL7. Of the haplotype methods, HL7 was selected because this 
is the one that should exhibit the most extreme test statistic inflation. This is because 
HL7 will have a large number of classes (i.e., haplotypes), some of which will be 
rare, and there is a greater probability that by chance a permutation creates spurious 
association between one of these haplotype classes and the sQTL. This is especially 
true for sQTL with low minor allele frequency, therefore of particular interest was 
how the test statistic of sQTL with low MAF behaved. Consequently, while six sQTL 
with differing MAF were permuted, four of these were sQTL with MAF < 0.05. The 
MAF of the six sQTL permuted were 0.018, 0.025, 0.037, 0.046, 0.252 and 0.457. 
For each method and sQTL combination, 1,000 permutations were performed. 
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The sQTL phenotypes were permuted over individuals, therefore breaking 
correlations between sQTL and SNPs, but retaining patterns of LD between SNPs. 
For each permutation, the whole of chromosome 4 was used to test for association 
(which lead to marginally different numbers of tests over methods, due to the 
differing window lengths). The most significant p-value from each permutation was 
retained, and a distribution of most significant p-values of length 1,000 was created 
for each method and sQTL combination. From this distribution of most significant p-
values, the 95th percentile was used to determine the true -log10 p-value required to 
reject the null hypothesis at a chromosome-wide significance level. 
 
Results for sQTL where no noise was added to the trait (i.e., the phenotype is the raw 
genotypic value 0, 1 or 2) are shown in Figure 4.1. Assuming a Bonferroni correction, 
the -log10 p-value for chromosome-wide significance for all methods is 5.53. As can 
be seen from Figure 4.1, the three regression methods have slightly elevated -log10 p-
values for the four SNPs with MAF below 0.05, but in comparison, the test statistics 
for HL7 are vastly inflated. Interestingly, -log10 p-values are all slightly below 5.53 
for the common sQTL. This is likely to be because for each method, tests for 
neighbouring SNPs / windows are correlated due to LD between markers, therefore 
the number of independent tests is less than the total number of tests performed, and 
the Bonferroni correction is too stringent. Tests for methods using more SNPs are 






Results of permutations for sQTL with 50% and 70% noise are shown in Figures 4.2 
and 4.3. These show that test statistic inflation for rare sQTL is greatly reduced by 
introducing noise to the raw sQTL value. The largest test statistic inflation is still seen 
for the sQTL with lowest MAF, however with 70% noise (Figure 4.3), the 95th 
percentile of the test statistic distribution for HL7 is just over seven for the rarest 
sQTL, and this drops to just over six for the rare sQTL with highest MAF (of the four 
rare sQTL).  This indicates that for rare sQTL, test statistic inflation for HL7 will be 
minimal. Test statistics for the other methods remain roughly constant across all 
sQTL for 50% and 70% noise. Note the greater reduction in test statistic for common 

























Figure 4.1 Empirical threshold for chromosome-wide significance for SSR, ML3, ML7 and 
HL7 for a variety of sQTL with different MAF. SNP numbers correspond to the six SNPs 
mentioned in the text to be used as sQTL. MAF for these sQTL are 0.018, 0.025, 0.037, 






Results from these permutations indicate that introducing noise to the sQTL is 
essential to prevent large inflations of the test statistic for sQTL with low MAF. At 

















































Figure 4.2 Empirical threshold for chromosome-wide significance for SSR, ML3, ML7 and 
HL7 for a variety of sQTL with different MAF. 50% noise is added to each of the sQTL. SNP 
numbers correspond to the six SNPs mentioned in the text to be used as sQTL. MAF for these 
sQTL are 0.018, 0.025, 0.037, 0.046, 0.252 and 0.457 respectively. 
Figure 4.3 Empirical threshold for chromosome-wide significance for SSR, ML3, ML7 and 
HL7 for a variety of sQTL with different MAF. 70% noise is added to each of the sQTL. SNP 
numbers correspond to the six SNPs mentioned in the text to be used as sQTL. MAF for these 
sQTL are 0.018, 0.025, 0.037, 0.046, 0.252 and 0.457 respectively. 
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means that p-value (or -log10 p-value) comparisons across methods for sQTL with 
MAF this low will be slightly biased in favour of HL7, since this method has higher 
test statistics under the null hypothesis. However, it is likely that the inflation for HL7 
still present at 70% noise is largely a problem unique to this method, since the 
number of classes for both HL3 and HL5 will be less (and the frequencies of these 
classes less likely to be very rare). Indeed, the average degrees of freedom fitted for 
each of HL3, HL5 and HL7 was 6, 12 and 22 respectively. Consequently, test statistic 
inflation should be much less, and perhaps not evident at all, for HL3 and HL5. 
Increasing noise further would greatly affect power for all methods, thus decreasing 
both the ability to distinguish between them, and the ability to draw meaningful 
conclusions about their relative performances. Therefore, a noise comprising 70% of 






To characterise the minor allele frequency distribution of the sQTL in this study, the 
MAF for each SNP used as a sQTL was calculated, and the sQTL placed MAF bins 
accordingly. Figure 4.4 shows the total number of sQTL in each MAF bin. The nine 
bins with MAF above 0.05 each contain more than 1,500 sQTL, and are comparable 
in sQTL number. The MAF bin with the most sQTL is 0.1 – 0.15, containing 2,121 
sQTL. The bin with the fewest sQTL is the one containing sQTL that would be 
classed as rare SNPs, the 0 – 0.05 category. There are only 579 sQTL in this category 
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- almost a third less than the next smallest group. This is almost certainly a 
consequence of ascertainment bias in the type of SNPs selected for inclusion on the 




The frequency distribution of the distance between adjacent SNPs is shown in Figure 
4.5. The plot shows the expected pattern, with a high proportion of adjacent SNPs 
being close to one another, and increasingly smaller proportions as distance becomes 
larger. Figure 4.6 shows the sizes of the 100-SNP test regions in Kb. Changes in 
density of the SNPs on chromosome 4 would cause the test region size to vary, which 
would make comparisons across sQTL less meaningful. In general the window sizes 
are fairly uniform, except for a large increase at around the 5000th sQTL. This is 
caused by a 3.05Mb gap between SNPs 5005 and 5006, and represents the location of 
Figure 4.4 The number of sQTL that have minor allele frequencies within each of ten 
different 0.05-wide MAF bins. 
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the centromere on chromosome 4. There are exactly 100 windows comprising this 
spike on the graph, as is consistent with a single large gap. The mean test region size 
is 1.12Mb while including the 100 centromeric test regions, and 1.10Mb without. It 
also appears that the sizes of the final thousand windows or so are slightly smaller. 
This is presumably because LD between neighbouring SNPs is relatively low for this 
region and therefore more are required for the appropriate level of coverage, hence 
decreasing the distance between the sets of 100 SNPs. It should be noted that the 






Figure 4.5 Distribution of distances between each adjacent pair of SNPs (in a 3’ to 5’ 
direction) used in the analysis. Groups are separated by 50,000bp (0.05Mb). Distances over 




Table 4.1 shows the mean, minimum and maximum test region sizes for sQTL 
separated into MAF bins. Interestingly, the mean test region size for the lowest MAF 
bin is higher than the rest of the means, and to a lesser extent so is the mean for the 
0.05 – 0.1 MAF bin. This phenomenon may again reflect the way SNPs were selected 
for the Illumina panel. Adjacent SNPs often have similar allele frequencies, and for 
these particular SNPs, MAF is very small. Low MAF SNPs were not selected by 
Illumina, therefore there is more likely to be a less densely packed region on the SNP 
panel near SNPs exhibiting low MAF. Low MAF SNPs present on the panel may just 
happen to have low MAF in this specific population, yet be above the cut-off MAF 
for the panel in the original discovery dataset. The pattern seen in Figure 4.6 is also 
produced by plotting the 11-SNP haplotype windows used in PHASE. Once again 
there is a spike corresponding to the centromere, and as expected there are ten 
windows comprising this spike (graph not shown). The average window size is 
112.26Kb including the ten centromeric windows and 110.12Kb not including them. 
 
Figure 4.6 Test region sizes in kilobases for each of the 16922 sQTL. 
 171 
MAF BIN MEAN MINIMUM MAXIMUM 
0 – 0.05 (bin 1) 1188041 446989 5523241 
0.05 – 0.1 (bin 2) 1147076 415616 5474898 
0.1 – 0.15 (bin 3) 1134994 423244 5527773 
0.15 – 0.2 (bin 4) 1125144 416672 5544199 
0.2 – 0.25 (bin 5) 1112178 415275 5523025 
0.25 – 0.3 (bin 6) 1103402 416916 5513875 
0.3 – 0.35 (bin 7) 1113161 426085 5521348 
0.35 – 0.4 (bin 8) 1084275 415127 5494813 
0.4 – 0.45 (bin 9)  1124262 429845 5512279 




Another important aspect to consider is the pairwise LD between SNPs. With 17,022 
SNPs, the full pairwise matrix would be extremely computationally demanding to 
calculate. Instead, overlapping windows of 5,000 SNPs were analysed, moving on 
3,000 SNPs each time. This meant there were at least 5,000 pairwise estimates for 
any given SNP, and at most there were 8,000. The distribution of pairwise r2 
estimates between all adjacent markers is shown in Figure 4.7. There is a large 
proportion of SNPs with low (0 - 0.05) r2 to adjacent SNPs, almost a quarter of all 
SNPs. This was expected as Illumina explicitly aims to select independent SNPs 
where possible. Interestingly, there are also a reasonable proportion of adjacent SNPs 
in high LD (15% have r2 of at least 0.7), and over 5% have an r2 of one. This may be 
a consequence of the fact that the sample size is relatively low, and that the data are 
from an isolated population where LD is expected to be higher. 
Table 4.1 Mean, minimum and maximum test region size for sQTL within 
the ten MAF bins. Bin numbers in parentheses denote how MAF bins are 




Pairwise r2 estimates were also used to calculate the mean sQTL-marker LD for each 
SNP position within the test region, and this was performed separately for each MAF 
bin. Averaging was over the marker-sQTL LD estimate for each sQTL within a MAF 
bin at that given position in the test region. A graph of this is shown in Figure 4.8. LD 
is greatest between SNPs which are closest to the sQTL, as would be expected, and 
tails off as distance increases. At either end of the test region all MAF bins have 
converged at a base level of average LD, of around 0.02. The differences in the peaks 
of LD for the lowest four MAF categories are quite pronounced, however the 
remainder of the MAF bins are fairly clustered. Even so, they follow the same general 
pattern that sQTL with larger MAF have greater average pairwise LD with SNPs at a 
given position within the test region. The maximum average level of LD for the 
highest MAF bin was 0.40, but just 0.13 for the lowest MAF bin. 
 
Figure 4.7 Distribution of pairwise LD between adjacent marker SNPs (in a 3’ to 5’ 






Figure 4.9.1 shows the mean proportion of sQTL variance explained by each SNP 
position within the test region, for each of the separate MAF bins. Along the x-axis is 
the position within the test region of the tested SNP, and the y-axis shows the mean 
proportion of variance explained. For all MAF bins, the SNPs closest to the sQTL 
position (i.e., the one on each side) explain on average the highest proportion of 
variance. For the lowest MAF bin the mean proportion of variance explained reaches 
just over 0.03 at SNPs adjacent to the sQTL. For the next two MAF bins the 
proportion of variance explained increases by around 0.017 each time, then the 
increase between neighbouring MAF bins tapers off. MAF bin 0.45 - 0.5 has the 
highest mean at just over 0.101 (10.1% of the total variance being explained). Note 
that while on average only 10.1% of the total variance is explained, this amounts to 
Figure 4.8 Mean pairwise LD between each SNP position and the sQTL, for each sQTL 
within a given MAF bin. All ten MAF bins are shown. The sQTL is located between the 50th 
and 51st SNPs. 
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just over 33% of the heritable variation, since each sQTL has a heritability of 
approximately 30%. As this is the average amount of variance explained, the 
maximum proportion of variance explained by SNPs in each bin would be higher. At 
only around 20 SNPs to either direction of the sQTL there is no appreciable 




Results in Figure 4.9.2 show the percentage of times each SNP position explains the 
largest proportion of variance. As expected, the closest SNPs to the sQTL are more 
often found to explain most variation, and this amount is greatest when MAF is large. 
As MAF of the sQTL drops, there is a greater chance that the SNP explaining most 
variation will be located further away. Even so, except for the lowest two MAF bins, 
the chance that a SNP will explain most variation is very small from around ten SNPs 
in either direction of the sQTL. For the lowest MAF bin, the SNP explaining the 
highest proportion of variance is located more than ten SNPs away in either direction 
Figure 4.9.1. Mean proportion of variance explained by each SNP position for single SNP 
regression. Averages are calculated separately for different sQTL MAF bins. SNP position 
within the 100-SNP test region is represented on the x-axis, the sQTL position is between the 
50th and 51st SNPs. 
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Figure 4.9.3 shows the mean –log10 p-values for each SNP position in the test region, 
once again separated by MAF bin. As in Figures 4.9.1 and 4.9.2, the MAF bins are 
ordered such that sQTL with the lowest MAF perform worst (i.e., have low –log10 p-
values), and sQTL with the highest MAF are performing best (have high –log10 p-
values). For the highest MAF bin, the most significant SNPs reach a –log10 p-value 
just under 12, and for the lowest MAF bin they are just over four. There is little 
separating the top few MAF bins; just 0.5 between the top six MAF bins, whereas 
there is almost 1.5 -log10 p-value units between each pair of adjacent MAF bins from 
the first to the fourth. 
 
 
Figure 4.9.2. Percentage of times each SNP position explains the highest proportion of 
variance, calculated separately for different sQTL MAF bins. SNP position within the 100-










In real GWA studies, the frequency of a causative QTL is unknown, therefore it may 
be instructive to compare overall results from each method averaged over all MAF 
bins, to see on average how well each method performs. Results from single SNP 
regression are also shown in this comparison. Figure 4.10.1 compares the overall 
mean variance explained by each SNP position for each of the four methods. Where 
the method involves multiple SNPs, the graph is aligned such that the middle SNP in 
each regression window is constant. 
 
 
Figure 4.9.3 Mean –log10 p-value for each SNP position for single SNP regression. Averages 
are calculated separately for different sQTL MAF bins. SNP position within the 100-SNP test 




In all instances the SNP or group of SNPs located closest to the sQTL explain the 
highest proportion of variance for a given method. Since the number of SNPs in a 
window is always odd, the sQTL is never positioned centrally, therefore just as with 
SSR there are always two windows which are expected to do equally well, and better 
than all others (one to either side of the sQTL). Looking at Figure 4.10.1 this does 
appear to be the case. The averages for the methods peak at around 0.08, 0.18, 0.22 
and 0.24 respectively for SSR, MR3 MR5 and MR7. These values correspond to 
approximately 26.7%, 60%, 73.3% and 80% of the sQTL variation. There is clearly 
an increase in the proportion of sQTL variance explained that is attributable to 
increasing the number of SNPs in the model. There is an initial fairly large step up in 
the proportion of variance explained by going from SSR to MR3, then the increases 
become smaller. Indeed, with each subsequent increase in the number of SNPs 
included, on average the amount of extra variance explained decreases. 
  
Figure 4.10.1 Mean proportion of variance explained over all MAF bins by each window 
position for single SNP regression and multiple regression using three, five and seven SNPs. 
Points are centred on the middle SNP of the regression window for the multi-SNP methods. 
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The comparison in Figure 4.10.2 is of the overall percentage of times each window 
position explains the largest proportion of variance. The general trend is that as the 
number of SNPs in the window increases, there are more windows which regularly 
explain the most variance, therefore the peak of the curve is wider. Consequently, the 
peak for methods with larger numbers of SNPs is lower; MR3 tops out at around 
18%, MR5 at just under 16% and MR7 at just under 13%. The SNPs most frequently 
explaining the highest proportion of variance for SSR do so approximately 16% of 
the time. Looking at the distributions as a whole also reveals a telling pattern. The 
cumulative frequency that a group of window positions explain the highest proportion 
of variance was calculated as distance from the sQTL was increased (by moving 
outwards one SNP at a time in each direction from the centre). This reveals that 
methods using larger numbers of SNPs are more precise; the number of SNPs / 
windows required in order to ensure a cumulative frequency of over 0.9 was 16 for 
SSR, but just 12 for each of MR3, MR5 and MR7. 
 
Figure 4.10.2 Percentage of times each window position explains the largest proportion of 
variance over all MAF bins for single SNP regression and multiple regression using three, 




The last overall comparison is of –log10 p-values, shown in Figure 4.10.3. There are 
considerable differences between the methods, the greatest of these being between 
single SNP regression and the remaining six. Each successive method performs better 
than the previous one for windows closest to the sQTL – further away from the sQTL 
all methods perform equally. The overall means at the sQTL-adjacent SNPs are 9.33, 
18.6, 21.7 and 22.4 respectively for SSR, MR3, MR5 and MR7. As previously noted 
with the mean proportion of variance explained, the increase from five to seven SNPs 
is not as great as that from three to five SNPs, which itself is not as great as the 
increase for three SNPs over a single SNP. The mean –log10 p-value centred at SNPs 
50 and 51 of the test region increases by 140% from SSR to MR7. At the tails of the 
graph, the –log10 p-values converge to approximately the same value. This is in 
contrast to Figure 4.10.1 (mean variance explained), where even at the tails there are 
consistent differences between methods. 
 
 
Figure 4.10.3 Graph showing the mean –log10 p-value over all MAF bins for each window 
position for single SNP regression and multiple regression using three, five and seven SNPs. 





For the remainder of the multiple regression method results, comparisons are made 
across MAF bins. Results for the proportion of variance explained by MR3 are shown 
in Figure 4.11.1. As with the equivalent single SNP regression results, there are clear 
distinctions between MAF bins. Once again, the pattern is such that as the sQTL 
MAF increases, a larger proportion of variance is explained. There is a noticeable 
increase in the amount of variance explained between each of the first four sQTL 




As expected, the peak for the sQTL MAF bin explaining most variance (the 0.45 - 0.5 
MAF bin) is higher than the overall peak (i.e., averaged over all MAF bins) for MR3 
seen in Figure 4.10.1. The peak here is 0.20, which is 11% higher than the 0.18 
corresponding to the overall mean. The overall mean has been dragged down by the 
Figure 4.11.1 Mean proportion of variance explained by each window position for all MAF 
bins for three-SNP multiple regression. Points are centred on the middle SNP of the 
regression window. 
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poor ability of windows to explain variation for sQTL with low MAF. The lowest 
MAF bin at most only explains just over 10% of the total variation (and 33% of 
heritable variation). The amount of variance explained by all MAF bins converges at 
around 20 SNPs in either direction from the sQTL, therefore regardless of the minor 
allele frequency of the sQTL, at this distance (or further away) from the tested SNP it 
will be almost impossible to detect since the proportion of variance explained is so 
low. 
 
Figure 4.11.2 displays the proportion of variance explained for MR5 over the 
different MAF bins. Again, the best results (on this criterion) belong to the two SNPs 
closest to the sQTL, although these are not in the highest MAF bin this time, but the 
0.4 - 0.45 bin instead. The peak for these windows is 0.24, which is 0.02 higher than 
the overall mean for this window length, and also 0.04 higher than the analogous 
point in the MR3 results. 
 
 
Figure 4.11.2 Mean proportion of variance explained by each window position for all MAF 
bins for five-SNP multiple regression. Points are centred on the middle SNP of the regression 
window. 
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Again the lowest MAF bin does worst, peaking at 0.15. This is only a 0.05 increase 
over the 0.1 for MR3. This makes it appear that the lowest MAF bin has experienced 
a smaller increase in the amount of variance explained than the highest MAF bin 
compared with the MR3 method. In actual fact however, the proportional increases 
are 19% for the highest MAF bin and 44% for the lowest, suggesting that the lowest 
MAF bin benefits more. 
 
Results for MR7 are shown in Figure 4.11.3. The 0.40 – 0.45 MAF category 
marginally produces the highest mean proportion of variance explained by any of the 
MAF bins. The highest value is 0.26, a 0.02 increase from the overall MR7 average, 
representing 85% of the total heritable variation. The most that the lowest MAF bin 
explains is just under 58% of the variance of the sQTL. The peaks of the curves are 
wider than is found for either of the other two multiple regression methods, or the 
single SNP regression method. This appears to be a gradual increase associated with 
having a larger number of SNPs in the model. 
 
Figure 4.11.3 Mean proportion of variance explained by each window position for all MAF 




The differences between the best results for this criterion for MR7 compared to those 
for SSR, MR3 and MR5 are 0.152, 0.053 and 0.017 respectively. This means that the 
increase in the proportion of variance explained over the differing window sizes for 
the highest MAF bin changes from 0.099 for SSR to MR3 (98% increase), to 0.036 
for MR3 to MR5 (18% increase), and to 0.017 for MR5 to MR7 (7% increase). For 
sQTL with a MAF of 0 – 0.05, the differences are 0.070 from SSR to MR3 (210% 
increase), 0.045 for MR3 to MR5 (44% increase), and 0.025 from MR5 to MR7 (17% 
increase). Thus, the benefit of using more SNPs is greater the smaller the number of 
SNPs there is to begin with. While the absolute gain from using more markers in the 
regression is greater for sQTL with a higher MAF (0.140 total increase in variance 
explained for lowest MAF bin compared to 0.152 for the highest), proportionally the 
increase is much better for the low MAF bins. The total increase for the lowest MAF 
bin over the four methods corresponds to a 422% increase, whereas for the highest 




Figures 4.12.1, 4.12.2 and 4.12.3 show, for each of the three multiple SNP regression 
methods, the percentage of times that each window position explains the largest 
proportion of variance for each sQTL MAF bin. These all show the familiar pattern 
(from the overall comparison) of curves becoming wider and lower as the number of 
SNPs in the model increases. Consequently, there is also a difference in how 







Figures 4.12.1 - 4.12.3 Percentage of times each SNP position explains the highest proportion 
of variance for each MAF bin for three-, five- and seven-SNP multiple regression. Points are 




With MR7, there is little change over different MAF compared with the MR3 results. 
In addition to the curves becoming lower as the number of SNPs increases, the low 
MAF bins have a wider spread (and consequently lower peak) than the higher MAF 
bins, as seen for SSR (Figure 4.9.2). This again implies that sQTL with lower MAF 
are more frequently explained best by windows other than those adjacent to them than 
sQTL with high MAF. For MR3 (Figure 4.12.1) the highest percentage a window 
position has is 21.6%; this drops to 18.0% for five SNPs, and then to 14.8% for MR7. 
For none of these methods is the 0.45 – 0.5 MAF bin the one with the highest 





The –log10 p-values for MR3 are shown in Figure 4.13.1, and those for MR5 and 
MR7 are in Figures 4.13.2 and 4.13.3. The three common observations from all 
results so far also hold for these results; as window length increases the performance 
improves (in this case –log10 p-value increases), as window length increases more 
windows within the test region perform better (i.e., the curves become wider), and the 
low MAF bins perform worse than high MAF bins, although generally little separates 








Figures 4.13.1 - 4.13.3 Mean –log10 p-value of each window position for each MAF bin, for 
multiple regression of three, five and seven SNPs. Points are centred on the middle SNP of the 
regression window. 
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For MAF bin 0 – 0.05 the peaks for MR3, MR5 and MR7 are 10.5, 14.1 and 15.5 
respectively. This represents an increase of 48% in mean –log10 p-value from MR3 to 
MR7. The three to five SNP and five to seven SNP jumps represent 34% and 10% 
increases. Again, there is little difference between the top MAF bins for any of the 
methods, and these differences diminish as the number of SNPs in the model 
increases. The maximum –log10 p-value for each method are all from the 0.40 – 0.45 
or 0.45 – 0.5 MAF bin, and the values are 21.1, 23.6 and 24.1 respectively. The 
overall increase is 13%, and the increases between neighbouring methods are 12% 
and 1% respectively. The increases are therefore larger for three to five rather than 
five to seven SNPs, and there is a greater benefit for sQTL in lower MAF bins. 
 
The larger increase for lower MAF bins is also reflected in the fact that the height of 
the lowest MAF bin peak proportional to the highest result increases as window size 
increases, i.e., the –log10 p-values for the top MAF bins and the 0 – 0.05 MAF bin are 
proportionally closer together for larger window sizes. For SSR the lowest MAF bin 
peak was 35% of the maximum, and this increased to 50%, 60% and 64% of the 
maximum value for MR3, MR5 and MR7 respectively. 
 
In summary, all multiple regression methods on average have greater power than SSR 
(see for example, Figure 4.10.3), and the amount by which they are superior varies 
depending on both the number of SNPs in the model, and the minor allele frequency 
of the sQTL. Methods with a larger number of SNPs are more powerful on average 
than those with fewer SNPs, although the difference between models with higher 
numbers of SNPs (i.e., MR5 and MR7) and those with lower numbers of SNPs (i.e., 
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SSR and MR3) are much smaller. For all method comparisons, the greatest increase 
in power afforded by a superior model is for the lowest MAF bin. Even so, all results 







The overall mean proportion of variance explained by each window position for the 
three haplotype methods is shown in Figure 4.14.1. Note again that haplotypes were 
phased with 11 SNPs, and the relevant n-SNP haplotypes for each individual were 
then extracted, therefore there are only 90 windows within each test region for all 
haplotype methods. As before, each window on the graph is represented by its central 
SNP. 
 
Figure 4.14.1 Mean proportion of variance explained for the three, five and seven-SNP 
haplotype methods over all MAF bins. Points are centred on the middle SNP of the regression 
window. 
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The two window positions expected to perform best have mean proportion of 
variance explained reaching 0.193, 0.250 and 0.294 for HL3, HL5 and HL7 
respectively. This corresponds to on average explaining 64%, 83% and 98% of the 
total heritable variation, therefore methods with a higher number of SNPs once again 
do best. This means that over all methods, the amount of sQTL variation explained is 
lowest using SSR, increases with each multiple regression method (i.e., as the number 
of SNPs in the model increases, see Figure 4.10.1), and except for HL3, is highest for 
the haplotype methods. Both MR5 and MR7 explain more variance than HL3 on 
average, although HL3 explains more than MR3. The overall change in the amount of 
heritable variation explained by the best window is around 71% (~27% for SSR and 
98% for HL7). 
 
Figure 4.14.2 shows for each haplotype length, the window positions that explained 
the largest proportion of variance most frequently. The percentages for the window 
positions doing best (which also happened to be those closest to the sQTL position) 
were around 20%, 17.5% and 12.5% respectively. Compared to the multiple 
regression results, each peak is slightly higher, meaning that the windows closest to 
the sQTL explained most variance more often. Consequently, each curve is slightly 
narrower too. There is a much larger gap between these three methods than observed 
for the three multiple regression methods. As previously seen, as haplotype length 
increases so does the width of the curve, although the height decreases. This 
represents a greater number of windows near the sQTL position being best more often 




The overall mean –log10 p-values for each of the haplotype methods are displayed in 
Figure 4.14.3. Interestingly, this is the first instance where there hasn’t been a direct 
trend of increasing –log10 p-value through the methods with increasing numbers of 
SNPs. The maximal overall mean –log10 p-values are from HL5, although HL7 still 
does better than HL3. The superiority of HL5 over HL7 occurs only for the central 
few windows however, and for the remainder HL7 is marginally superior. Maximum 
–log10 p-values for HL3, HL5 and HL7 respectively are 18.4, 20.2 and, 18.9, 
therefore HL7 is closer to HL3 than it is to HL5. 
 
Figure 4.14.2 Percentage of times for haplotype method with three, five and seven SNPs that 
each window position explained the highest proportion of variance. Points are centred on the 
middle SNP of the regression window. 
Figure 4.14.3 Mean –log10 p-value over all MAF bins for each window position for the three-, 
five- and seven-SNP haplotype methods. Points are centred on the middle SNP of the 
regression window. 
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Regardless of the internal ordering, all haplotype methods represent a large increase 
over single SNP regression, but not over the multiple regression methods. In 
ascending –log10 p-value, the average values at the most significant SNP / window 
are 9.33 (SSR), 18.4 (HL3), 18.6 (MR3), 18.9 (HL7), 20.2 (HL5), 21.7 (MR5) and 
22.4 (MR7). A haplotype method never does better on average than the method with 
equivalent number of SNPs in multiple regression. Both five-SNP methods do better 
than HL7. However, even the worst of the haplotype methods (HL3) has on average 




Results for the proportion of variance explained by HL3, HL5 and HL7 are shown in 
Figures 4.15.1, 4.15.2 and 4.15.3. There is an across-the-board increase in the 
proportion of variance explained for all MAF bins as the number of SNPs in the 
haplotype window increases. Within each method the highest results marginally 
belong to the 0.45 – 0.5 MAF bin, although there is no appreciable difference 
between the top five MAF bins. The maximum proportions of variance explained for 
the three methods respectively are 0.212, 0.264 and 0.304. On average the top five 
MAF bins for HL7 explain more heritable variance than is really present in the 
“trait”, which is a consequence of the haplotype windows happening, by chance, to 
explain a very small proportion of variance which is not in fact heritable. HL7 







Figures 4.15.1 - 4.15.3 Mean proportion of variance explained by each window position for all 
MAF bins for the three-, five- and seven-SNP haplotype methods. Points are centred on the 
middle SNP of the regression window. 
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In comparison to multiple regression, the haplotype-based methods are able to 
explain more variance than the equivalent multiple regression method (i.e., the 
method with the same number of SNPs). All methods are far superior to single SNP 
regression. The best results for each method categorically show this (percentage of 
heritable variation shown in parentheses): 0.101 for SSR (34%), 0.200 for MR3 
(67%), 0.236 for MR5 (79%), 0.255 for MR7 (85%), 0.212 for HL3 (71%), 0.264 for 
HL5 (88%) and 0.304 for HL7 (~100%). For the lowest sQTL MAF bin, the overall 
improvements look as follows; 0.033 for SSR (11%), 0.103 for MR3 (34%), 0.148 for 
MR5 (49%), 0.173 for MR7 (58%), 0.127 for HL3 (42%), 0.197 for HL5 (66%) and 
finally 0.251 for HL7 (84%). Once again, it is interesting that for the same number of 
SNPs, haplotype methods are able to explain much more variation than multiple 
regression methods. No method is able to explain as much variance for sQTL with 
low MAF as they do for high MAF, although incredibly, haplotype analysis using 
seven SNPs captures 84% of the heritable variance in a sQTL with a minor allele 
frequency under 0.05. 
 
As seen with multiple regression it appears that the most beneficial transition between 
haplotype methods is from three to five SNPs. The percentage increase from HL3 to 
HL5 for the lowest MAF bin was 55.4%, and was 27.0% for HL5 to HL7. The 
increases for the MAF bin with the highest results were 23.8% for HL3 to HL5 and 
15.3% for HL5 to HL7. Not only is the jump from three to five SNPs again better 
than five to seven, but also the increase is once again proportionally greater for the 
lower MAF bins (for both three to five, and five to seven SNPs). Again, one visible 
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consequence of this in the figures is that the lines for different MAF bins become 




Figures 4.16.1, 4.16.2 and 4.16.3 display the percentage of times that each window 
does best at explaining sQTL variance. The overall patterns are the same as those for 
the equivalent graphs for multiple regression. The major difference between the two 
sets of graphs however is that in the three pertaining to haplotype analyses, the 
percentages at the peaks are all higher, meaning there is a greater proportion of times 
in which the window explaining most variation is located in close proximity to the 
sQTL. Consequently, the distribution for each MAF bin is also slightly narrower. For 
HL3, the closest two windows to the sQTL position for the highest sQTL MAF bin 













The MAF-separated mean –log10 p-values for the three haplotype methods are shown 
in Figures 4.17.1, 4.17.2 and 4.17.3. The maximum –log10 p-values for each of the 
haplotype lengths are 20.3, 21.3 and 19.5, and for MAF bin 0 – 0.05 they are 11.6, 
Figures 4.16.1 - 4.16.3 Percentage of times each window position explains the largest 
proportion of variance for all MAF bins for the three-, five- and seven-SNP haplotype 
methods. Points are centred on the middle SNP of the regression window. 
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15.5 and 16.0. The MAF bins producing the highest –log10 p-values were 0.45 – 0.5 
for HL3, 0.4 – 0.45 for HL5 and 0.25 – 0.3 for HL7. This last one in particular 
illustrates how similar the results are for all sQTL with a minor allele frequency of at 
least 0.25. The most striking part of these results is that, as was suggested by the 
results averaged over all MAF bins, the trend for more SNPs to give better 
performance no longer holds. The only MAF bin this does still hold for is the lowest 
(i.e., 0 - 0.05) – the intermediate bins see HL7 falling gradually further behind HL5. 
 
While it may no longer necessarily hold that the model with most SNPs in is superior, 
all haplotype methods are clearly far superior to SSR. The ordering of the haplotype 
and multiple regression methods is more complex however, and depends on the MAF 
of the sQTL. To make a consistent comparison instead of switching reference MAF 
bin, results from the highest MAF bin (0.45 – 0.5) are used despite not necessarily 
being the best –log10 p-values, since differences were very small in any case. The 
ordered maximum –log10 p-values are as follows; 11.7 (SSR), 19.2 (HL7), 20.3 
(HL3), 21.1 (MR3), 21.2 (HL5), 23.5 (MR5) and 23.9 (MR7). The equivalent results 
for the lowest MAF bin were 4.06 (SSR), 10.5 (MR3), 11.6 (HL3), 14.1 (MR5), 
15.53 (MR7), 15.54 (HL5) and 16.00 (HL7). For lower MAF, haplotype methods 









Figures 4.17.1 - 4.17.3 Mean –log10 p-value produced from each window position for each 
MAF bin for the three-, five- and seven-SNP haplotype methods. Points are centred on the 
middle SNP of the regression window. 
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When comparing different methods with the same number of SNPs (e.g., MR3 and 
HL3), the haplotype analysis results increased the –log10 p-values for sQTL with low 
MAF, but decreased them for sQTL with high MAF. For the 0 – 0.05 MAF bin, the 
increases in –log10 p-values of the haplotype methods amounted to 10.7% for the 
three-SNP methods, 9.9% for the five-SNP methods and 3.0% for the seven-SNP 
methods. For the highest MAF bin, the decreases in –log10 p-value were 3.6%, 10.1% 
and 19.6% respectively. Therefore, haplotypes improve analysis for sQTL with small 
MAF. Where minor allele frequency is moderate to large, the gain in –log10 p-value 
from haplotype analysis observed at lower MAF becomes a loss, and multiple 
regression does better. The numbers above also show there is a larger proportional 
increase (or smaller proportion decrease) in -log10 p-value for changing from multiple 




Where previously it was how methods performed on average across the test region 
that was examined, in this section it is how the best result for a method changes (on 
average) over the MAF bins that is considered. Figure 4.18 shows the means of the 
best –log10 p-values selected for each sQTL separated by MAF bins, within each 
method. For example, take the 0 – 0.05 bin for SSR, for each of the 579 sQTL there is 
one SNP that produced the best –log10 p-value for that sQTL – so the mean displayed 
is the mean of those 579 –log10 p-values. SSR always has the lowest average best –
log10 p-value, although it does increase substantially as MAF increases, up to a point 
where SSR is nearly as good as the next best method (HL7). For the lowest MAF bin, 
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the three haplotype methods all have the highest averages, although from the third 
MAF bin onwards HL7 is only better than SSR. HL3 is the best method most often 
for this criterion, having the highest best p-value average for five of the MAF bins 
(from 0.10 - 0.35), before MR5 becomes marginally better for the final three MAF 
bins. From a sQTL MAF of around 0.15, all methods except SSR and HL7 are very 
clustered however; for the 0.45 – 0.5 bin all have an average best –log10 p-value 




One further thing worth examining is how accurately each method is able to locate 
the position of the sQTL. One way to estimate how well each method performs at this 
is to see how far the best window position is from the known position of the sQTL. 
For SSR, it is easy to count the number of SNPs in-between the most significant 
results and the sQTL; for the multiple SNP methods, the central SNP in the window 
is used. Figure 4.19 shows on average how far away (in SNPs) the true sQTL position 
Figure 4.18 Means of the best –log10 p-values for each sQTL in each MAF bin for all methods. 
Note the y-axis begins at 10 for better resolution. 
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is from the most significant window position for each method. This reveals a similar 
grading of methods to that already seen. SSR does worst (i.e., is least accurate), but 
also shows the greatest improvement as MAF increases. SSR is followed by a cluster 
of the remaining methods, although the two seven-SNP methods appear to be slightly 
less accurate than the rest. All methods are better at defining the correct location of 




A similar statistic to the accuracy of the methods (shown in Figure 4.19) is the 
proportion of times the best results for a method (i.e., highest -log10 p-value) are those 
which either flank (for single SNP analysis) or overlap with (for multi-marker 
methods) the position of the sQTL. This is shown in Figure 4.20. There is a slightly 
different pattern to that seen in Figure 4.19; as the number of SNPs included in the 
model increases (and therefore the number of windows that overlap with the sQTL 
also increases), the greater the proportion of times that the most significant analysis 
Figure 4.19 Average distance (in SNPs) between the sQTL and the most significant SNP / 
window position for each method. For window based methods (multiple regression and 
haplotypes method), the central SNP in the window is used. 
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overlaps or flanks the sQTL. For example, for the two seven-SNP methods, the 
windows that overlap the sQTL produce the best result for almost 70% of sQTL 
(Figure 4.20). The seven-SNP models are followed in turn by the five-SNP methods, 
then HL3, MR3 and SSR produce the least amount of best results flanking the sQTL. 
Interestingly, for bins 4-10, MR7 is marginally ahead of HL7, becoming the method 




In addition to determining how well each method performed on average, the method 
performing best most often was calculated. For each sQTL one specific window 
position / method combination produced the best result for that sQTL. On this 
occasion, best is meant in terms of most significant p-value, since this takes into 
account the differences in degrees of freedom, as already explained. Below, the 
percentage of times each method provides the best p-value for a sQTL is shown: 
 
Figure 4.20 Proportion of times the best SNP / window for a model is flanking / surrounding 
the position of the sQTL, shown for each MAF bin. 
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  SSR:  28.13% HL3:  15.50% 
  MR3:  22.49% HL5:  7.83% 
  MR5:  12.55% HL7:  3.70% 
  MR7:  9.80% 
 
Interestingly, single SNP regression is best for over a quarter of the sQTL, despite the 
much higher (i.e., less significant) p-values on average. The two three SNP methods 
are the next most frequently best methods. The five- and seven-SNP haplotype 
methods are best least of all. 
 
These results have been dissected to see how the distribution of the best results 
changes over methods across the different MAF bins, and are shown in Figure 4.21. 
The figure illustrates that the relative performance of the methods is dynamic, and 
heavily dependent upon the minor allele frequency of the sQTL. Similar to the overall 
results, the method which is best most often for the majority of the MAF bins is SSR. 
This is best most often for eight of the bins, although it is overtaken by MR3 for the 
0.40 – 0.45 MAF bin. Most interesting are the changes to the graph over the first 
three MAF bins. For the lowest bin, HL3 is best most often, followed by HL5, and 
then by SSR and HL7 which have very similar percentages. The three multiple 
regression methods do worst for this MAF bin. As MAF increases, the haplotype 
methods fall off, and the multiple regression methods and SSR in particular, begin 
taking over. For the highest MAF bin, the haplotype methods have become the three 
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worst performing methods, and the remainder of the methods are ordered in terms of 
the number of SNPs in the model. 
 
 
The comparisons above do not tell the whole story however. When comparing all 
seven methods SSR generally does best most often, but this may be because when 
SSR is not best, there is no one other method that is consistently better. Put another 
way, on the occasions where SSR is not best, the method which is best may vary 
among all other methods, meaning that no one other method is best overall more than 
SSR. One way of testing this theory is to plot the percentage of times SSR does best 
in a series of pairwise comparisons with all other methods. This is shown in Figure 
4.22 for all MAF bins. All methods are uniformly better than SSR when compared on 
a pairwise basis. The only method which is not better more often than SSR for all 
MAF bins is HL7, although it is still better more often for the lowest four MAF bins. 
All haplotype methods do very well for the lowest MAF bin, being better than SSR 
around 75% of the time, however from the third MAF bin onwards the multiple 
Figure 4.21 Percentage of times for each MAF bin that each method produced the most 
significant p-value. 
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regression methods are better than SSR more often than the haplotype methods. Even 
so, HL3 remains better than SSR around 60% of the time from a sQTL MAF of 0.25 
onwards. The best of the multiple regression methods (MR5) is better than SSR 




To further clarify the difference in performance between single SNP regression and 
the best of the haplotype methods (HL3), the best p-values for these methods for 
sQTL in each of the lowest and highest MAF bins are plotted in Figures 4.23 and 
4.24. On these figures is a line representing the event that p-values for SSR and HL3 
are equal, and the density of points is illustrated by shading. Points above / to the left 
of the line indicate that the p-value is larger (i.e., less significant) for HL3, and the 
converse is true for points below / to the right of the line. Figure 4.23 shows that for 
sQTL for which SSR does better than HL3 (those above the line), the difference in 
best p-value between the methods is generally small. Contrastingly, for sQTL where 
HL3 does best, often the difference is very large - for the most extreme of these, SSR 
Figure 4.22 Pairwise comparisons between single SNP regression and each of the other six 
methods. For each bin, the percentage of times the alternate method has a more significant 
best p-value than SSR is shown. 
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has a best p-value greater than 1×10-10 when HL3 reaches significance in the region 
of 1×10-40. The figure also shows that there is a greater density of points where p > 
1×10-10, which is expected given that power is low for rare sQTL. Additionally, in 
concordance with Figure 4.22, there are more points below the line, i.e., where HL3 






In comparison to Figure 4.23, results for the highest MAF bin (Figure 4.24) show that 
there are slightly more points above the line, i.e., where SSR has smaller best p-value, 
and the greatest density of point is at a much smaller p-value. This verifies again that 
for common sQTL it is difficult to do better than SSR since there is a high probability 
Figure 4.23 P-values for the best SNP / window for SSR and HL3 plotted against 
one another for all sQTL in the 0 - 0.05 MAF bin. The central SNP of the HL3 
windows is used for the comparison. The dotted red line represents x = y. 
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that at least one marker is in high LD with the causal variant. However, just as in 
Figure 4.23, where HL3 does do better than SSR, the difference in best p-value for 










The results indicate there is no overwhelming distinction between model types in 
terms of their performance (i.e., irrespective of number of SNPs used). For example, 
Figure 4.24 P-values for the best SNP / window for SSR and HL3 plotted against 
one another for all sQTL in the 0.45 - 0.5 MAF bin. The central SNP of the HL3 
windows is used for the comparison. The dotted red line represents x = y. 
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while SSR is the model which most often produces the single best p-value for a given 
sQTL, when categorised into separate MAF bins, for sQTL with lowest MAF HL3 is 
best most often (Figure 4.21). Interestingly, even though SSR is most frequently the 
model with the best p-value, SSR also has the highest average p-values (i.e., lowest -
log10 p-values - see for example Figure 4.18). This may come about because for those 
sQTL which have at least one SNP in high LD – over 15% of adjacent SNPs had r2 of 
at least 0.7 – very little extra variation can be explained by extra parameters, but there 
are fewer degrees of freedom to test with when they are present. All multi-marker 
methods will have smaller –log10 p-values in this situation. When LD drops between 
the sQTL and individual markers, multi-marker methods can perform much better 
than SSR, thus boosting the average -log10 p-value, however it is likely that fewer 
sQTL have no tagging SNP than have at least one. 
 
Using the criterion of the proportion of variance explained by a model (and assuming 
that the larger the proportion of variance explained, the better the model is), the 
methods are ordered as follows for the overall results; SSR (0.08), MR3 (0.18), HL3 
(0.19), MR5 (0.22), MR7 (0.24), HL5 (0.25) and HL7 (0.29). This indicates that 
although haplotype methods always explain more variation than the equivalent 
multiple regression method (i.e., the method with the same number of SNPs), 
haplotypes are not consistently better than multiple regression irrespective of window 
length. A better way to compare models is using -log10 p-value, and overall results for 
these are; SSR (9.33), HL3 (18.4), MR3 (18.6), HL7 (18.9), HL5 (20.2), MR5 (21.7) 
and MR7 (22.4). Once again neither multiple regression nor haplotype analysis is 
definitively better irrespective of SNPs / window length, although multiple regression 
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does better for the same number of SNPs. This pattern changes depending on the 





Within the multiple regression and haplotype analysis methods, window lengths of 
three, five and seven SNPs were tested. While there were only subtle differences in 
performance across different types of method irrespective of SNP number, there were 
more clear differences in how alternative window lengths performed both within and 
across method types. This is especially clear using the example of the proportion of 
variance explained by the models, which as expected increases as the number of 
parameters increases. Haplotype analysis is able to explain more variance than the 
equivalent number of SNPs in multiple regression, because not only marginal effects 
of the SNPs are captured, but also any interaction effects. More importantly however, 
the order is slightly different for the overall –log10 p-values. In general, significance 
still increases on average as the number of SNPs increases, but this is not true for 
HL7, which is only marginally better than the two three-SNP methods. This is 
because the trade-off between the proportion of variance explained and the number of 
degrees of freedom left to test with has become too great. The average degrees of 
freedom for HL7 was 22, which is ten more than the next highest of 12 (on average) 
for HL5. HL3 had just under six degrees of freedom on average, while SSR, MR3, 
MR5 and MR7 had one, three, five and seven degrees of freedom respectively. 
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Another consistent finding from within-model comparisons was that the overall 
increase in model performance in terms of significance (where there is an increase) 
becomes smaller as the number of SNPs gets bigger. The only times there is not an 
increase is in the case of the HL5-HL7 comparison; HL7 does worse than HL5 for all 
situations except when the sQTL MAF is under 0.05. However, for the rest of the 
results this finding remains true. For example, on average the proportional increases 
in –log10 p-values from SSR to MR3, MR3 to MR5 and from MR5 to MR7 are 99%, 
17% and 4% respectively. This means that the change from SSR to MR3 is greater 
than the change from MR3 to MR5, which in turn is larger than from MR5 to MR7. 
Analogous conclusions can be drawn from individual MAF bin results with both the 
multiple regression and haplotype method results - with the exception of those 
already mentioned above. This suggests that although MR7 may produce more 
significant p-values on average than MR3 and MR5, a step up from one SNP to three 
SNPs will already account for a large proportion of the benefit of jumping straight to 
seven SNPs. 
 
One other finding was that as the number of SNPs in the model increased, there were 
a greater number of windows performing well (manifested by an increase in the width 
of the curves). As seen in Figure 4.20, this is partly a consequence of an increase in 
the number of windows overlapping the true position of the sQTL, since these will do 
better and there are more of them for larger window sizes. MR3 and HL3 each have 
two windows in which the position of the sQTL is surrounded, and this increases to 
four and six windows for the five- and seven-SNP methods. Even so, it is important 
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to note that this improvement in accuracy would still be valid in real GWA studies 




The conclusions drawn thus far could largely have been made independently of 
results from individual MAF bins (although supporting evidence from these results 
back the conclusions up). However, one consistent finding throughout all results is 
that the ability to predict sQTL varies considerably depending on their minor allele 
frequency. Each method exhibited a gradual improvement in performance as sQTL 
minor allele frequency increased; the lowest MAF bin always performed worst, and 
in general the highest MAF bin performed best. At the higher end of the MAF range 
results became homogeneous for some methods, although this tended to happen more 
for methods explaining nearly all heritable variance. For example, results for SSR and 
MR3 are distinguishable for all MAF bins, however for HL5 and HL7 the top five 
MAF bins are almost inseparable. This is likely to be a consequence of the fact that 
the models were limited to explaining only the 30% of variance which was heritable 
(unless by chance some random noise was also captured). Once the 30% heritability 
was accounted for, different MAF bins had no room to continue improving over one 
another and therefore appear close in terms of performance. 
 
One of the more interesting findings from these results is that across different 
methods some MAF bins experience larger proportional increases than others, in 
otherwise identical comparisons. The lowest MAF bin experiences the greatest 
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increase, and the highest MAF bin experiences the smallest increase (at least until 
higher MAF bins become inseparable). All intermediate bins form a sliding scale 
between these two extremes. For example, the percentage increases in proportion of 
variance explained from one method to the next for the lowest MAF bin are as 
follows; 210% increase from SSR to MR3, 44% increase from MR3 to MR5, 17% 
increase from MR5 to MR7, 56% increase from HL3 to HL5 and 27% increase from 
HL5 to HL7. The percentage increases become lower for the next MAF bin (0.05 – 
0.1), and so on up to the highest MAF bin where the figures are at their lowest. This 
is also the case for the increases between methods when comparing –log10 p-values. 
Of particular note is that only the lowest MAF bin still experiences an improvement 
at all in the average –log10 p-value comparing HL5 and HL7. 
 
It might be expected that lower MAF bins experience a larger increase than the higher 
MAF bins for methods where most heritable variation is being explained, since in 
these methods only small improvements are possible for the higher MAF bins. 
Indeed, this is probably a contributing factor to the fact that only MAF bin 0 – 0.05 
experiences an improvement in mean –log10 p-value between HL5 and HL7. 
However, as shown above, the bigger improvement of low MAF bins is present 
between all methods, not just those performing best overall, so the phenomenon is not 
unique to only the best models. This may have implications with regard to the optimal 
GWAS analysis method, given that more complex methods take longer to perform. If 
the majority of the benefit (in terms of variance explained, if not power) of using 
seven-SNP models is also captured with only three SNPs, then in terms of efficiency 
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of time, and negating the issue of power loss from over-parameterisation, then three-




In the seven-way comparison of which method most often produced the most 
significant p-value across MAF bins (Figure 4.21), for eight of the MAF bins this was 
SSR. For the 0 – 0.05 bin, HL3 produced the most significant results for nearly twice 
as many sQTL as SSR, and HL5 also does better than SSR. However, for all 
remaining MAF bins except 0.4 - 0.45 (when MR3 is best), SSR is the best method. 
This result is quite striking, and seems to imply that SSR is the best method to 
analyse GWAS data. However, as suggested by Figure 4.22, this conclusion is not 
based on the optimal comparisons. Given that single SNP regression is currently the 
favoured method for analysing GWAS data, it is pertinent to compare results from 
each of the methods directly with the SSR results. These comparisons reveal that on a 
pairwise basis, with the exception of HL7 at moderate to high sQTL MAF, SSR is 
best less often than all other methods. 
 
Initially this appears to contradict the results shown in Figure 4.21, however the 
reason for this apparent reversal in performance of SSR is that in general the sQTL 
can be grouped into two categories. The first of these contains sQTL which have one 
or more markers in high r2 (note that these sQTL are thus more likely to be common), 
and the second category contains sQTL where there are no markers in high LD. SSR 
will have greater power than the alternate methods to detect sQTL in group one, 
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however crucially, any of the other methods might be best for detection of sQTL in 
the second group. In essence, for occasions where SSR is not best, the best method is 
shared out among the remaining methods, and this will depend on the local pattern of 
genetic architecture (i.e., allele frequencies and LD). The evidence to support this is 
present in Figure 4.22, since not only do all methods other than HL7 consistently 
outperform SSR on a one-to-one basis, but the relative difference in performance is 
greatest for the lower MAF bins (as predicted because higher MAF sQTL are more 
likely to have markers in high LD). 
 
Given that it appears fewer common alleles affecting complex disease remain to be 
found and the CD/RV hypothesis is gaining popularity, it is encouraging that the 
alternate methods analysed here seem to have greater power to detect rare loci. Figure 
4.22 shows that HL3 is the method which outperforms SSR most often for sQTL 
where MAF is under 0.05, and while other methods outperform SSR more than HL3 
does at higher MAF bins, HL3 is still best more often than SSR throughout the whole 
MAF range. More encouraging still however, is that even for the situations where 
SSR is the optimal method of analysis to use, HL3 does not do much worse than SSR, 
i.e., HL3 still has appreciable power. Results in Figures 4.23 and 4.24 indicate that 
although SSR does better than HL3 around 27% and 41% of the time for the lowest 
and highest MAF bins (see Figure 4.22), on these occasions the best p-value is only 
marginally better than that produced by HL3. However, when HL3 is the better 
method, frequently it outperforms SSR in terms of p-value by many orders of 
magnitude. This suggests that although minimal power maybe lost with haplotype 
methods for the detection of common variants, they are not markedly inferior to 
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single SNP regression. Contrastingly, when it comes to the detection of rare QTL, 
haplotype methods are vastly superior. It should also be noted that the conclusions 
drawn here are based on analyses where the MAF distribution of the “disease-
causing” allele (i.e., sQTL) is biased towards intermediate frequencies due to SNP 
selection. If the real MAF distribution of variants involved in common complex 





One of the main drawbacks of these analyses is that there are only limited estimates 
of the type I error rate of the methods. Although some permutations were performed 
to ensure test statistics were the appropriate size for all sQTL MAF bins under the 
null hypothesis. a more detailed investigation involving more sQTL would have 
allowed a better look at the empirical distribution of the test statistic for each method, 
and therefore determination of type I error rates. False positive rates are just as 
important as the power of the test, since even with high power, it is impossible to tell 
whether significant results are real if the type I error rate is also high. A more detailed 
permutation investigation of false positive rates for methods in this study was not 
performed due to time constraints, given the computationally demanding nature of 
these analyses. 
 
Another aspect of these analyses which could have been improved upon without time 
and computational constraints was the amount of heritability simulated for the sQTL. 
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In these analyses a heritability of 30% was used, however, individual complex 
disease loci identified to date rarely explain even a tenth of this. Simulating smaller 
effect sizes may reflect true complex disease loci more accurately, however in this 
study, power would have been reduced to a point where the ability to make 
meaningful comparisons between methods was compromised. Ideally, larger sample 
sizes and smaller sQTL effects would have been investigated, however this would 
have increased the duration of the analyses substantially, and moreover, should 
produce similar overall conclusions. Therefore, while not ideal, the use of high 
heritability is more of a means to clarify discrepancies between the methods, and is 
not of intrinsic importance to the results. 
 
There are a number of other things which would have been interesting to investigate 
with these data. For example, it would be interesting to compare how well haplotypes 
would perform if only the most likely haplotype pair was used for each individual. 
The literature implies that this technique would not perform as well as the haplotype 
method employed in this study (Morris et al., 2004), however it would be good to 
verify this and quantify any differences there were. Assuming that using the most 
likely diplotype per individual as if it were known did indeed perform worse than 
utilising all possible haplotypes for each individual, it would be interesting to see 
whether this method still managed to out-perform single SNP or multiple SNP 
regression. 
 
One further aspect of this work that could have been explored was how alternate 
ways of dealing with rare haplotypes affected the conclusions. In these analyses, no 
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haplotype classes were removed, regardless of how rare, since the best way of dealing 
with rare haplotype classes is not clear, and discarding information is innately 
unappealing. However, this approach may not be optimal, as frequency estimates for 
rare haplotypes can have large variances due to sampling variation (Fallin and 
Schork, 2000), and parameter estimates when using rare haplotypes will also have 
large variances (Schaid, 2004). In addition, using rare haplotypes is likely to have 
contributed to the fact that HL7 is unable to keep up with the performance of HL5, 
since on average there were around 10 extra degrees of freedom taken up in the HL7 
analyses. Pooling rare haplotype classes or using a clustering algorithm are both 
methods that could have been compared, along with variable selection type methods 




Results of this study have direct implications for detection of QTL in GWA studies. 
The most widely (and often only) analysis method used in GWA studies is analysis of 
a single SNP. Frequently, where alternative forms of analysis are used, it is only in 
regions already implicated by prior results, therefore it is rare for an exhaustive, 
genome-wide scan to be performed using any of the multiple SNP methods compared 
in this study. However, results from this chapter support those already in the literature 
suggesting that analysing GWA data using multi-marker methods can be beneficial. 
For example MR3 is the best method for detecting sQTL with moderate to high MAF 
almost as often as SSR (Figure 4.21), indicating that multiple regression may have 
greater power to detect some associations than single SNP regression, even when the 
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frequency of the sQTL is high. The pairwise method comparison results offer more 
compelling evidence in favour of multi-marker methods however. From Figure 4.22, 
MAF bin 0.1 - 0.15 is the one where SSR has the most favourable comparisons to all 
other methods (i.e., it is better more frequently in this MAF bin than for other MAF 
bins), but even here HL3, MR3 and MR5 have smaller best p-values for 60% of the 
sQTL. 
 
It is for very low sQTL MAF that most benefit from using haplotype analysis is seen 
however. In the seven-way comparison, haplotype methods together produce the most 
significant p-value for around 67% of sQTL when MAF is 0 – 0.05, and both HL3 
and HL5 perform better than SSR. In the pairwise comparison, HL3 is better than 
SSR almost 75% of the time for this MAF bin however, and even HL7, which in 
general does worse than SSR (is better less than 50% of the time) is also better than 
SSR 75% of the time. Together with results from Figures 4.23 and 4.24, this suggests 
that for detection of rare QTL, the gain in power from haplotype methods is 
considerable. The fact that HL7 also does well for low MAF sQTL also gives some 
impression of how the optimal length of haplotype window is dynamic, and will vary 
according to local genetic architecture. Where there are dense SNPs and longer 
stretches of LD, haplotype windows can be longer without risk of there being too 
many haplotypes in the population and causing over-parameterisation of the model. 
Conversely, having short haplotypes in regions of high LD will not add much 
information to a model, since in this case haplotypes tend towards biallelic markers. 
Therefore the optimal choice of haplotype window length is a delicate balance that 
depends on marker density and local patterns of LD. There are some methods which 
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have attempted to alter the size of the window tested by using local LD patterns, but 
these are currently not widely used (e.g., Browning, 2006; Li et al., 2007). 
 
The results for rare sQTL are of particular relevance to current literature. As will be 
discussed in greater detail in the final chapter, there is currently concern that GWA 
studies are failing to detect QTL accounting for the majority of heritable variation for 
human complex diseases, and complex traits in general (Maher, 2008). For this 
reason the common disease / rare variant (CD/RV) hypothesis is gaining popularity as 
a potential explanation of where some of this heritable variation may be hiding (Reich 
and Lander, 2001). It certainly seems the case that, even with larger and larger GWA 
studies, not enough common QTL are being identified to account for the heritable 
variation present in these traits, and there must come a time where no more can be 
found. If the CD/RV hypothesis is correct, then the analyses performed here suggest 
that haplotype methods may be even more valuable, since detecting rare variants is 
where the advantage of using haplotypes is most keenly seen. While it is easier to 
implement single- and multiple-SNP regression since it can be achieved without 
haplotype estimation, haplotypes are far more likely to detect rare QTL. Given that 
there are fast and accurate haplotyping algorithms freely available to the scientific 
community, and that haplotypes may provide the boost in power required for rare 









In the previous chapter, a number of multi-marker methods for analysing genome-
wide association study (GWAS) data were compared to single SNP regression (SSR), 
currently the most popular way of analysing such data. Results suggested that single 
SNP regression was not always likely to be the most effective way to perform 
genome-wide association (GWA), and that both multiple regression and haplotype 
analysis may be preferable in certain situations. The phenotypes used in these 
analyses were not real however, instead consisting of SNP genotypes with added 
noise to make the trait quantitative, and to reduce heritability from one to 0.3 (on 
average). Simulating phenotypes in this way was useful because it allowed 
comparisons to be made where the real “answers” were known, therefore it was 
possible to identify which methods were performing best. However, it would also be 
interesting to apply these methods to real GWAS phenotype data to see how results 
differ from those when using single SNP regression. 
 
In this chapter, phenotypic data was selected from the CROAS dataset on which to 
perform the analysis methods from the previous chapter. Performing GWA using all 
seven methods on the entire set of phenotypes collected as part of CROAS would be 
prohibitively time-consuming, therefore a single trait was chosen; uric acid. Although 
the choice of phenotype was largely arbitrary, uric acid was chosen due to the 
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identification of SLC2A9 as a urate transporter in the initial GWAS, since it would be 
interesting to see how well this association was picked up by the alternative methods. 
 
The aim of using multiple regression and haplotype analysis methods on real 
phenotype data is to identify some of the so-called “missing heritability” of traits 
involved in common complex disease. Rare variants (<5% frequency) are currently 
postulated as one of the reasons for the failure to explain all genotypic variance 
displayed by multifactorial diseases (Maher, 2008). The haplotype method in 
particular has more chance of detecting rare variants affecting complex disease than 
both single- and multiple-SNP regression due to the fact that haplotypes are better 
able to tag rare SNPs (as described in chapter four). 
 
Assuming rare variants are responsible for an appreciable proportion of unexplained 
heritability in common complex disease, it is reasonable to expect that this is because 
they are relatively young rather than due to selection; variants with a strong enough 
effect on disease to be under purifying selection are likely have been discovered 
already. As a consequence of their young age, undiscovered rare disease-influencing 
variants are likely to be on one or a small number of haplotype backgrounds, and 
their r2 with any given pre-existing SNP is unlikely to be high due to allele frequency 
differences, particularly as the allele frequency difference between the new QTL and 
pre-existing SNPs becomes more extreme. The local haplotype background may 
define the new variant rather well however. In these situations haplotype analyses 
should perform better than the more widely used approach of SSR, and potentially 






Both phenotypic and genotypic data for these analyses came from the CROAS project 
described in chapter two. Rather than using all traits, the only trait analysed here was 
uric acid, although unlike chapter four, all chromosomes were analysed. To be 
consistent across methods, not all individuals from the dataset were used. This was 
because the study population is a mixture of unrelated and related individuals, 
causing haplotyping of all individuals jointly to become more complex, since most 
haplotyping algorithms assume populations are either entirely related or entirely 
unrelated. The haplotype estimation software used for these analyses, PHASE 
(Stephens et al., 2001), uses an algorithm assuming independence of each individual. 
Therefore to avoid the difficulties associated with haplotyping a study population 
with mixed levels of relatedness, only unrelated and founder individuals were used. 
Eight founder / unrelated individuals did not have uric acid phenotypic records and 
were also excluded. Quality control was performed for this reduced dataset, since 
exclusion of extra samples may result in a different set of SNPs not reaching the call 







Analyses were performed as described in chapter four, with the exception that 
relevant fixed effects and covariates (as decided from analysis in chapter two) were 
also fitted in the model. These were BMI, an age-by-sex interaction and structure 
(i.e., which group the individual belonged to as determined by the program 
STRUCTURE (Pritchard et al., 2000) - roughly corresponding to village for this 
dataset). The random polygenic effect accounting for genetic covariances caused by 
family structure was omitted, since only founder and unrelated individuals were used 
in these analyses. This model was used to test all SNPs in a single SNP regression 
framework. For multiple regression, a sliding window of n SNPs (where n equals 
three, five, and seven respectively) was used in a global test for association (model 
described in chapter four, section 4.2.3.3), such that for a chromosome of length N 
SNPs there were N-n+1 tests. No windows spanned two chromosomes. Multiple 
regression methods are referred to as MR3, MR5 and MR7, depending on the number 
of SNPs used (n). 
 
For the haplotype analyses, as in chapter four every possible consecutive 11-SNP 
window was phased, regardless of the window length tested in the model (i.e., three, 
five or seven SNPs), although this was performed for all chromosomes in this 
chapter, not only chromosome 4. Haplotypes used to perform the test were extracted 
from the centre of the 11-SNP windows. As previously described, 11 SNP-windows 
were phased to ensure that the estimated haplotypes were as accurate as possible, 
without causing the time taken to perform the phasing to become unfeasible. Phasing 
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of windows on chromosome 4 was already complete since it had been done for the 
analyses in chapter four. For a chromosome of N SNPs there were N-11+1 tests, since 
each test was performed on haplotypes from the centre of an 11-SNP window that did 
not span more than one chromosome. Haplotype methods are referred to HL3, HL5 
and HL7, depending on the length of window used. 
 
A Bonferroni correction was used independently for each of the methods in order to 
correct for multiple testing. This was to better reflect a true GWAS, where only one 
method would be used to initially scan the data. As the number of tests performed 
was approximately equal for each method, the Bonferroni correction was identical to 






Manhattan plots showing genome-wide results for each of the methods are presented 
in Figures 5.1 - 5.7. There is no line indicating Bonferroni significance in the figures 
as no results exceeded this threshold, although some came close. It should be noted 
however that the Bonferroni correction is very stringent due to correlations present 
between SNPs in the form of linkage disequilibrium (LD). Additionally, for the 
multiple SNP methods there is an extra source of correlation introduced by re-using 
SNPs in numerous tests, which acts to make the correction factor even more stringent. 
Therefore “suggestive” results close to Bonferroni significance may still be worthy of 
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closer examination. Accordingly, the top 20 results for each method are examined 
more closely and compared across methods, and Figure 5.8 (shown later in the 
chapter) displays the top 50 results for each method for clarification and ease of 
reference. 
 
Genome-wide results for single SNP regression can be seen in Figure 5.1. The closest 
to obtaining genome-wide significance for SSR was rs1323771 on chromosome 9, 
with a p-value of 3.38×10-7. This association consists of only a single SNP, as no 
other nearby SNPs show suggestive association. There are no SNPs in the dataset that 
are in particularly high LD with rs1323771 however, the highest two being 
rs10114830 (r2 = 0.52) and rs10117817 (r2 = 0.47). The p-values for these two SNPs 
are 0.006 and 0.001 respectively, therefore these SNPs do stand above the 
background noise. The fact that these two SNPs have the highest LD with rs1323771 
of any in this dataset may explain why no other SNPs reach a similar level of 
significance as rs1323771. 
 
Figure 5.1 Genome-wide results for uric acid analysed using single SNP regression. 
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Also of interest for SSR are three SNPs in the top 20 results spanning a 165Kb region 
on chromosome 14 (two of which are consecutive), the most significant of which, 
rs858893, with a p-value of 1.87×10-5. There are other occurrences of consecutive 
suggestively significant SNPs on chromosomes 7 (at 155Mb), 8 (at 4.6Mb), and 9 (at 
87Mb). Also worthy of note is that a SNP tagging the SLC2A9 finding on 
chromosome 4, rs7659670, is among the top 20 hits. 
 
Results for the multiple regression methods are displayed in Figures 5.2 - 5.4. No test 
has a p-value more extreme than 1×10-6, and only six have a p-value more extreme 
than 1×10-5 for the three methods. However, three of these windows are positioned 
very close to rs1323771 on chromosome 9, which produced the most significant 
result for SSR, and one of the remaining three tags SLC2A9. The remaining two 
windows were found with MR5 and are located 52Mb into chromosome 17. 
 





On chromosome 14, in total 12 results (amounting to seven different SNPs / 
windows) over the regression methods (i.e., SSR, MR3, MR5 and MR7) are located 
near to one another at 46Mb. There are also regions shared in common in the top 20 
hits for the four regression methods on chromosomes 7 (at 155Mb), 8 (at 109Mb) and 
16 (at 10Mb). Within each multiple regression method almost all top results have at 
least one other result in the top 20 from a nearby window; there are five regions 
taking up 14 of the top 20 results for MR3, six regions encompassing 14 results for 
MR5 and five regions taking up 15 of the top results for MR7. This reflects the extra 
source of correlation between tests mentioned earlier. 
 
 







Figures 5.5 - 5.7 show the Manhattan plots for the haplotype methods. Again no 
windows exceed Bonferroni significance, and only one exceeded 1×10-6. This 
window centred on rs2033188 on chromosome 16 for HL7, with a p-value of 
5.67×10-7. No window for any haplotype method shows strong support for the 
significant results for SSR and the multiple regression methods on chromosome 9. 
There are four occurrences for both HL3 and HL7 where two nearby windows are in 
the top 20 results, but none of the 20 most significant windows for HL5 are located 
close to one another. This is marked contrast to the multiple regression methods 
where most of the top results had another significant window close by. Two of the top 
20 windows for HL3 are on chromosome 14, as is one of the top 20 for HL5, 
supporting the associations found using the other methods at this location. These 
windows differ from those previously identified, but are all located nearby. Unlike 




the other methods, HL3 has a top hit located inside the SLC2A9 gene. The four 
regression methods and HL5 all have windows tagging the association further 
upstream than the gene itself, although interestingly, there are no windows tagging 







Figure 5.8 plots the top 50 hits for each method on the same graph, with different 
colours representing the alternate methods. The majority of points represent p-values 
greater than 1×10-5, highlighting the general lack of highly significant results. Two of 
the three most significant points are on chromosome 9, one corresponding to 
rs1323771 identified using SSR, and the other corresponding to a MR7 window 
centred on rs7041080. The string of results at the beginning of chromosome 4 is at 
the SLC2A9 locus; the most significant window (centred on rs4697674) has p-value 
6.08×10-6, and was produced using the HL3 method. There are a number of other 
occurrences of a string of results at a particular locus, and these may be indicative of 
additional real associations. These have all been mentioned above, and are examined 
more closely subsequently. 
 
Figures 5.5 - 5.7 Genome-wide results for uric acid analysed using three-, five- and 










A plot of each method and chromosome combination was examined in addition to the 
genome-wide Manhattan plots. This allows easier identification of signals that look 
promising by virtue of multiple close associations, and also shows where there is a 
lack of support. Viewing the results in this manner also ensures any suggestive 
regions are still found should none of the individual SNPs / windows be in the top 20 
results of any method. However, the only region not already identified that was 
showing slightly elevated significance for a cluster of windows was on chromosome 
12, the most significant of which was from HL5 (see Figure 5.8). Numerous SNPs / 
windows at 79Mb stand above the background noise, however the p-value of the most 
Figure 5.8 Top 50 results for each of the methods. Colours distinguish the 
alternate methods. Note that the y-axis starts at 3.5. 
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significant test is only marginally less than 1×10-5, therefore the overall evidence for 
association is not very strong. Several method and chromosome combinations for the 
results discussed previously are presented below, however the entire set of graphs is 
not shown since there are too many (23 for each of the seven methods). 
 
The single most significant result from these analyses was on chromosome 9 from the 
SSR method, although other methods also produced significant results at this locus. 
The association is shown for SSR in Figure 5.9. There is a single SNP reaching a -
log10 p-value of around 6.5, however the next most significant result in the same peak 
has a -log10 p-value just under 4. As explained earlier, it not surprising that there are 
no more supporting SNPs for this association, as the most significant SNP 
(rs1323771) is not in high LD with any other SNPs. 
 
 
Another of the most strongly supported associations identified from the top results 
was that on chromosome 14. Figure 5.10, showing results for this chromosome 
analysed using MR7, illustrates this. There are many windows in the peak at around 
Figure 5.9 Results from single SNP regression analysis on chromosome 9 for uric acid. 
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46Mb into the chromosome, however even the most significant of these only reaches 
1.78×10-5. It should be noted for this particular method however, that correlations 
between tests may inflate the number that show suggestive significance. 
 
 
Figure 5.11 shows chromosome 1 analysed using HL7. Five SNPs / windows across 
all methods showed an association 71Mb into the chromosome, but from this figure 
the evidence for association is poor. In addition to lacking a genome-wide significant 
p-value, there is a large amount of background noise from which the “significant” 
results barely stand out. Based on this, it would appear that no true association is 
picked up on chromosome 1. 
 
Figure 5.10 Results from seven-SNP multiple regression analysis on chromosome 14 for uric 
acid. 
Figure 5.11 Results from seven-SNP haplotype analysis on chromosome 1 for uric acid. 
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Figure 5.12 shows a putative association at 103Mb on chromosome 2 for SSR. This 
association is another consisting of only a single SNP (rs11123953) that does not 
exceed Bonferroni significance, but is suggestive. The SNP with highest r2 to this 
SNP in the dataset is rs10176694, which has an r2 of only 0.26 with rs11123953, and 
a p-value of 0.006. As with rs1323771 on chromosome 9, the lack of SNPs in high 




Figures 5.13 and 5.14 show three other potential associations on chromosomes 16 and 
17 respectively. The associations on chromosome 16 (Figure 5.13, showing MR3) are 
at 10Mb and 25Mb into the chromosome, and on this occasion there are more 
convincing strings of less significant results which also implicate the regions, while 
the level of background noise appears to be slightly less. The final association, shown 
in Figure 5.14, is around 52Mb into chromosome 17. Again, while significance is 
low, numerous windows support this association, although as in Figure 5.10 these 
may be due to the correlations between tests, since the method producing these results 
is MR7. 









Results from this chapter were compared with the original uric acid analysis results 
from chapter two to determine whether the most significant results were also showing 
elevated significance in the original study. Since it was not restricted to only founder 
and unrelated individuals, the original study therefore had increased power in this 
Figure 5.13 Results from three-SNP multiple regression analysis on chromosome 16 for uric 
acid. 
Figure 5.14 Results from seven-SNP multiple regression analysis on chromosome 17 for uric 
acid. 
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respect. However, results from the original scan do not provide overwhelming 
supporting evidence for an association at the most significant locus identified in these 
results - 85Mb into chromosome 9 (see Figure 5.15). There are a cluster of SNPs at 
around 80 - 87Mb into the chromosome showing elevated significance, however the 
most significant has a -log10 p-value of less than 4.5. Original analysis results are 
similar for the association 46Mb into chromosome 14 (see Figure 5.16) Although the 
most significant result for this chromosome is at the correct place, and there is also a 
small cluster of nearby SNPs with the same level of significance, the absolute 
significance level is too low to suggest association. 
 
 
Figures 5.15 - 5.16 Results for chromosomes 9 and 14 from the original uric acid analysis 
performed in chapter two. The test used in this analysis was the additive (1df) test. 
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Figure 5.17 shows the results for chromosome 1 from the original uric acid analysis, 
and there is clearly no supporting evidence to suggest the presence of a QTL on this 
chromosome. Likewise, Figure 5.18 shows original analysis results for chromosome 
2, where another putative QTL is located. This is the association shown in Figure 
5.12 that consists of a single SNP from the SSR method, which, similar to the 
association on chromosome 9, has no other SNPs in high LD. There is no support for 
this association from any of the other methods, and also no indication of an 





Figures 5.17 - 5.18 Results for chromosomes 1 and 2 from the original uric acid analysis 
performed in chapter two. The test used in this analysis was the additive (1df) test. 
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The remaining three putative associations are those on chromosomes 16 and 17, 
displayed in Figures 5.13 and 5.14. Corresponding graphs for the original analysis are 
shown in Figures 5.19 and 5.20, and overwhelmingly suggest that there are no true 
associations with uric acid as no SNPs from the original analysis attain anywhere near 
genome-wide significance. While both chromosomes 16 and 17 have one or a number 
of SNPs that stand out above background noise at the locations specified, the level of 





Figures 5.19 - 5.20 Results for chromosomes 16 and 17 from the original uric acid analysis 






Ensembl genome browser (Hubbard et al., 2007) was used to determine which genes 
the most significant hits fell in, or which genes were closest if the SNPs were not 
intragenic. While no results reached genome-wide significance, it may still be 
instructive to look at the genes underlying regions showing suggestive significance, 
since the Bonferroni threshold used was very stringent, particularly for the multi-
marker methods. The majority of genes that contained or were near suggestive SNPs 
had no known function to implicate them in uric acid regulation however. Only 
results implicating plausible genes for uric acid regulation are subsequently 
discussed. 
 
Table 5.1 shows five genes whose current known functionality does not preclude an 
effect on uric acid levels. The first of these genes is PTGER3 on chromosome 1. The 
product of PTGER3 is known to be an inhibitor of sodium and water reabsorption in 
the kidney tubules. Most uric acid reabsorption occurs in the proximal tubules of the 
kidney, and it has been shown that the product of SLC22A12 (URAT1) - thought to 
be responsible for around 50% of urate transport - is driven by sodium-anion 
transporters (MyPhuong at al, 2008). An earlier study also associates high serum uric 
acid with an increase in proximal tubular sodium reabsorption, although only in men 
(Cappuccio et al., 1993). PTGER3 may therefore have an effect on uric acid 




GENE NAME CHR PUTATIVE FUNCTION 
PTGER3 1p31 Inhibition of sodium and water reabsorption in kidney 
tubules 
SLC9A2 2q12 Sodium ion transport; pH regulation 
SLC9A4 2q12 Sodium ion transport; pH regulation; 
Rectifying cell volume in kidney cells 
SLC5A11 16p12 
Co-transport of D-glucose and D-xylose; 
Regulation of myo-inositol concentration in serum via 
reabsorption in proximal tubule of kidney 
C17orf67 17q22 Uncharacterised protein 
 
Two more genes with a plausible effect on uric acid levels lie adjacent to one another 
on chromosome 2. These genes, SLC9A4 and SLC9A2, are approximately 300Kb 
upstream of the associated SNP rs11123953, and are members of the solute carrier 
family 9. Both genes have a role in sodium ion transport in the kidney and are 
involved in pH regulation, and SLC9A4 has also been implicated in rectifying cell 
volume in response to hyperosmolar-stimulated cell shrinkage. The importance of 
sodium has already been stated above, but pH also plays a key role in the properties 
of uric acid. Conversion of uric acid to urate is highly dependent upon pH, and uric 
acid solubility is also greatly affected by pH; the more acidic uric acid is, the less 
soluble it becomes. Furthermore, urate excretion is affected by the pH of kidney 
tubules (Fahlen and Agraharkar, 2009). It is entirely possible therefore, that these two 
genes can facilitate an effect on uric acid in this manner. SLC9A4 may further 
influence uric acid levels through its effect on cell volume, since “extracellular 
volume expansion or contraction, respectively, enhances or reduces uric acid 
excretion though the paired movement of sodium” (Fahlen and Agraharkar, 2008). 
 
Table 5.1 Gene names, locations and current known functions of genes identified as putative QTL 
affecting uric acid. 
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SLC5A11 on chromosome 16 (the association at 25Mb, Figure 5.12) may also affect 
uric acid regulation. SLC5A11 is another gene of the solute carrier families; solute 
carrier family 5, member 11. The known functions of this gene include co-transport 
of D-glucose and D-xylose, and also a role in the regulation of myo-inositol 
concentration in serum, which involves reabsorption in the proximal tubule of the 
kidney. An effect on uric acid may be mediated indirectly as an effect of this myo-
inositol regulation. Phytic acid, itself composed of inositol (inositol 
hexakisphosphate), is a known inhibitor of xanthine oxidase (XO), the enzyme that 
produces uric acid (Muraoka and Miura, 2004). If SLC5A11 regulates inositol in the 
serum, this may in turn regulate the amount of phytic acid which is present, and 
therefore affect the amount of XO which is inhibited. It should also be noted that 
SLC5A11 is a glucose transporter, which was the only role known of the SLC2A9 
gene product before its role as a uric acid transporter was discovered (Vitart et al., 
2008). 
 
The final gene in Table 5.1 is C17orf67 of chromosome 17, which codes for an 
uncharacterised protein. This does not provide any explicit support for an effect on 





In addition to searching for putative QTL, these analyses were also performed as a 
basis for comparison between the seven methods used. The results indicate that the 
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four regression methods are highly correlated; that is, there are similar patterns of 
association across the methods, which are more obvious where strength of association 
is greater. However, as the number of SNPs in the model increases so too does the 
number of results exhibiting higher significance, and in addition to this the level of 
background noise decreases. This is illustrated in Figures 5.21.1 - 5.21.4, which show 
the results briefly mentioned earlier for chromosome 12 for each of the four 
regression methods. There are numerous (moderate) associations which become 
supported by a greater number of tests as the number of SNPs in the method 
increases. In Figure 5.21.1 there are SNPs showing weak association at regions 
around 80Mb, 100Mb and both before and after 120Mb into the chromosome. These 
associations are each found again with greater numbers of tests using MR3, MR5 and 
MR7, and are also made more prominent since the base level of significance for tests 
showing no association decreases. This latter phenomenon is likely to be a 
consequence of the extra degrees of freedom used in tests involving more SNPs at 











Figures 5.21.1 - 5.21.4 Results from single SNP regression and three-, five- and seven-SNP 
multiple regression on chromosome 12 for uric acid. 
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The pattern described above is not always the case for the haplotype analyses. For 
example, all associations on chromosome 12 (Figures 5.21.1 - 5.21.4) except one (just 
after 120Mb) disappear for the haplotype methods. Some associations are present 
across all methods however – the one on chromosome 14 for example. In addition to 
some association signals disappearing from multiple regression to haplotype analyses, 
other associations are found where previously there were none. For instance, there is 
a reasonably strong signal on chromosome 10 for HL5 and HL7 (there is a single test 
showing association for HL3 too), that is not present for any of the other methods. 
There is also a difference between the background noise levels of the methods. The 
base level of significance for windows showing no association appears to be less for 







There were no genome-wide significant results produced in this study, however 
numerous tests provided suggestive significance for association. The most significant 
result was produced using SSR for a SNP on chromosome 9, although there was 
supporting evidence from a number of other methods. The SNP identified using SSR 
was rs1323771, and as described earlier, this SNP has no other SNPs (in this dataset) 
in high LD. When this is the case it can be hard to know whether the lack of LD is a 
consequence of local genetic architecture at the locus, or due to some other reason. 
 244 
For example, it is possible for low LD to exist as a consequence of poorly clustered 
SNPs for which the calling algorithm was unable to accurately assign genotypes, thus 
breaking SNP correlations. 
 
One way to identify SNPs such as these is to test for Hardy-Weinberg equilibrium 
(HWE), as SNPs where genotypes have been badly called often have a significantly 
different distribution of genotypes than would be expected given their allele 
frequencies. Another way is to examine the cluster plots of intensity data from which 
the genotypes were called, using software such as Evoker (Morris et al., 2010). This 
can be particularly important for rare SNPs, which are typically harder to call than 
common SNPs due to the difficulty of assigning points to three unique clusters, where 
one cluster may be absent or consist of very few points. Finally, it is also possible to 
check for poorly called SNPs by comparing levels of LD between SNPs in the study 
population to those in the publicly available data such as the HapMap. 
 
A HWE test for rs1323771 on chromosome 9 had a p-value of 0.82, thus indicating 
that the genotype calling for this SNP may be good. Additionally, r2 between 
rs1323771 and the two SNPs in highest LD with rs1323771 in this dataset is similar 
to that in the European (CEU) HapMap data (rs10114830 has r2 = 0.65 in HapMap 
and 0.52 in this dataset; rs10117817 has r2 = 0.46 in HapMap and 0.47 in this 
dataset). It should be noted that for this population HapMap may not be ideally 
suited, given that this population is a genetic isolate and therefore may differ in allele 
frequency from the HapMap population; nevertheless, the r2 values are in general 
agreement. To conclusively demonstrate that rs1323771 was called accurately in this 
 245 
dataset the intensities would need to be examined, however intensity data for the 
genotypes analysed here were not available to this study. Although poor clustering 
cannot be ruled out with certainty, it seems probable based on the HWE test and LD 
comparison with HapMap that this association is not due to an artefact. 
 
The case is not quite so clear for the other association consisting of a single SNP 
association from the SSR method (rs11123953 on chromosome 2). The HWE p-value 
for this SNP is 0.0015, suggesting that either the calling is imperfect or a deviation 
from HWE exists due to population genetic factors such as selection. The MAF of 
this SNP is 0.047 however, and as already stated, rare SNPs are harder to accurately 
assign genotypes to. Additionally, r2 between rs11123953 and rs10176694 (the SNP 
in highest LD with rs11123953 in this dataset) is 0.26 in this dataset and 0.25 in 
HapMap, suggesting that this association is also not artefactual. It should be noted 
that while the above associations do not appear to be due to an artefact this does not 
necessarily mean they represent true associations, since the associations may still be 
spurious. Nevertheless, the possibility also remains that these two SNPs tag true 
causal variants that are not in LD with any other SNPs on the panel. 
 
The association to rs11123953 is one of the five results that implicate genes in the 
regulation of uric acid levels (Table 5.1). However, the fact that these results do not 
reach genome-wide significance means that any subsequent study would not 
constitute a replication in the statistical sense. In order to truly implicate these genes 
in affecting uric acid, it is likely that two additional studies would need to find the 
association; one to obtain genome-wide significance, and the other to replicate this 
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again. One thing to note however is that the SLC2A9 finding originally reported in 
chapter two does not reach genome-wide significance here either. This means the lack 
of genome-wide significance for suggestive loci identified here does not preclude 
them being real associations. Given the small sample size for these analyses, it is 
doubtful the study was powered to detect many effects at a genome-wide level. 
However, there is also no evidence from the original analyses to back up the new 
putative QTL identified in this chapter. In some regards this is not too problematic; 
the benefit of the haplotype methods is that they should be able to detect QTL that 
SSR cannot (namely rare QTL) - it just leaves the problem of determining the validity 
of these novel associations. 
 
One way in which the validity can be tested is to compare the results against those 
already published. In a recent meta-analysis of over 28,000 individuals for uric acid 
five novel QTL were identified (Kolz et al., 2009), adding to the four loci already 
known; SLC2A9 (4p16), ABCG2 (4q22), SLC17A1 (6p23-21.3) and SLC22A12 
(coding for URAT1 - 11q13) (Vitart et al., 2008; Dehghan et al., 2008; Enomoto et 
al., 2002). Examination of results in this study from SNPs within loci known to affect 
uric acid reveals that none of the previously identified QTL show even suggestive 
significance, with the exception of SLC2A9. Moreover, comparisons with the largest 
uric acid GWA study to date (Kolz et al., 2009) indicate that none of the putative 
genes identified here represent true associations. Given the difference in power 
between the Kolz et al. meta-analysis and the study presented here, it is highly 






While it is tempting to speculate about the potential involvement of the genes in 
Table 5.1 with uric acid regulation, it is important to note that there was not enough 
statistical evidence to reject the null hypotheses of no association. None of the p-
values for association exceeded Bonferroni significance, and even the closest were 
over an order of magnitude away. However, the Bonferroni correction is too stringent 
since it does not take into account that many tests are correlated due to the presence 
of LD. Methods involving multiple SNPs suffer worse from the Bonferroni correction 
than SSR, and more so as the number of SNPs in the method increases. This is 
because there is an extra source of correlation for multi-SNP methods in addition to 
that caused by the correlation between tests on single SNPs in LD. With three-SNP 
multiple regression for example, not only are tests correlated because the starting 
SNP for each window is directly next to (and therefore in moderate LD with) the 
previous starting SNP, but also because two of the SNPs within any given test were 
also part of the previous test. It is probable therefore that the true, empirical, 
distribution of the test statistic for multi-marker methods would result in a far less 
stringent p-value for genome-wide significance than for single SNP regression. It 
should be noted that this is less of a problem for the study presented here than it may 
be for other studies using a different genotyping platform however, since this study 
uses a panel designed to reduce redundancy between SNPs. 
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It is not possible to determine what the appropriate level of genome-wide significance 
for the multi-marker methods is without performing permutation analyses. Given that 
seven methods were used in these analyses, and that permutation is time-consuming 
and computer intensive for determining the appropriate threshold even for a single 
analysis, permutation analyses were not performed here. Consequently, some of the 
results presented may be a lot closer to true genome-wide significance than it would 
first appear. While the putative associations from these analyses cannot yet be 
regarded as real, it may be premature to rule them out entirely, particularly where 




As already stated, directly comparing the methods is difficult when it is uncertain 
how much there is to find, and particularly when power for all methods is low, thus 
obscuring any differences. Comparisons would be made easier if the type I error rate 
and power for each of the analyses were known more accurately and for all methods, 
however determining these would have required extensive permutation, which for 
seven methods was clearly not feasible. Power for haplotype analyses is particularly 
difficult to assess since it depends on a great many parameters (many of which are 
unknown), not least the actual model specified to analyse the data. It is also 
dependent on the distribution of haplotypes and the amount of variance that the model 
will explain (Schaid, 2005). 
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Based on literature using a similar haplotype trend regression (HTR) method to the 
one used here, there is reason to believe that the type I error rate of the global F-test 
for association may be the correct size (Zaykin et al., 2002). This study used 
simulated quantitative phenotypes and five-SNP haplotypes to assess the type I error 
rate in a number of LD scenarios, and always found the size of the test did not exceed 
0.05. Similar findings about the type I error of the global F-statistic were also 
reported in a more recent paper (Schaid, 2005). In the same study, Schaid also 
calculated the sample sizes required for a certain level of power, depending on other 
parameters such as the haplotypic distribution and amount of variance the method is 
able to explain (dependent upon the QTL heritability and level of LD between the 
QTL and marker loci). With a sample size similar to that of this study, along with the 
likely haplotypic distribution, it was shown that theoretical power to detect an effect 
explaining 5% of the phenotypic variance (estimated effect of the marker, therefore 
QTL effect would be greater) is less than 80% (Schaid, 2005). Effect sizes of this 
magnitude for common complex disease are not common in the literature to date, 
therefore it is unlikely many exist and remain to be found. Power to detect variants as 
small or smaller than 0.01 of the total phenotypic variance, however, will be 
negligible. It is also worth noting that for rare variants, to achieve an effect size 
explaining 5% of the phenotypic variance or less the effect must be extremely large 
on the trait mean scale. 
 
In the absence of type I error rate and / or power calculations to guide conclusions, it 
is left to the known results to inform about the relative performance of the methods. 
The only previously known QTL for this trait that was identified at a suggestive level 
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was SLC2A9 on chromosome 4. All seven methods picked up this association, 
although some methods did better than others. For example, HL3 was the only 
method to associate a window from within the SLC2A9 gene itself with a moderate 
level of significance. Ordering the methods by significance of the most significant 
SNP / window within the SLC2A9 gene produced the following; HL3 (6.08×10-6), 
SSR (1.72×10-4), MR5 (2.05×10-4), MR7 (2.08×10-4), HL5 (2.26×10-4), HL7 
(6.86×10-4) and MR3 (9.94×10-4). HL3 also produced the two most significant p-
values of any method in the vicinity of the QTL location (i.e., the SLC2A9 gene plus 
100Kb in either direction), although MR3 had a result almost as significant (Figure 
5.8). 
 
It is interesting that the most significant result for HL3 within SLC2A9 is two orders 
of magnitude more significant than the top SNP for SSR, because in the initial study 
only SSR was used (Vitart et al., 2008). This suggests that the haplotype analysis is 
capturing extra information included in the interactions between SNPs. In the initial 
analysis of uric acid, no boost in significance was required to detect SLC2A9, 
however this may not always be the case, and for other QTL using haplotypes may be 
crucial for detection. HL5 and HL7 did not do as well as HL3 in detecting SLC2A9, 
therefore it would appear that the extra information provided by HL5 and HL7 did 
not compensate for the additional degrees of freedom used in the model. Results from 
chapter three indicate that the causal variant at this locus may have a moderate allele 
frequency (thereby allowing shorter haplotypes to capture all relevant variation more 
easily), which would support this suggestion. 
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An interesting phenomenon from these analyses is how the number of results at a 
given significance level increases as the number of SNPs in the method being used 
increases. As already discussed, this is due to correlations induced between adjacent 
tests for the multi-marker methods since they only move on one SNP at a time. For 
example, a SNP showing significance when analysed singly, if incorporated into three 
separate tests using three-SNP multiple regression, is likely to elevate all those 
windows to a comparable significance level, even if the other SNPs add little or no 
extra information. This phenomenon is indiscriminate with regard to whether an 
association is real or spurious, therefore care must be exercised in interpreting results 
of a sliding-window technique that analyses each possible window of consecutive 
SNPs. This is analogous to the expectation that single SNPs in high LD show similar 
results, but on a larger scale; with multi-marker methods, two associated SNPs in LD 
would elevate the test statistic of many more windows - regardless of whether the 
association was real or false. In light of this, allowing multiple regression to advance 
more SNPs at a time, or potentially even the entire window of used SNPs, may be 
preferable. Alternatively, calculating an appropriate threshold empirically that 




Analyses in this chapter yielded no results that exceeded Bonferroni significance, 
therefore no putative QTL were strongly implicated. There were a number of 
suggestive associations, however these were not validated by the original uric acid 
analysis, and must therefore remain doubtful. Three-SNP haplotype analysis was able 
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to detect the SLC2A9 association best, both in terms of significance and proximity to 
the gene, suggesting that haplotype methods may have an important role to play in the 
detection of QTL, and that single SNP regression is not always necessarily the most 
effective way of analysing GWAS data. 
 
These analyses provide an interesting insight into the similarities and differences of a 
number of ways to analyse GWAS data. In order to make better comparisons of these 
methods, permutations to determine the empirical distribution of the test statistic 
under the null hypothesis would need to be performed. Power for these methods was 
low as a consequence of small sample size, but again, extensive simulations would be 
required to estimate power empirically. Theoretical power for haplotype analyses is 
complex to determine, and furthermore depends on the distribution of haplotypes, 
which will vary from one window to the next. Clearly much work is still required to 
determine how useful multi-marker approaches will be for GWA studies in the future, 
and real datasets will be an important part of this. One useful strategy may be to use 
large datasets including associations already known to exist, in order to see how well 













Genome-wide association (GWA) studies are currently the most popular way of 
searching for quantitative trait loci (QTL) involved in common complex disease. One 
of the main reasons for this is the ability of GWA studies to exploit the mass of 
human genetic variation data made available through projects such as HapMap (The 
International HapMap Consortium, 2005; The International HapMap Consortium, 
2007), and consequently the ability to use indirect mapping approaches lacking pre-
defined and often constrained hypotheses. While candidate gene studies can still play 
an important role in QTL identification, the agnostic philosophy of GWA studies 
makes them very powerful since hypotheses are no longer dependent upon prior 
knowledge. Also, due to their genome-wide nature, these studies are no longer 
specific to any one trait (by virtue of candidate genes), meaning that analysis of vast 
numbers of traits in one study is possible, acting to further enhance their utility. 
 
Recent literature is filled with GWA studies reporting discovery of novel QTL 
affecting complex diseases and their risk factors. As of March 2010 there were a total 
of 779 published genome-wide association study (GWAS) hits exceeding a genome-
wide significance threshold of 5×10-8 across 148 traits (Hindorff et al., accessed 
04/06/2010), and the rate of progress since the early days of GWA studies is 
dramatic. For example, in 2008 there were 20 QTL known to be involved in each of 
Crohn’s disease and type 2 diabetes, and 40 for height. In 2006 these numbers were 
 254 
just two, three and zero respectively (Donnelly, 2008). This highlights just how far 
the field has moved, and how quickly the great leaps forward in QTL detection for 
genetic traits have been achieved. 
 
While intellectually rewarding to understand the genetic mechanisms affecting any 
heritable trait (not least because this may in turn lead to better understanding of other 
traits), of more consequence from a public health perspective is to determine the 
genetics underlying common complex diseases. Detecting disease-related QTL is of 
great importance to public health both in terms of prediction and prevention of 
disease, and also to potentially treat the disease after diagnosis. As a result, QTL 
identified as affecting intermediate phenotypes are frequently treated as candidate loci 
to analyse with respect to related disease phenotypes. This is a useful strategy, 
however it does not always lead to successful association with disease since the QTL 
may have an extremely small odds ratio for disease if it is only one contributing 
factor of many, and sample size thus is too low to confer significance. 
 
Proof of principle regarding the utility of GWA studies, particularly in conjunction 
with intermediate phenotypes, was provided by analyses in chapters two and three of 
this Thesis. Complex diseases were not analysed directly, instead underlying 
quantitative traits (QTs) were used, which provided greater power for the analyses. 
Although it is likely this study was underpowered to detect very small QTL as a 
consequence of a small effective sample size (both due to low number of samples and 
because many of these samples were related), one novel QTL was nevertheless 
identified with this population. Prior to this study, SLC2A9 was a known glucose and 
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fructose transporter, but has now been found to preferentially transport uric acid 
(Vitart et al., 2008). Crucially, SLC2A9 was then also found to have an effect on gout, 
a disease associated with (although not necessarily a consequence of) high uric acid 
levels, in a much larger study (Dehghan et al., 2008). Not only does this demonstrate 
that QTL of moderate effect can be detected using studies with limited power, but 
also that the strategy of detecting QTL affecting disease through the use of 
intermediate phenotypes is valid. The lower heterogeneity and a greater signal to 
noise ratio for QTL underlying intermediate phenotypes allows easier identification 




Despite the early success of linkage, and the more recent success of GWA studies, in 
detecting QTL involved in common complex disease, it is becoming increasingly 
evident that there is a problem: large proportions of the genetic contribution to 
common disease remain hidden. As more QTL are discovered it is becoming clear 
that for the majority of complex traits, irrespective of the total number of QTL found 
to date, the total proportion of trait variation that the known QTL explain is much less 
than the trait heritability. This fact is particularly worrying because for a reasonable 
number of traits, all large or moderate effect size genes are likely to have already 
been identified by virtue of well-powered GWA studies with large sample sizes. A 
much-used example is that of height, a trait with 80 – 90% heritability, where a recent 
study took the number of known QTL past 40, yet altogether these loci only account 
for just over 5% of the total genetic variation (Gudbjartsson et al., 2008). 
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This situation is now becoming the rule rather than the exception, and as a result there 
is much debate over where the remainder of the genetic portion of phenotypic 
variance is hiding, and why current GWA studies are unable to account for it (Maher, 
2008). There will inevitably be a number of variants of such small effect that studies 
of any reasonable sample size would still fail to detect them. However, given that the 
effects would need to be small, for these variants to be the whole explanation for the 
missing heritability, the number of such variants would need to be immensely large. 
There are a variety of alternate explanations for where parts of the missing heritability 




One of the current hypotheses concerning the missing heritable variation of common 
complex disease suggests that rare variants are responsible (i.e., causative variants 
with a MAF under 5% - or sometimes even more stringently, under 1%). Variants 
that are rare are not only difficult to discover in the first place, but they are also 
problematical to genotype, and furthermore, provide statistical problems when it 
comes to analysis. Historically, these variants have therefore not been well 
represented in either candidate gene or GWA studies. However, suggesting that rare 
variants are responsible for the remaining phenotypic variation is contradictory to the 
theory typically thought to describe the underlying architecture of human complex 
disease, the so-called common disease / common variant (CD/CV) hypothesis. 
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The CD/CV hypothesis posits that there are a moderate number of genes affecting 
any given common complex disease, and that these have an appreciable population 
minor allele frequency (Reich and Lander, 2001). One particularly attractive property 
of the CD/CV hypothesis is that under this model of disease common disease variants 
are able to explain a large proportion of disease prevalence even with only a small 
effect on disease risk (Gorlov et al., 2008). There is some theoretical evidence (Reich 
and Lander, 2001), and also a vast body of empirical evidence in the literature to 
support the CD/CV hypothesis, however this is unsurprising given that most 
discoveries to date are from studies only powered to detect QTL of moderate minor 
allele frequency (Hirschhorn et al., 2002). 
 
As implied above, there are many reasons why the literature may be enriched with 
associations to common QTL. For instance, the majority of genotyping panels that 
GWA studies are based on explicitly only include common SNPs. Therefore, any 
association detected using these panels by definition has to have been identified by a 
SNP that was common in the initial discovery dataset (thus also likely to be common 
in the study population), and therefore is highly likely to be tagging a causal variant 
that is also common. While it is possible for a SNP to have low frequency only in the 
study population, this situation would be rare since most GWA studies remove all 
SNPs below a certain threshold (usually 2%) in their population to begin with due to 
the afore-mentioned genotype-calling and statistical analysis problems associated 
with rare SNPs (Gorlov et al., 2008). 
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It would also be possible for the causative variant driving a SNP association to be rare 
itself, however few rare QTL would be found in this way since power is dependent on 
allele frequency and the LD between marker and QTL alleles, which in general will 
be low between common SNPs on marker panels and rare QTL. This explains why 
GWA studies are generally only sufficiently powered to detect variants that are not 
rare, and therefore why the literature is biased towards reporting common QTL. 
Given the loss of power due to poor tagging of rare (untyped) SNPs by common 
SNPs on genotyping panels, the sample size required to detect slightly rare variants 
(i.e., those between 2-5% MAF) would need to be considerably greater than those of 
most current studies, while variants even more rare would never be detected using 
single SNPs (Bodmer and Bonilla, 2008). 
 
The CD/CV hypothesis is not the only theory pertaining to the allelic spectrum of 
common complex disease. One of the original alternatives to the CD/CV hypothesis 
was the genetic heterogeneity model, which states that for any given disease, multiple 
rare alleles exist at numerous loci, all of which are fully penetrant and therefore 
disease-causing if present (Smith and Lusis, 2002). This model fits well with the 
breast cancer genes BRCA1 and BRCA2 for example (Wang and Pike, 2004), 
however it is quite different to the CD/CV hypothesis in that each variant essentially 
acts in a Mendelian fashion with respect to disease, which is certainly not the case for 
all QTL. Another suggestion is that the allelic spectra of variation involved in 
complex disease is no different to the allelic spectrum of the entire genome, i.e., the 
MAF frequency distribution of disease-affecting QTL over the genome as a whole is 
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U-shaped and has large numbers of rare alleles but much fewer alleles at intermediate 
MAF (Wang and Pike, 2004). 
 
A similar version of this latter theory is currently gaining much popularity however – 
the common disease / rare variant (CD/RV) hypothesis. In contrast to suggesting that 
the MAF distribution of disease-influencing variants is similar to that of the genome 
as a whole, the CD/RV hypothesis posits that a much larger proportion of the 
inherited susceptibility to common disease is due to the effects of independent low 
frequency variants (Bodmer and Bonilla, 2008). This theory is less extreme than the 
genetic heterogeneity theory however, since in the CD/RV hypothesis each rare 
variant confers only a small to moderate increase to disease risk, instead of being 
fully penetrant. 
 
There is theoretical evidence to support the CD/RV hypothesis. Using stochastic 
modelling, one study found that for common complex disease “it is unlikely that any 
single mutation will constitute a large fraction of the susceptible class” when the 
mutation rate was at the upper end of its predicted range (Pritchard, 2001). Another 
study concluded that if common diseases were caused by multiple loci then a diverse 
allelic spectrum with rare causal alleles is expected (Peng and Kimmel, 2007). 
Additionally, there is an increasing volume of empirical evidence supporting the 
CD/RV hypothesis; see for example LpL gene function (Nickerson et al., 1998), 
numerous phenotypes in a follow up study (Crawford et al., 2004), and cystic fibrosis 
(Bobadilla et al., 2002). One recent paper also points out that GWA studies appear to 
be reaching their limit in identification of common variants affecting complex human 
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disease, and that rare variation is one likely source of new QTL that is as yet largely 
unexplored (Schork et al., 2009). 
 
Another recent study in particular greatly enhances the argument for a considerably 
larger role in the development of complex diseases for rare variants than previously 
assumed. Using all SNP data, therefore including rare (<5% MAF) SNPs, from both 
ENCODE (ENCODE Project Consortium, 2004) and HapMap (Thorisson et al., 
2005), the study analysed the proportion that were predicted to be functional in each 
of 20 equally-sized MAF bins (Gorlov et al., 2008). The study reported three 
findings; there was a higher prevalence of non-synonymous SNPs in low MAF bins, 
there was evidence for purifying selection at the lower MAF bins, and there was an 
inverse correlation between the proportion of predicted protein damaging SNPs and 
MAF (Gorlov et al., 2008). This last conclusion was in agreement with two other 
studies reporting the same negative correlation (Cargill et al., 1999; Wong et al., 
2003). 
 
It should also be noted that, as predicted from the expected U-shaped distribution, 
rare SNPs constitute proportionally by far the larger of the two groups (common or 
rare); around 50% of the SNPs in ENCODE were rare, and 38% of the HapMap 
SNPs, despite the space for being declared rare encompassing only 10% of the total. 
Furthermore, ENCODE sequencing was based on a limited number of individuals, 
meaning that 50% is likely an underestimate of the total proportion of rare SNPs in 
the genome (since large numbers of rare SNPs, by virtue of being rare, will not be 
present in limited samples of individuals). Consequently, this may have resulted in 
 261 
observing a lower prevalence of non-synonymous SNPs in low MAF bins than really 
exists. 
 
Gorlov et al. also suggest that there may be as many as two or three "slightly 
deleterious" SNPs per gene in the genome, even ignoring regulatory regions, and that 
their effects on fitness in the population are low enough to allow them to persist due 
to mutation-selection balance. The proportion of disease in the population caused by 
any given variant (which can be expressed as the population attributable fraction 
(PAF)) is directly related to frequency of the variant; as MAF increases so does PAF. 
For example, it has been estimated that a MAF of 1% is around the upper limit 
attainable by clearly deleterious alleles sustained by mutation-selection balance 
(Bodmer and Bonilla, 2008). This may suggest that rare variants (in the 1-5% range) 
constitute a reasonable proportion of these slightly deleterious SNPs, since they can 
act in a largely evolutionarily neutral manner by virtue of their small PAF (Gorlov et 
al., 2008). The fact that each variant contributes little at the population level would be 
offset by the fact that so many of these QTL exist in the genome, allowing rare 
variants to cumulatively have an appreciable effect on disease prevalence. Needless to 
say, if this is truly the case, there is much work still to be done before we are in a 
position to detect most of these variants. 
 
One way in which rare variants may influence disease risk is for some number of 
individually rare, non-synonymous, mutations within a gene to each disrupt gene 
function, as opposed to a single more common mutation (Schork et al., 2009). This 
gene perturbation effect has been witnessed in “driver” cancer mutations for example 
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(Wood et al., 2007). Techniques for detecting rare variants involved in complex 
disease however are currently very few and in their infancy, due to the much greater 
focus on detecting common variants. Presently, the most popular method of detecting 
rare variants is based on the candidate gene case-control approach, since it requires 
the cohort to be fully sequenced in the regions of interest. This identifies all variants 
(rare or otherwise) within the candidate region in the study cohort, and tests for 
significant allele frequency differences between cases and controls. This can be 
performed either for each rare SNP singly, or for groups of rare SNPs within a given 
region (Schork et al., 2009). Potential functional consequences of a mutation can be 
used to help identify disease-related loci, for example by virtue of location within a 
conserved sequence, by causing a non-synonymous mutation, or by causing an amino 
acid charge change (Bodmer and Bonilla, 2008). 
 
Candidate gene studies currently need to sequence regions of interest to capture rare 
variation, which highlights one of the greatest challenges to our ability to uncover 
rare disease-related genetic variation. The dominance of the CD/CV hypothesis until 
recently inevitably led to genotyping companies, and hence GWA studies, focussing 
almost entirely on common variation, and this has been at the expense of rare SNPs 
(Gorlov et al., 2008). Even the rare genetic variation which has so far been uncovered 
from projects such as ENCODE and HapMap only tell part of the story, since the 
population sizes are fairly small, and, in the case of ENCODE, do not cover the entire 
genome. In order to detect rare variants influencing disease, first there must be further 
attempts to catalogue the extent of rare variation present in the human genome. At 
present very few sources of information provide the level of coverage sufficient to 
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find large amounts of genome-wide rare variation. Studies sequencing the whole 
genome of specific individuals are useful (see for example Levy et al., 2007), but this 
would need to be performed on a much larger scale to be truly informative. One such 
study has already discovered de novo mutations which are functional (Ng et al., 
2008), therefore prospects for identifying more functional de novo and rare variants 
seem good. The 1,000 genomes project, which aims to characterise sequence 
variation in 1,000 individuals should greatly facilitate the discovery and utility of rare 
SNPs in disease mapping in the near future (www.1000genomes.org/). 
 
In the absence of detailed information about the extent of rare human genetic 
variation and also the absence of methods to effectively use this information to detect 
QTL, at the current time knowledge of many rare disease-influencing loci may be 
unobtainable. Results in chapter four of this Thesis strongly suggest that better use of 
current information and readily available tools would greatly enhance the chances of 
detecting rare disease-influencing loci however, since haplotypic analysis was shown 
to perform vastly better than either single SNP or multiple SNP regression when the 
sQTL in question had low MAF. There are also other situations in which haplotypes 
will vastly outperform single SNP regression however, for example where multiple 
rare variants affecting disease exist in a single gene. Long haplotypes each associated 
with a single rare variant could thus capture all variation at the locus, providing 
power to associate the gene with disease. This would require testing in a variance 
components style analysis as opposed to fitting each haplotype as a fixed effect as in 
chapter four, to avoid the number of degrees of freedom used in the test becoming 
prohibitively large. Given the mounting evidence to indicate an important role for 
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rare variants in common disease, and that rare variants are so ubiquitous in the 
genome, haplotypes may thus have a crucial part to play in understanding the genetic 




Rare SNPs are just one of the possible ways in which the unexplained variation in 
heritable traits may be hidden. Another potential source of missing heritable variation 
concerns a different type of genetic variation altogether, indeed variation on a totally 
different scale from that of a single base pair. This variation is known collectively as 
structural variation, although the name encompasses many distinct types of genetic 
variation. The presence of very large structural variants in the genome has been 
known since chromosomes were first examined under the microscope, but these 
observable variations were originally limited to phenomena such as aneuploidy (the 
presence of an abnormal number of chromosomes – such as in Downs’ Syndrome for 
example) or large unbalanced mutations (resulting in a net loss or gain of DNA, 
unlike translocations) such as insertions, deletions or duplications. 
 
Microscopic structural variation of this sort generally involves stretches of DNA 
upwards of 3Mb in size. At the other extreme, much is known about genetic variation 
at the single nucleotide level through SNPs, and also variation up to around 1Kb 
through mini- and microsatellites. However, until recently very little was known 
about the genetic variants occupying the middle ground of variation encompassing 
between 1Kb and 3Mb of DNA, and consequently any possible effects of these on 
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disease susceptibility. Recent technological advances have enabled detection of these 
sub-microscopic variants, and early studies have discovered a surprising amount of 
structural variation that was previously unknown (Iafrate et al., 2004; Eichler et al., 
2007; Kidd et al., 2008). Sub-microscopic variation consists of all the same types of 
variation that exist on a larger scale; insertions, deletions, translocations, 
transversions and duplications among others. Another type of sub-microscopic 
variation has also been found however, and is surprisingly abundant in the genome. 
These new variants are analogous to microsatellites, only much larger, and have been 
called copy number variants (CNVs). 
 
Copy number variants are defined as segments of DNA of 1Kb or larger that are 
present at variable copy number in comparison to a reference genome (Feuk et al., 
2006), therefore classes of CNV can also include insertions, deletions and 
duplications. Early studies based on fairly small segments of the genome found an 
average of 12 CNVs per genome (Iafrate et al., 2004), however since then research 
has suggested there may be over 100 CNVs per genome of at least 50Kb in size, and 
many more of a smaller size (Feuk et al., 2006). Another study, using the HapMap 
data, found almost 1,500 large CNV regions covering 12% of the genome (Redon et 
al., 2006). One of the largest studies looking at smaller-scale copy number variation 
to date, also using the HapMap data, found that a comparison of any two genomes 
yielded almost 1,100 CNVs of less than 1Kb. Unsurprisingly then, studies also report 
that many novel CNVs are found when comparing these genomes to the human 
reference assembly, NCBI36. For example there are 23 novel CNVs in the genome of 
James Watson (Wheeler et al., 2008), and 34% of the structural variants in a 
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sequenced Asian individual were also novel (Kidd et al., 2008). This suggests that 
large numbers of individuals would need to be analysed to fully capture the diversity 
of structural variation in the human genome (Henrichsen et al., 2009). 
 
There are already reports that CNVs and other sub-microscopic structural variants can 
affect gene expression, Mendelian disorders, and common complex disease (Conrad 
et al., 2009). For example, lower than average copy number of the chemokine 
receptor gene CCL3L1 is associated with markedly higher susceptibility to HIV 
infection (Gonzalez et al., 2005), and numerous associations of CNVs and other 
structural variants to various related disorders such as schizophrenia, autism and 
mental retardation also exist (Henrichsen, 2009). One study found that genes 
harbouring CNVs with an effect on gene dosage (i.e., expression level) were enriched 
for genes involved in immune response and responses to biotic stimuli (Feuk et al., 
2006), and another found that the CNVs they identified overlapped with 13.4% of 
genes, and altered the structure of 12.5% of transcripts (Conrad et al., 2009). Studies 
have also found evidence for selection on CNVs (Perry et al., 2007), and also on 
other types of sub-microscopic variation, for example a 900Kb inversion on 
chromosome 17 (Stefansson et al., 2005). 
 
It appears likely that more QTL consisting of CNVs and other types of structural 
variation will exist, and as more about the distribution of these variants becomes 
known it will be important to investigate whether this is the case. Indeed, on a 
nucleotides-per-genome basis CNVs alone encompass more DNA than SNPs, 
highlighting their potential importance in understanding the genetics behind complex 
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disease (Redon et al., 2006). Recent work also suggests the possible existence of 
“CNV hotspots”, which may provide a starting point to look for association to disease 
(Lee et al., 2008).  
 
In the short term it may be possible to test a subset of CNVs for association with 
disease by virtue of proxy SNPs in high LD, but this approach may not be optimal. 
There was initially much debate as to what extent SNPs and CNVs co-locate; initial 
studies in the mouse found that CNVs are significantly enriched among sequences 
with low and moderate SNP coverage (Cutler et al., 2007), however the more 
extensive study performed by Conrad et al. suggests that common (>5%) CNVs of 
around 1Kb are particularly well tagged by the set of HapMap SNPs (77% of 
common CNVs tagged at r2 of at least 0.8). An even more recent and comprehensive 
study conclusively indicates that 2- and 3-class CNVs (i.e., CNVs that are biallelic) 
are tagged well by SNPs on the Affymetrix 500k, Affymetrix 6.0 and Illumina 1.2M 
arrays; 79% with MAF > 0.2 have r2 > 0.8 with at least one SNP, and 22% with MAF 
< 0.05 have r2 > 0.8 with at least one SNP (The Wellcome Trust Case Control 
Consortium, 2010). The study also suggests that these biallelic CNVs are the 
predominant type of CNV in the genome, comprising 88% of their dataset after 
quality control, although it should be noted that this may represent an upwards bias 
due the ability of existing CNV-discovery methods to reliably identify this type of 
CNV above others. 
 
It would thus appear that a substantial proportion of copy number variation is 
captured indirectly through LD to SNPs. However, even if the majority of CNVs 
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present in the genome are essentially biallelic markers and are tagged to the same 
extent as untyped SNPs by existing SNP panels, this means that CNVs will also 
suffer from the same shortfalls as SNPs. Rare CNVs would still not be particularly 
well tagged, and ideally a method of testing each variant for association with disease, 
whether directly or indirectly, is required. Typing rare SNP variation may help 
capture a greater proportion of total copy number variation, but ultimately there will 
also be CNVs missed by relying on SNPs. Contrastingly, if the estimated proportion 
of biallelic CNVs has been vastly inflated by the study above, then there is the even 





While both rare SNPs and sub-microscopic structural variants may account for some 
of the missing heritable variation of common complex disease, it is still unlikely they 
will explain it all. One of the likely alternative sources of missing variation is 
interactions, and these can be of a gene-by-gene (i.e., epistatic) or gene-by-
environment nature. Knowledge of the existence of gene-by-gene interactions is not 
new; the term “epistasis” was first used by William Bateson to describe deviations 
from Mendelian inheritance over 100 years ago (Phillips, 1998). At the time, Bateson 
was referring to what is now known more generally as biological epistasis (i.e., 
masking of an allele at one locus by expression of alleles at another locus), although 
more recently the focus has turned to identifying statistical epistasis between 
polymorphisms (Moore and Williams, 2009). Statistical epistasis was defined by 
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Fisher as an explanation for departure from additivity in linear models (Fisher, 1918), 
and the distinction between the biological and statistical definitions of epistasis is 
important with regard to interpretation of the recent GWA studies into gene-by-gene 
interactions. One recent review has defined terms for three different types of gene-by-
gene interaction in an attempt to distinguish concepts that are often confused under 
the ambiguous title of epistasis (Phillips, 2008). 
 
Statistical interactions between markers can be explicitly modelled and tested in 
GWA studies. From a practical point of view however, GWA studies are generally 
unable to consider all potential two-way marker interactions (much less higher order 
interactions) as this causes a massive multiple testing problem in addition to the extra 
computational demand (Moore and Williams, 2009). The approach is more feasible in 
candidate gene studies however, where the number of markers is significantly less 
and multiple testing becomes less of an issue. There are also others ways to go about 
detecting (statistical) epistasis that reduce the search space for gene-by-gene 
interactions, and thereby avoid exhaustive genome-wide tests. 
 
One of the ways to detect gene-by-gene interactions in GWA studies without 
incurring a prohibitive multiple testing burden is to only test for interactions between 
SNPs already exceeding significance in a test of marginal effects. It should be noted 
however, that for QTL exhibiting significant gene-by-gene interactions any 
independent marginal effects may not necessarily be large, therefore the level of 
significance required to take forward loci for interaction analysis is typically less than 
genome-wide. This approach vastly reduces the number of tests performed, however 
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it will miss epistatic effects where one or both of the genes involved do not have 
marginal effects (Cordell, 2009). It is currently far from clear that all statistically 
interacting loci do have marginal effects, for example, genes interacting with no 
marginal effects were discovered for susceptibility to cancer in mice (Fijneman et al., 
1996). As is often the case with in human genetics however, the problem of detecting 
epistatic effects is exacerbated by the fact that more complex study designs cannot be 
used; the study of cancer in mice cited above was performed using a study design that 
could not have been applied to humans (Jannot et al., 2003). 
 
It is currently unknown how important the role of gene-by-gene interactions may be 
in the control of complex traits. This is one area of research that holds promise, but at 
present may be difficult to get to grips with due to the high dimensionality of current 
GWA datasets, and the lack of an appropriate way to systematically test for these 
interactions (Moore and Williams, 2009). Consequently, there are few reports of 
statistical interactions in the literature to date, although some do exist. For example, 
epistasis has been discovered at QTL affecting coronary artery disease (Tsai et al., 
2007), diabetes (Wiltshire et al., 2006), and multiple sclerosis (Gregersen et al., 
2006). For many of the QTL with interaction effects that have been detected however, 
the functional basis of the interaction has not been identified, highlighting the 
challenge of interpreting statistical interaction, and relating it to the underlying 
biology (Phillips, 2008). 
 
While the biological interpretation of epistatic interactions can often by obscure, this 
is not always the case with gene-by-environment (G×E) interactions. Similar to 
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epistasis, G×E interactions represent the joint effect of a gene and an environmental 
factor above that of the marginal effect of the gene individually, and were originally 
tested for primarily in candidate gene based studies. Testing for G×E interactions may 
be important for a number of reasons, the foremost of which is to establish a greater 
understanding of the biological mechanisms and pathways that underlie common 
complex disease. Other potential uses for knowledge of G×E interactions are to 
increase understanding of heterogeneous results across different studies of the same 
trait (resulting, for example, in lack of replication), better characterisation of the 
individual components constituting any given environmental effect (for example, air 
pollution - Hunter, 2005), and identifying environmental factors that may adversely 
affect subgroups of individuals (Thomas, 2010). For these reasons, more interest has 
been shown in detecting G×E interactions in recent GWA studies. One of the major 
difficulties of searching for these interactions however, is that very often GWA 
studies do not collect extensive data on environmental factors. 
 
In addition to the frequent lack of appropriate information with which to test for G×E 
interactions, the best study designs for detection of these effects are different to those 
of a normal GWAS (Le Marchand and Wilkens, 2008). For example, sample-size 
requirements to have reasonable power to detect G×E interactions are suggested to be 
at least four times that needed to detect main effects of a similar magnitude (Smith 
and Day, 1984). This means tens of thousands of individuals would be required to 
detect G×E interactions using the typical study design that is pre-eminent in GWA 
studies at the present time, and would thus necessitate large consortia dedicated to 
finding them (Thomas, 2010). Using large consortia raises issues regarding 
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consistency across each of the study participants however, as otherwise there is the 
potential to introduce sources of heterogeneity. An additional problem regarding G×E 
effect detection in general is that the majority of environmental factors have 
exposures that vary over time, and most will also be dependent upon features such as 
duration of exposure or age at exposure (Thomas, 1988). Also, some environmental 
factors are comprised of multiple components, each of which could be measured and 
analysed individually for better interpretation and understanding of the underlying 
pathways. One such example is air pollution, as mentioned above, which is comprised 
of a mixture of gases and particles (Hunter, 2005). 
 
These difficulties have lead some to suggest that searching for G×E interactions may 
not be worthwhile (Clayton and McKeigue, 2001). Nevertheless, examples in the 
literature do exist to indicate that G×E interactions can have important enough effects 
on the prevalence of common complex disease to be of value for study. For example, 
there is the effect of smoking and the NQO1 gene on risk of lung cancer (Xu et al., 
2001), folate status and the MTHFR gene on colorectal cancer (Le Marchand et al., 
2005) and multiple genes showing environmental interactions for posttraumatic stress 
disorder (Koenen et al., 2009). Clearly there is an important role of G×E interactions 
for some common complex diseases, and this is one direction that should not be 
ignored. Future challenges for the advancement of G×E effect detection include 
finding more robust methods of testing for G×E interactions in genetic studies that do 
not compound the problem of multiple testing, and more detailed exposure 





Another source of variation contributing to complex traits is what are known 
collectively as expression QTL (eQTL). eQTL are genomic loci that regulate gene 
expression, therefore mutations at these loci lead to altered transcript levels of the 
genes they regulate. These changes can be detected by measuring transcript levels 
(using DNA microarrays, for example), and subsequently treating gene expression as 
a quantitative trait to analyse in an identical way to conventional QTs. eQTL can be 
either cis- or trans-acting, reflecting their proximity to the genes they regulate, and 
are also classified as “static” or “dynamic” depending on whether they are 
consistently active, or cell-type-specific (Gerrits et al., 2009). 
 
There is evidence to show that eQTL play a role in the control of complex human 
disease. For example, eQTL affecting childhood asthma (Moffatt et al., 2007), age-
related macular degeneration (Coleman et al., 2008) and Crohn’s disease (Barrett et 
al., 2008) have already been identified. Another study has even suggested that many 
of the trait-associated SNPs already identified through GWA studies are likely to be 
eQTL (Nicolae et al., 2010). In their study, 625 of 1,598 confirmed trait-associated 
SNPs taken from the GWA study catalogue (Hindorff et al., accessed 29/06/09) 
would have been classified as eQTLs with a p-value of 1×10-4. Thus, current 
challenges of considerable importance are to assess the extent of genes acting in an 
expression-related manner, and detecting the genetic determinants of this expression 
variation. Recent studies have begun gathering genome-wide expression data and 
providing publicly available database resources for the research community to 
interrogate with regard to trait-associated SNPs identified through GWA studies (see, 
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for example, Dixon et al., 2007). Projects like these are essential to begin addressing 
the challenges mentioned above, and herald the next wave of trait-associated variants 




One other possible explanation for not finding all heritable components of phenotypic 
variation is phenotypic misclassification. This is more problematic for some traits as 
opposed than others, but can greatly hinder attempts to detect genes involved in such 
traits. Inclusion of individuals suffering from slightly different diseases, or not 
suffering from disease at all would add noise to a study and decrease power. Such 
misclassifications are possible for example in threshold traits where diagnosis is 
dependent upon instruments introducing a degree of error, or in cases where diagnosis 
is a result of the subjective decision of a doctor. Also, due to the very large sample 
sizes of modern GWA studies, it is not uncommon that samples for a single study are 
collected from different centres, thus relying on the opinions of different doctors and / 
or measuring apparatus. 
 
In the case of misclassification of one disease for another, power is decreased because 
the genes causing disease in some individuals will not be the same as those causing 
disease in others, and this will obscure any association (Maher, 2008). This effect is 
similar to genetic heterogeneity with multiple loci exhibiting low penetrance, except 
that in the case of genetic heterogeneity at least all disease alleles are consistent 
across the sample. Note that while misclassification would also affect heritability 
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estimates in the given study (therefore meaning the heritability was never actually 
present to be found missing in that study), poorly collected study data may 
nevertheless be one reason that some of the true genetic proportion of complex 
disease cannot be found. Ironically however, in order to better diagnose samples for 
GWA studies, it may require an understanding of the genetic mechanisms and 




Even with ever-increasing sample sizes and new study populations, the continuing 
success of GWA studies can only last so long. As already described, there is still 
much to be learned about the genetics of complex disease, and it appears that many of 
the upcoming challenges cannot be tackled using existing methods. While rare SNP 
detection continues in projects such as the 1,000 genomes, and other studies elucidate 
the full extent of CNV and other sub-microscopic structural variation in the human 
genome, it is important to make the best use possible of data already available. There 
is much debate over the benefit of using SNPs in new ways in an attempt to glean 
extra information from what already exists, and results presented in this Thesis add to 
that currently in the literature suggesting that utilising multi-SNP methods, in 
particular haplotype analysis, may do just that. Results from chapter four show strong 
evidence that haplotypes greatly assist the detection of rare variants, and these are 
looking to have a more prominent role in disease than previously thought. 
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For the longer term, the most important aim must be the construction of more detailed 
maps to characterise rare SNP variation, CNVs and other sub-microscopic variation 
present in the genome. This is going to require the in-depth sequencing of large 
numbers of individuals, assuming that results from the first attempts at cataloguing 
this information are accurate, and may be a particularly important challenge with 
respect to CNVs, given that at the present time much work is focussed on CNV 
discovery rather than genotyping (Conrad et al., 2009). However, once this 
information has been gathered the prospects of taking our understanding of complex 
human disease to a new level are excellent. As our knowledge of individual diseases 
increases, it is possible that ever widening networks of genes will be discovered to be 
linked, and that many underlying genetic pathways may be shared between diseases 
that now seem disparate. Integral to this broadening of knowledge will be expanding 
our understanding of the ways genes interact both with each other and the 
environment, and also how other phenomena such as epigenetics (through 
mechanisms such as DNA methylation and chromatin remodelling, for example) act 
to affect disease aetiology. 
 
Nearly 75 years on from his prophetic statement, it seems unlikely that Ronald Fisher 
could have imagined just how long the search for “linkage” would indeed turn out to 
be. However, if the search for linkage was at first disappointing, the advancement in 
understanding the genetic architecture of both Mendelian and common complex 
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